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Abstract 
Tuberculosis (TB) is the leading cause of death by an infectious disease, recently surpassing 
HIV/AIDS. The causative agent, Mycobacterium tuberculosis, is difficult to treat as it can 
survive harsh conditions and can switch between an active infection, which causes ~1.5 million 
deaths a year, and a latent state, which infects up to one third of the world’s population. M. 
tuberculosis is also becoming more resistant to frontline drugs, making it a dangerous world 
epidemic. It is therefore essential that new treatments are developed to help combat TB. A new 
enzyme superfamily has recently been discovered that utilises the rare co-factor F420, which is 
not produced or utilized by humans, allowing for specific drug targeting of the mostly 
uncharacterized enzymes that utilise it. The aim of this thesis is to better understand the roles 
of these enzymes in Mycobacteria and to investigate the mechanism by which M. tuberculosis 
might evolve resistance to a new class of prodrugs that are activated by the F420-dependent 
enzyme deazaflavin-dependent nitroreductase (Ddn). 
 Prodrugs that are activated by Ddn include pretomanid and delamanid, which are 
effective against both an active and latent TB infection. Ddn is natively a quinone reductase, 
but also reacts with these drugs to reduce them, thereby releasing nitrous oxide and other 
breakdown products that are thought to inhibit hydroxymycolic acid dehydrogenase. 
Resistance against pretomanid in vitro has been documented in laboratory studies to occur via 
mutations to the F420 biosynthetic pathway, the enzyme F420-dependent glucose-6-phosphate 
dehydrogenase that reduces F420, and Ddn. However, the fitness cost of such mutations, i.e. 
whether they would still be virulent and transmissible, has not been studied. This important 
question will determine whether such genetic changes could lead to clinically relevant 
resistance. I explored this question with a detailed study of Ddn to establish (i) whether its 
activity is essential for the fitness of M. tuberculosis and (ii) whether any mutations could 
knock out the prodrug-activating activity without substantially affecting the native quinone 
reductase activity. I investigated this by better defining the physiological role of Ddn, showing 
that it can reduce menaquinone, and that this activity can enhance respiration of the cell by 
coupling with cytochrome bd. I also demonstrated that Ddn orthologues have similar quinone 
reductase activity as Ddn, but have no activity with pretomanid, except for the M. marinum 
orthologue that has activity with both. Through site directed mutagenesis I have identified a 
number of mutations to Ddn’s active site that eliminate activity with pretomanid while retaining 
some quinone reductase activity. A clinical strain that had acquired one of the tested mutations 
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through neutral genetic drift/variation showed resistance to pretomanid, despite never having 
been exposed to the compound.  Interestingly, the other nitroimidazole prodrug, delamanid, 
was still effective Computational modelling suggets this to be due to the way that each 
nitroimidazole binds Ddn. 
 The first step to developing a new drug to target an F420-dependent enzyme, we first 
need to identify genes/proteins that are essential for some aspect of the life cycle of M. 
tuberculsosis. Collaborators have shown that the F420-dependent enzyme Rv0121c 
(homologous to MSMEG_6526 in Mycobacterium smegmatis) from the flavin/deazaflavin 
oxidoreductase (FDOR) protein superfamily is essential for escape from dormancy. As a model 
for M. tuberculosis we made a MSMEG_6526 knockout in M. smegmatis and confirmed that 
it is conditionally essential. This was demonstrated by the slower growth rate of Δ6526 
compared to wildtype in minimal media with several different carbon sources, and the lack of 
growth on acetate and pyruvate. Proteomics showed the upregulation of the methylcitrate cycle, 
glyoxylate cycle, and several F420-dependent enzymes, including the Ddn orthologue 
MSMEG_2027. Proteins that were downregulated were part of the Kerbs cycle, late stage 
glycolysis, and several amino acid metabolomic pathways. This was complemented with 
metabolomics, revealing several metabolites that were affected by the MSMEG_6526 
knockout. The pathway that these metabolites were involved in included the Krebs cycle and 
several related amino acid metabolic pathways. This suggests that MSMEG_6526 is somehow 
involved in amino acid metabolism. The crystal structures of Rv0121c and MSMEG_6526 in 
complex with F420 were solved, revealing homodimers of the split β-barrel fold that defines the 
FDOR super family. The structures revealed three extended loops, two of which made a more 
defined active site compared to other FDORs. The third loop was not involved with the active 
site and is not conserved between the two enzymes, while the active site and F420 binding are 
highly conserved. The structure was also used to identify the type of substrates that can bind 
these enzymes. 
 The other chapters presented in this thesis are collaborative projects that I had 
contributed towards. These include detailed characterization of the FDOR superfamily in 
which a number of specific sub-groups of the FDOR superfamily based on sequence similarity 
and structural motifs. We also identified novel F420-dependent biliverdin reductases in M. 
tuberculosis that reduce bilirubin, a known antioxidant. Finally, we expand the list of chemicals 
that FDORs has promiscuous activity with, including antimicrobials that we show are more 
vi 
 
potent with F420 knocked out. The final chapter is a comprehensive review of F420, it precursor 
Fo, and related enzymes in Mycobacteria, methanogens, and other bacteria that utilise it.  
  
vii 
 
Table of Contents 
 
Declaration .................................................................................................................................. i 
Acknowledgements .................................................................................................................... ii 
Abstract ..................................................................................................................................... iv 
Chapter 1: Introduction .............................................................................................................. 1 
1.1 Mycobacterium tuberculosis ....................................................................................... 2 
1.2 Next generation Anti-mycobacterials.......................................................................... 4 
1.2.1 Bedaquiline ............................................................................................................... 5 
1.2.2 Nitroimidazoles, Pretomanid and Delamanid ........................................................... 9 
1.3 The Co-Factor F420 ....................................................................................................... 12 
1.3.1 F420 Distribution ...................................................................................................... 14 
1.3.2 F420 Biosynthesis ..................................................................................................... 15 
1.4 F420-dependent enzymes................................................................................................. 19 
1.4.1 Luciferase-like Hydride Transferases ..................................................................... 20 
1.4.2 FDOR-A Enzymes .................................................................................................. 24 
1.4.3 FDOR-AA Enzymes ............................................................................................... 26 
1.4.4 FDOR-B Enzymes .................................................................................................. 27 
1.5 Thesis Outline ................................................................................................................ 31 
1.5.1 Chapter outlines ...................................................................................................... 31 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis ................. 33 
2.1 Introduction .................................................................................................................... 34 
2.2 The evolution of nitroimidazole antibiotic resistance in Mycobacterium tuberculosis . 35 
2.3 Supplementary Materials ............................................................................................... 60 
Chapter 3: The role of MSMEG_6526 in Mycobacteria ......................................................... 85 
3.1 Introduction .................................................................................................................... 86 
3.2 Materials and Methods ................................................................................................... 88 
viii 
 
3.2.1 Mycobacterial strains, media, and growth conditions ............................................ 88 
3.2.2 Construction of M. smegmatis Δ6526 mutant ........................................................ 88 
3.2.3 Proteomic preparation and analysis ........................................................................ 89 
3.2.4 Metabolomic preparation and analysis ................................................................... 90 
3.2.5 Protein expression and purification ........................................................................ 91 
3.2.6 Protein crystallography ........................................................................................... 92 
3.2.7 Computational substrate docking ............................................................................ 94 
3.3 Results ............................................................................................................................ 95 
3.3.1 Growth of Δ6526 on Primary Carbon Sources ....................................................... 95 
3.3.2 The Changes in Protein Expression in Δ6526 ........................................................ 96 
3.3.3 Growth Curves of Δ6526 on Central Metabolism Intermediates ......................... 106 
3.3.4 The Change in the Metabolome of Δ6526 ............................................................ 110 
3.3.5 The Structures of MSMEG_6526 and Rv0121c ................................................... 114 
3.4 Discussion .................................................................................................................... 121 
Chapter 4: Structure and Function Classification of Flavin/Deazaflavin Oxidoreductases .. 125 
4.1 Introduction .................................................................................................................. 126 
4.2 Sequence–Structure–Function Classification of a Catalytically Diverse Oxidoreductase 
Superfamily in Mycobacteria ............................................................................................. 128 
4.3 Supplementary Material ............................................................................................... 147 
4.4 Rv2074 is a novel F420H2‐dependent biliverdin reductase in Mycobacterium tuberculosis
............................................................................................................................................ 157 
Chapter 5: The Promiscuous Mechanism of F420-Dependent Enzymes in Detoxification by 
Mycobacteria ......................................................................................................................... 176 
5.1 Introduction .................................................................................................................. 177 
5.2 The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds 
and mediates a reductive detoxification system ................................................................. 178 
5.3 Supplementary Material ............................................................................................... 188 
ix 
 
5.4 Mycobacterial F420H2-dependent reductases promiscuously reduce diverse compounds 
through a common mechanism .......................................................................................... 198 
5.5 Supplementary Material ............................................................................................... 209 
Chapter 6: Literature Review of Fo and F420 .......................................................................... 225 
6.1 Introduction .................................................................................................................. 226 
6.2 Physiology, Biochemistry, and Applications of F420-and Fo-Dependent Redox Reactions
............................................................................................................................................ 228 
Chapter 7:Conclusions and Future Directions ....................................................................... 272 
7.1 Summary ...................................................................................................................... 273 
7.2 Future Directions ......................................................................................................... 277 
References .............................................................................................................................. 280 
 
 
  
1 
 
 
Chapter 1 
 
Introduction 
  
Chapter 1: Introduction 
2 
 
1.1 Mycobacterium tuberculosis 
 
In the 2016 World Health Organisation (WHO) tuberculosis report, tuberculosis was declared 
in the top ten causes of death, and is the leading cause of death by infectious disease, surpassing 
HIV/AIDS. In 2015 alone, 1.8 million people died (Fig. 1.1a), with 10.4 million people falling 
ill from tuberculosis. It is estimated that one third of the world’s population is infected with 
latent Mycobacterium tuberculosis, the causation of tuberculosis (WHO, 2016). 
 The standard treatment for tuberculosis since the 1980s, is a four drug cocktail 
(isoniazid, rifampin, pyrazinamide, and ethambutol) over six months (Lienhardt et al., 2012). 
This therapy was only completely effective until the 1990s, after which major issues arose, 
including high costs per patient, poor compliance and management, and extensive drug-drug 
interactions (Zumla et al., 2013). Due to these problems, tuberculosis acquired extensive 
resistance towards these drugs and is now a major problem (Jain et al., 2008). This rise in 
resistance reflects the biology of M. tuberculosis, which can transition between chronic and 
latent infection states allowing the ability to evade the immune system and resist drug treatment 
(Boshoff and Barry, 2005). In 2015, there were 480,000 new cases of multi-drug resistant 
tuberculosis (MDR-TB); tuberculosis that is resistant to the two most powerful anti-
tuberculosis drugs (Isoniazid and Rifampicin), and 100,000 new cases of Rifampin-resistant 
tuberculosis (RR-TB). The majority of these cases come from China, India, and Russia (Fig. 
1.1b). The proportion of MDR-TB that were extensively-drug resistant tuberculosis (XDR -
TB); tuberculosis that is resistant to at least four of the front line anti-TB drugs, was 9.5 % 
(WHO, 2016).  
The rise of tuberculosis that is resistant to frontline drugs has been increasing, and it is 
therefore important to develop new drugs to combat tuberculosis, including new strategies that 
not only target active tuberculosis, but latent tuberculosis. Unfortunately, the gap in funding 
for implementation of detection and treatment, and research and development is short of what 
is needed (WHO, 2016). Despite this, there are new drugs that are promising but the possibility 
and impact of resistance is not fully understood. Therefore, it is important to understand the 
mechanisms by which resistance to new drugs might arise, and to understand the physiology 
and function of potential new targets to develop novel treatments to continue the improvement 
of tuberculosis treatment. The overall aim of this thesis is to further understand the 
physiological, promiscuous, and drug related function of F420-dependent enzymes in 
Chapter 1: Introduction 
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Mycobacteria. This will allow for the improvement of the current tuberculosis drug regime, 
the development of new antimycobacterials, and to provide a molecular basis for enzyme 
engineering of F420-dependent enzymes for biosynthetically useful reactions.  
 
 
 
 
 
  
Figure 1.1. Global impact of tuberculosis. (A) Estimated TB mortality rates in HIV-
negative people in 2015. (B) Estimated incidence of MDR/RR-TB in 2015, for countries 
with at least 1000 cases. Adapted from WHO 2016. 
A 
B 
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1.2 Next generation Anti-mycobacterials 
 
Until recently, no new anti-tuberculosis drug had been approved in more than 40 years. In 2012 
and 2014, the diarylquinoline, Bedaquiline, and the nitroimidazole, Delamanid, were 
conditionally approved respectively for treatment against MDR-TB (Mahajan, 2013; Ryan and 
Lo, 2014). These two classes of drugs are discussed in Section 1.2.1 and Section 1.2.2. Another 
nitroimidazole, Pretomanid, which predates Delamanid in development, is in phase III trials, 
in regimens that include Bedaquiline and the repurposed antibiotic, Linezolid, or with 
Pyrazinamide and the repurposed antibiotic, Moxifloxacin (Fig. 1.2a) (Dawson, Diacon, 
Everitt, Niekerk, Donald, Burger, Schall, Spigelman, Pym, Groote-bidlingmaier, Mendel, et 
al., 2015; Tasneen et al., 2016). There is a regimen of Pretomanid with Bedaquiline and 
pyrazinamide also in phase III trials (Diacon et al., 2015). Another repurposed antibiotic, 
Rifapentine, is in phase III trials with Moxifloxcin to reduce the treatment time of drug-
susceptible tuberculosis down from over six months to four months (Jindani et al., 2014).  
Between 2015 and 2016 two drugs were abandoned in clinical trials, AZD5847, due to 
the lack of demonstrated anti-tuberculosis activity, and a third generation nitroimidazole, TBA-
354, due to toxicity found in the Phase I trial (WHO, 2016). Despite this, there are three new 
drugs in early clinical trials. In Phase I trials, there is the imidazopyridine amide, Q203, that 
targets the respiratory cytochrome bc1 complex, and the piperazine‐containing 
benzothiazinones, PBTZ169, which inhibits decaprenylphosphoryl‐beta‐D‐ribose 2‐
epimerase, an essential flavoenzyme involved in cell wall synthesis (Pethe et al., 2013; 
Makarov et al., 2014; WHO, 2016). The oxazolidinone Sutelozid, an analogue of Linezolid 
that inhibits protein synthesis is in phase II trials (Fig. 1.2a) (Williams et al., 2009; WHO, 
2016).  
Vaccines against tuberculosis are limited with the Bacille-Calmette-Guérin (BCG) 
vaccine, a attenuated vaccine containing the strain M. bovis BCG, as the only available vaccine,  
having limited use due to its variable efficacy (Colditz et al., 1994). As of 2016, there are five 
vaccines in phase I trials, seven in phase II trials, and one in phase III trials (Fig.1.2b). These 
vaccines includes recombinant BCG strains whole-cell derived vaccines, recombinant viral-
vectored platforms, protein and adjuvant combinations, and mycobacterial extracts. They aim 
to prevent infection, prevent primary progression to disease, or the reactivation of latent 
tuberculosis infection (WHO, 2016). 
Chapter 1: Introduction 
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Figure 1.2 Current tuberculosis treatments in development. (A) Anti-tuberculosis drugs 
in development. (B) Current tuberculosis vaccines treatments in development. Adapted 
from WHO 2016  
A 
B 
Chapter 1: Introduction 
6 
 
1.2.1 Bedaquiline  
 
 
 
 
 
In 2012, Bedaquiline (Fig. 1.3) was conditionally approved and was the first anti-tuberculosis 
drug with a novel mode of action to be approved since 1974, with the approval of Rifampicin 
(Deoghare, 2013; Mahajan, 2013). It is a diarylquinoline that is effective against both active 
and latent M. tuberculosis, MDR-TB, and other Mycobacteria species including, M. ulcerans, 
M. abscessus and M. smegmatis (Andries et al., 2005; Koul et al., 2008). Initial studies of 
bedaquiline showed that it binds to the c-subunit of the ATP synthase and is able to inhibit the 
synthesis of ATP in the cell (Andries et al., 2005; de Jonge et al., 2007; Koul et al., 2007).  
The crystal structure of the M. phlei ATP synthase revealed a binding pocket in the c-
subunit that provides hydrogen bonding between a conserved glutamic acid and the 
dimethylamino moiety of bedaquiline. Mutations found in bedaquiline resistant strains have 
shown to directly or indirectly disrupt this hydrogen bonding (Segala et al., 2012; Preiss et al., 
2015). Specificity of bedaquiline to Mycobacteria ATP synthases is due to a phenylalanine that 
provides a hydrophobic platform for bedaquiline to bind. This phenylalanine is highly 
conserved across Mycobacterial species but is not found throughout other bacteria and 
eukaryotes, (Preiss et al., 2015). This interaction allows bedaquiline to bind the Mycobacteria 
ATP synthases 20,000 times more effectively than the mitochondrial ATP synthase (Haagsma 
et al., 2009).  Initial human trials showed mild to moderate side effects to bedaquiline, which 
was expected due to its specificity to the Mycobacterial ATPase (Diacon et al., 2009). 
Unfortunately, further trials have raised concern over bedaquiline having a higher mortality 
rate when compared to the placebo and has received a black-box warning for risk of death and 
arrhythmias (Cox and Laessig, 2014; Diacon et al., 2014). The effect of bedaquiline does not 
increase with higher concentrations, and studies suggests a time dependent mechanism rather 
than a concentration-dependent effect (Koul et al., 2014). Early studies suggested bedaquiline 
Figure 1.4 Structure of Bedaquiline. 
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to be an inhibitor of ATP synthase due to the decreases in ATP (Koul et al., 2008). Further 
studies showed that the presences of bedaquiline removes the proton gradient, eliminating the 
proton-motive force across the membrane, while maintaining the difference in pH, which is 
most likely due to another salt such as K+. Therefore, the proposed mechanism is, bedaquiline 
binds to the c-subunit of the ATP synthase that forms a gap between the c-subunit and the a-
Chapter 1: Introduction 
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subunit that allows an uncontrolled proton leak, eliminating the proton motive force (Fig.1.4) 
(Hards et al., 2015). 
Figure 1.4 The mechanism of Bedaquiline. The majority of ATP synthesis is respiratory 
(a), driven by the PMF. The binding of bedaquiline (b) to the c-ring creates a gap in the a-
c subunit interface, causes an uncontrolled proton leak uncoupled from ATP synthesis and 
resulting in a futile proton cycle. The membrane potential is most likely compensated by 
the exchange of other cations (i.e. K+). BDQ, bedaquiline. Adapted from Hards et al. 2015  
A 
B 
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1.2.2 Nitroimidazoles, Pretomanid and Delamanid 
 
Nitroimidazoles (Fig. 1.5) are a class of prodrugs that have been shown to have 
promising effects on both active and latent M. tuberculosis (Greening et al., 2016; Chen et al., 
2017). They are activated by the enzyme deazaflavin-dependent nitroreductase (Ddn, Rv3547) 
through a two electron hydride transfer from F420H2 (Stover et al., 2000; Ji et al., 2006; 
Manjunatha et al., 2006). Ddn orthologues are conserved throughout mycobacteria (except M. 
leprae), although related species have been shown to be resistant to pretomanid and delamanid, 
due to the difference in sequence identity that leads to a lack of activity with nitroimidazoles 
(Ji et al., 2006; Manjunatha et al., 2006; Cellitti et al., 2012; Gurumurthy et al., 2012) 
Resistance in M. tuberculosis towards nitroimidazoles has been shown to arise through 
mutations in the F420 biosynthetic pathway (see Section 1.3.2), the enzyme F420-dependent 
glucose-6-phosphate dehydrogenase (fgd), that reduces F420 to F420H2 (see section 1.4.1), or 
Ddn (Feuerriegel et al., 2011; Haver et al., 2015). Nitroimidazoles have also been shown to be 
effective against visceral leishmaniasis, a diseased caused by the protozoan parasites, 
Leishmania donovani, or L. infantum (Patterson et al., 2013; Patterson et al., 2016). The 
activation of Nitroimidazoles in Leishmania is by a FMN-dependent NADH oxidoreductase 
(NTR2) (Wyllie et al., 2016). 
The first nitroimazole to be shown to be effective against M. tuberculosis was CGI-
17341 (Ashtekar et al., 1993). It is suggested to be activated by several F420-dependent enzymes 
as well as Ddn, as it still effective when Ddn is knocked out, but loses activity when F420 
biosynthesis is eliminated. The promiscuity of CGI-17341 is most likely due to the lack of 
Figure 1.5 Structures of Nitroimidazole Prodrugs 
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hydrophobic tail and phenyloxazole resides found on pretomanid and delamanid (Manjunatha 
et al., 2006; Gurumurthy et al., 2012). Unfortunately, CGI-17341  is mutagenic, which is seen 
with most nitroimidazoles that have a mono- or di-alkyl tail, and development has been 
discontinued (Stover et al., 2000; Matsumoto et al., 2006). Pretomanid was developed from 
CGI-17341 by replacing the short alkyl substitution with a longer hydrophobic tail. This made 
it non-mutagenic but can only activated by Ddn (Stover et al., 2000; Gurumurthy et al., 2012). 
Delamanid has a longer lipophilic tail than pretomanid that leads to a higher potency but at the 
cost of a poor pharmacokinetic profile (Matsumoto et al., 2006; Upton et al., 2015). To try and 
improve the solubility while maintaining high potency,  TBA-354 was developed, but has been 
discontinued due to its toxic side effects and lack of novelty  (Tasneen et al., 2015; Upton et 
al., 2015). 
 The reduction of nitroimidazoles leads to the decomposition into three metabolites, 
predominantly a des-nitro compound, and nitric oxide or nitrous oxide (Fig. 1.6) (Matsumoto 
et al., 2006; Singh et al., 2008). The activation of nitroimidazoles in Ddn is stabilised by a 
serine hydrogen bonding to the nitrogen group. This stabilises the transition intermediate after 
the initial hydride transfer from F420H2, allowing a second hydride transfer leading to the 
rearrangement of the imidazole group, releasing nitric oxide or nitrous oxide (Singh et al., 
2008). This reaction needs to be protected from the solvent that is provided through a 
hydrophobic barrier provided by three tyrosines in the active site of Ddn  (Mohamed et al., 
2016). The reduction of nitroimidazoles has a dual bactericidal effect as a result of the products 
formed (Manjunatha et al., 2009). The initial bactericidal effect is through the release of the 
reactive nitrogen species, which react with cytochromes and cytochrome c oxidase, which in 
turn interferes with the electron flow of the electron transport chain leading to respiratory 
poisoning (Singh et al., 2008). The primary metabolite formed, the des-nitro compound, 
inhibits the oxidation of hydroxy-mycolic acid to keto-mycolic acid, a key component of the 
cell wall of M. tuberculosis that enhances it pathogenic nature, by inhibiting the enzyme F420-
dependent hydroxymycolic acid dehydrogenase (fHMAD) (see section 1.4.1) (Stover et al., 
2000; Matsumoto et al., 2006; Purwantini and Mukhopadhyay, 2013)  
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Figure 1.6 Mechanism of nitroimidazole reduction by the activation of F420H2. Adapted 
from Greening et al. 2016.  
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1.3 The Co-Factor F420 
The cofactor, F420 (Fig. 1.7), was first identified from methanogen crude lysate in 1972. The 
components that were identified through acid hydrolysis were glutamate, an acid-stable 
chromophore, phosphate, and an ether-soluble phenolic component. It was also noted that F420 
could be reduced using either sodium dithionite or sodium borohydride (Cheeseman et al., 
1972).  The full structure was characterised using  spectroscopic analysis of its degradation 
products and validated by chemical synthesis (Eirich et al., 1976; Ashton et al., 1979; Ashton 
and Brown, 1980; Pol et al., 1980). F420 is named due to its characteristic absorbance at 420 
nm, giving a yellow-green colour, which disappears when reduced to F420H2 (Fig.1.8) 
(Cheeseman et al., 1972).  
F420 is structurally similar to flavins (Riboflavin, FMN, and FAD), except for a carbon 
atom substituted for the N-5 atom of the isoalloxazine ring, C-8 is hydroxylated, and C-7 is 
demethylated (Fig. 1.7). It is a obligate two-electron carrier, whereas flavins can be a one or 
two electron carrier (Edmondson et al., 1972; Xia et al., 2015). This is due to the C-5 substitute 
in F420 that does not allow it to be stabilised as a semiquinone, whereas the N-5 unpaired 
electrons in flavins can delocalise throughout the isoalloxazine, allowing them to be stable as 
a semiquinone (Fisher et al., 1976). The N-5 substitution to carbon gives F420 a lower redox 
potential (-340 mV) compared to riboflavin (-210 mV), FAD (-220 mV), or FMN (-190mV). 
This makes F420 functionally more similar to NADH/NADPH (-320 mV) (Thauer et al., 1977; 
Jacobson and Walsh, 1984; Walsh, 1986; Buckel and Thauer, 2013) Due to its low redox 
potential, F420 is capable of reducing a wide range of organic compounds that are otherwise 
difficult to activate and can be utilized by aerobic bacteria in hypoxic and anoxic environments, 
potentially substituting for NADH/NADPH (Ebert et al., 1999; Lapalikar et al., 2012; Greening 
et al., 2016; Jirapanjawat et al., 2016).  
Figure 1.7 Structure of Riboflavin, F420, and NADH. 
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The physiological roles of F420 in methanogens, and certain non-methanogenic archaea, 
include energy metabolism, NADP reduction, oxygen detoxification, and sulfite reduction 
(Yamazaki et al., 1980; Schauer et al., 1986; Seedorf et al., 2004; Johnson and Mukhopadhyay, 
2005). In contrast, the physiological role of F420 in Mycobacteria is not fully understood. 
Current studies have shown that F420 may have a role in a defence against oxidative stress. This 
is suggested by its ability to reduce nitrogen dioxide, F420 knockouts are more prone to oxidative 
stress, and F420 levels are elevated when mycothiol and ergothioneine, glutathione analogues 
that maintain redox homeostasis, are absent (Purwantini and Mukhopadhyay, 2009; 
Gurumurthy et al., 2013; Singh et al., 2016). F420 is also suggested to protect the cell against 
xenobiotic agents, as Mycobacteria that cannot produce F420 are more susceptible to 
bactericidal agents (Gurumurthy et al., 2013; Jirapanjawat et al., 2016)  
  
Figure 1.8 UV-visible absorption spectra of F420 (blue) and F420H2 (red). Adapted from 
Purwantini et al. 2009. 
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1.3.1 F420 Distribution 
Bioinformatic analysis has revealed that the F420 biosynthesis genes (cofC, cofD, cofE, cofG 
and cofH) are present in at least 653 bacterial and 173 archaeal species. The ecosystems of 
these species are mostly soil and marine environments (Fig. 1.9) (Ney et al., 2017). Among 
archaea, F420 is thought to be distributed in all methanogens and is proposed that F420 is central 
to the metabolism of the various anaerobic methanotrophic archaea  (Cheeseman et al., 1972; 
Eirich et al., 1979; Haroon et al., 2013). F420 has been shown to be present in many 
hydrogenotrophs and has been identified in several non-methanogenic euryarchaeota, 
including three species of the sulphate-reducing genus, Archaeoglobus, and seven species of 
the photosynthetic genera, Halobacteria, and Halococcus (Beelen et al., 1983; Dolfing and 
Mulder, 1985; De Wit and Eker, 1987; Möller-Zinkhan et al., 1989; Vornolt et al., 1995). The 
ammonia- and cyanate-oxidizing thaumarchaeon, Nitrososphaera gargensis, is shown to 
produce high levels of F420 (Spang et al., 2012). Comparative genomics identified the F420 
biosynthesis genes present in Thaumarchaeota, Aigarchaeota, Geoarchaeota, Bathyarchaeota, 
and Lokiarchaeota (Wu et al., 2009; Kozubal et al., 2013; Rinke et al., 2013; Evans et al., 
2015; Spang et al., 2015). The presence of F420 has been reported in both Sulfolobus and 
Thermoplasma, but the genomes lack the known genes to synthesis it (Lin and White, 1986). 
Within bacteria, F420 has been identified in Mycobacteria including the major obligate 
pathogens M. tuberculosis, M. bovis, and several opportunistic species (Purwantini et al., 
1997). M. leprae, which has undergone a genome reduction event, also produces F420, 
suggesting the importance of F420 to Mycobacteria species (Purwantini et al., 1997; Cole et al., 
2001). F420 is found in representatives of the actinobacterial genera including Streptomyces, 
Nocardia, and Nocardioides (Kuo et al., 1989; Purwantini et al., 1997; Ebert et al., 1999). 
Comparative genomic analyses show that F420 biosynthesis genes are found in representatives 
of the Chloroflexi, Alphaproteobacteria, Betaproteobacteria, and Gammaproteobacteria 
(Selengut and Haft, 2010; Ahmed et al., 2016). The biosynthetic pathway of F420 is proposed 
to have evolved in bacteria after acquiring from archaea the biosynthetic genes for Fo, a redox 
chromophore used in oxidoreductases and photocatalytic systems that contains the same 
isoallazine rings as F420 but lacks the lactate moiety and glutamate tail (Walsh, 1986; Hossain 
et al., 2015; Ney et al., 2017). Phylogenetic studies of each of the F420 biosynthetic genes 
suggest the biosynthesis of Fo was developed in an early methanogen. This pathway was 
acquired by actinobacteria that evolved the genes to synthesis F420 from Fo. Multiple gene 
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transfers allowed for other bacteria and archaea to acquire the ability to synthesis F420 (Nelson-
Sathi et al., 2015; Ney et al., 2017). 
 
1.3.2 F420 Biosynthesis 
The biosynthesis of F420 starts with the synthesis of its precursor Fo. This biosynthesis uses the 
flavin pathway which condenses pyrimidine ribityldiaminouracil (5-amino-6-ribityl-amino-
2,4[1H,3H]-pyrimidinedione), derived from GTP, with 3,4-dihydroxy-2-butanone 4-phosphate 
to make 6,7-dimethyl-8-ribityllumazine.  Two of these molecules condense to regenerate 5-
amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione with concomitant production of riboflavin 
(Fischer and Bacher, 2011) For the biosynthesis of Fo, pyrimidine ribityl diaminouracil from 
the flavin pathway is condensed with tyrosine by cof G and H (Fig.1.10) (Graham et al., 2003; 
Berteau, 2012). The formation of Fo in Mycobacteria, is catalysed by fbiC, an ezyme that 
contains two subunits homologous to cof G and H. (Choi et al., 2001).  
Mechanistic studies of fbiC demonstrated that the formation of the heterocycle depends 
on the coordinated action of two radical S-adenosylmethionine (SAM) sites contained in each 
domain. In the CofG domain the SAM abstracts a hydrogen atom from tyrosine that fragments 
to form a p-hydroxybenzyl radical and a glycine imine, which undergoes hydrolysis to form 
Figure 1.9 Genomic and metagenomic distribution of the cof genes that encode F420 
biosynthesis enzymes. (a) Distribution of cof genes by phyla in the NCBI Reference 
Sequence database. (b) Distribution of cof genes in 19 publicly available metagenomes by 
enzyme. (c) Distribution of cof genes in 19 publicly available metagenomes by phylum of 
the closest BLAST hit (>60% identity). Adapted from Ney et al. 2016. 
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glyoxylate. The p-hydroxybenzyl radical attacks pyrimidine ribityldiaminouracil to form an 
intermediate that is transferred to the cof H domain. The SAM of cofH abstracts a hydrogen 
from the intermediate allowing for electron rearrangement leading to the cyclisation and 
oxidation of the radical electron forming Fo (Berteau, 2012; Philmus et al., 2015). 
 
  
  
Figure 1.10 Biosynthesis of F0 from the flavin biosynthesis pathway. Adapted from 
Greening et al. 2016. 
Chapter 1: Introduction 
17 
 
There are two major steps in the formation of F420 from Fo (Fig. 1.11). The first step requires 
the condensation of Fo with L-lactyl-2-diphospho-5-guanosine (LPPG), synthesised from 
lactate, to form the phosphodiester F420-0 (F420 containing no glutamate side chain) (Graupner 
and White, 2001). This reaction is catalysed by a 2-phospho-L-lactate transferase, fbiA in 
Mycobacteria, and CofD in archaea (Choi et al., 2001; Graupner et al., 2002). The crystal 
structure of CofD from Methanosarcina mazei, revealed that the deazaflavin ring of Fo interacts 
with a hydrophobic pocket and two water molecules, while the nucleotide moiety of LPPG is 
accommodated in a Rossmann fold domain with a Mg2+ ion. The proposed mechanism is that 
conformational changes in the binding pocket caused by the substrates binding puts the 
terminal hydroxyl group of Fo close to the β-phosphate of LPPG. After the extraction of the 
terminal proton from Fo by a general base, the two molecules are condensed (Forouhar et al., 
2008).  
The pathway that produces LPPG is not fully understood. It is assumed that 2-phospho-
L-Lactate, is the precursor for LPPG. The proposed pathway  is from the reduction of 
methylglyoxal or the aldol cleavage of fuculose-1-phosphate, which is then oxidized to lactate 
by the NAD+-dependent L-lactaldehyde dehydrogenase, CofA (Graupner et al., 2000; 
Grochowski et al., 2006) L-lactate is phosphorylated in a GTP-dependent manner to form 2-
phospho-L-Lactate (Graupner and White, 2001). The enzyme that catalyses this reaction is yet 
to be discovered. The final step involves the conversion of 2-phospho-L-Lactate to LPPG by 
the GTP-dependent enzyme 2-phospho-L-lactate guanylyltransferase (CofC) (Graupner et al., 
2000; Graupner and White, 2001; Guerra-Lopez et al., 2007)  
The second major step in the formation of F420 from Fo, is the addition of the glutamate 
tail to F420-0. The L-Glutamate residues are added in a sequential manner via γ-linkages 
catalysed through a GTP-dependent manner by the nonribosomal peptide synthase F420:γ-L-
glutamyl ligase CofE (Choi et al., 2001; Li, Graupner, et al., 2003; Nakano et al., 2004; Bashiri 
et al., 2016) The structure of the Archaeoglobus fulgidus CofE orthologue reveals a butterfly-
like homodimer that accommodates GTP and Mn2+ at the dimer interface. The addition of 
glutamate is catalysed by the phosphorylation of F420 at the terminal hydroxyl group of the 
lactate moiety or the terminal glutamate. The resulting acyl-phosphate is then subject to 
nucleophilic attack by the amino group of the incoming glutamate residue (Nocek et al., 2007). 
The Mycobacterial CofE orthologue, fbiB, has an N-terminus domain that is homologous with 
the A. fulgidus CofE, but the C-terminus domain is homologous to an enzyme of a FMN-
dependent nitroreductase family. The N-terminus alone of fbiB can only produce F420-1 and the 
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C-terminus alone cannot add any glutamate to F420-0, but both domains are needed to elongate 
the tail by more than one glutamate. (Bashiri et al., 2016). In some archaea, a terminal α-linked 
glutamate residue is also added by the enzyme, γ-F420-2:α-L-glutamate ligase (CofF) (Graupner 
and White, 2003; Li, Xu, et al., 2003). The number of glutamate residues on F420 is dependent 
of the species. This number can range from two or three residues in methanogens without 
cytochromes, four or five in methanogens with cytochromes, or five to seven in Mycobacteria 
(Gorris and Van der Drift, 1994; Bair et al., 2001). The reason for the difference in glutamate 
chains is unknown.  
 
  
Figure 1.11 F420 biosynthesis pathway.  Adapted from Greening et al. 2016. 
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1.4 F420-dependent enzymes 
 
F420-dependent enzymes mediate a wide range of redox reactions in biological systems 
(Hemmerich et al., 1970). The role of F420-dependent enzymes is well defined in methanogenic 
archaea as the primary catabolic electron carrier, but the physiological role in Mycobacteria is 
not well understood (Thauer et al., 2008; Greening et al., 2016). Despite this, studies of these 
enzymes have shown that there is a great diversity within Mycobacteria showing two distinct 
super families, which also include FMN/FAD binding proteins and vary in their catalytic 
mechanisms (Greening et al., 2016). Initial phylogenetic profiling revealed 28 F420-dependent 
enzymes present in M. tuberculosis, which were separated into three groups, luciferase-like 
monooxygenase, pyridoxamine 5’-phosphate oxidase, and deazaflavin-dependent 
nitroreductase family (Selengut and Haft, 2010). Further studies revealed that the pyridoxamine 
5’-phosphate oxidase, and deazaflavin-dependent nitroreductase families are part of the same 
flavin/deazaflavin oxioreductase super family, and the luciferase-like monooxygenases were 
renamed to Luciferase-like Hydride Transferases (LLHT) due to the observation that they are 
not oxygen dependent (Taylor et al., 2010; Ahmed et al., 2015; Greening et al., 2016). 
LLHTs can be defined by their TIM barrel fold (Fig. 1.13), and have a primary sequence 
of approximately 360 amino acids, and a molecular weight of approximately 38 kDa (Fisher et 
al., 1996; Kertesz et al., 1999; Chaiyen et al., 2001; Bashiri et al., 2008). FDORs are defined 
by their split β-barrel fold (Fig. 1.16), and have a primary sequence of approximately 150 
amino acids, and a molecular weight of approximately 15 kDa (Ahmed et al., 2015; Greening 
et al., 2016). The FDORs have been separated into three groups based on their sequence and 
function. These three groups include FDOR-A, FDOR-AA, and FDOR-B and are separated 
into several clades within each group (Fig. 1.12) (Ahmed et al., 2015). Molecular dynamics 
and binding studies of F420H2 bound to an FDOR  revealed that it is in its deprotonated state 
and the ribityl-phospholactyl region is stable while the oligoglutamate tail is more mobile 
(Ahmed et al., 2016; Mohamed et al., 2016).  
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1.4.1 Luciferase-like Hydride Transferases  
LLHT enzymes are known to bind different co-factors (Greening et al., 2016). F420-dependent 
LLHTs are defined by a conserved glycine residue, not found in other flavin-binding LLHTs, 
which binds the phosphate group of F420 without steric hindrance caused with other flavins. 
(Aufhammer et al., 2005). Within Mycobacteria, 48 F420-dependent LLHTs have been 
identified from a possible 86 LLHTs in M. smegmatis and 14 F420-dependent LLHTs from a 
possible 17 LLHTs are identified in M. tuberculosis (Selengut and Haft, 2010). Three F420-
dependent LLHTs in Mycobacteria have been functionally characterise, Rv2951c, which codes 
for a F420-dependent phthiodiolone ketoreductase (fPKR), Rv0132c, which codes for fHMAD, 
Figure 1.12 Sequence similarity network of FDOR in Mycobacteria.  Each node 
represents an individual protein and edges represent E-values between proteins generated 
by BLAST. Proteins from M. tuberculosis H37Rv and M. smegmatis strain MC2 155 are 
marked as black triangles and those structurally characterised in Ahmed et al., 2015 are 
marked as pink triangles. Structures solved in other studies are marked as blue triangles. 
Nodes are coloured based on their cofactor binding, F420 (green), FMN (yellow), FAD 
(Orange), Heme (red), and cyan (unknown). Nodes within the Red box belong to the FDOR-
A or AA clades and Nodes within the blue box belong to the FDOR-B clades. The node 
clustering represented here have a logE cutoff of −3. Adapted from Ahmed et al., 2015 
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and the most studied Mycobacterial LLHT, Rv0407 including the M. smegmatis orthologue, 
MSMEG_0777, which codes for FGD.  
 The reduction of F420 in most species, including Methanogens and Streptomyces, is 
achieved by the oxidation of NADPH to NADP+ by the enzyme, F420-dependent NADPH 
dehydrogenase (fno) (Berk and Thauer, 1997). FGD is the primary enzyme that reduces F420 to 
F420H2 in Mycobacteria, Nocardia, and Rhodococcus by the oxidation of Glucose-6-phosphate 
(G6P) to 6-phospogluconolactone (Purwantini and Daniels, 1996; Purwantini et al., 1997; 
Nguyen et al., 2016). The use of G6P over NADPH is thought to be due to the role of G6P as 
an electron store that FGD mobilises in response to oxidative stress (Hasan et al., 2010). This 
is evident by the high levels of G6P in Mycobacteria compared to other bacterial species,  is 
the preferred gluconeogenesis intermediate, and M. smegmatis is more sensitive to oxidative 
stress when FGD activity is knocked out (Hasan et al., 2010).  
   
 
Figure 1.13 Structure of the F420-dependent Luciferase-like Hydride Transferase, F420-
dependent glucose-6-phosphate dehydrogenase with F420 bound (PDB ID 3B4Y). The 
structure of FGD with F420 (yellow) bound, which exhibits the conserved TIM barrel fold 
that structurally defines the LLHT. Alpha helices are coloured teal and beta sheets are 
coloured magenta.   
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The crystal structure of FGD from M. tuberculosis revealed a homodimer, with each 
dimer composing an (α/β)8 TIM barrel. Although FGD shares only 20-30% amino acid 
sequence identity with other LLHT proteins from methanogens, this structure closely 
resembles the structure of F420-dependent secondary alcohol dehydrogenase (ADF), which 
reduces F420 through the oxidation of secondary alcohols, and F420H2-dependent methylene-
H4MPT reductase (MER), which reduces CH2=H4MPT to CH3-H4MPT by oxidising F420H2, 
(Bashiri et al., 2008; Greening et al., 2016). The binding of F420 into FGD revealed by the 
structure shows the isoallazine ring binding adjacent to a budge in a β-strand containing a non-
prolyl cis-peptide bond, and the poly-glutamate tail extending into the solvent. Binding of G6P 
is achieved by the sugar ring being sandwiched by a leucine and F420. The phosphate moiety is 
accommodated by a positively charged pocket provided by two lysines and an arginine. This 
pocket can also facilitate the binding of citrate that is competitive inhibitor of G6P. This pocket 
is not conserved in LLHT orthologues that do not exhibit FGD activity  (Bashiri et al., 2008; 
Nguyen et al., 2016). The reaction mechanism of FGD relies on a base, yet to be identified, to 
remove the hydrogen of the hydroxyl group on G6P that allows a hydride transfer onto the C5 
of the F420 molecule and forms the carbonyl group on G6P. A conserved glutamate of FGD acts 
as a general acid by donating a hydrogen onto the N2 of F420 forming F420H2 (Oyugi et al., 2016; 
Oyugi et al., 2017). 
fHMAD has 36 % sequence identity to FGD and was annotated as fgd2 in M. 
tuberculosis, but does not have FGD activity (Bashiri et al., 2012). Further studies revealed 
that the activity of fHMAD involves reducing F420 to oxidize hydroxyl-mycolic acid to keto-
mycolic acid, which is found in the cell wall of pathogenic Mycobacteria, thereby enhancing 
pathogenicity (Dubnau et al., 2000; Purwantini and Mukhopadhyay, 2013). Strains lacking 
oxygenated mycolic acids such as keto-mycolic acid, have altered envelope permeability, are 
more susceptible to antibiotics, and are attenuated in macrophages and mice (Yuan et al., 1998; 
Sambandan et al., 2013). The expression of fHMAD is controlled by the sigma factor, sigF, a 
transcription factor contributing to the pathogenesis of Mycobacteria and is upregulated when 
the cell is under stress and in the late stationary stage. M. tuberculosis is attenuated when sigF 
is knocked out (DeMaio et al., 1996; Geiman et al., 2004).  The N-terminus of fHMAD 
contains a twin–arginine translocation (TAT) motif, and a lipobox motif that mediates lipid 
modifications to anchor it to the cell envelope. This motif in LLHT is highly conserved in the 
M. tuberculosis complex (M. bovis, M. africanum, M. microti and M. canetti) and other 
pathogenic Mycobacteria orthologues, but is not found in non-pathogenic Mycobacteria 
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paralogues such as M. smegmatis (Bashiri et al., 2012). fHMAD is inhibited by des-nitro 
products formed from the reduction of pretomanid and delamanid (Stover et al., 2000; 
Matsumoto et al., 2006; Purwantini and Mukhopadhyay, 2013) 
The biosynthesis of the cell surface lipid, phthiocerol dimycocerosates (DIM A), relies 
on the reduction of phthiodiolone dimycocerosates (DIM B) by the F420-dependent LLHT, 
fPKR (Simeone et al., 2007; Purwantini et al., 2016). The synthesis of DIM A is a two-step 
process that starts with the reduction of the keto group of DIM B to an alcohol by F420H2 using 
fPKR (Fig. 1.14). This alcohol is methylated by the enzyme Rv2952, which is present in the 
same open reading frame (Purwantini et al., 2016). Diacylated polyketides, including DIM A 
and B, are found in the cell wall of pathogenic Mycobacteria and are virulence factors in M. 
tuberculosis that protects it from the early innate immune response of an infected host (Daffé 
et al., 1987; Guenin‐Macé et al., 2009; Day et al., 2014). DIM A and B are only present in 
slow growing Mycobacteria (Onwueme et al., 2005; Purwantini et al., 2016).   
Figure 1.14 Biosynthesis of phthiodiolone dimycocerosates (DIM B) to phthiocerol 
dimycocerosates (DIM A) in mycobacteria using the F420-dependent LLHT, fPKR. 
The biosynthetic pathway that converts phthiodiolone dimycocerosates (DIM B) to 
phthiocerol dimycocerosates (DIM A) in mycobacteria via the intermediate formation of 
phthiotriol dimycocerosates by the F420H2-dependent phthiodiolone ketoreductase (fPKR). 
fPKR is encoded by the gene Rv2951c in M. tuberculosis and by BCG_2972c in M. bovis 
BCG. The R1 groups represent the structures of the three classes of dimycocerosates. R2 
and R3 represent the extend structures found in all dimycocerosates. Adapted from 
Purwantini et al. 2016. 
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1.4.2 FDOR-A Enzymes 
The first identified FDOR-A, Rv3547, was renamed to deazaflavin-dependent nitroreductase 
(Ddn) due to its ability to reduce pretomanid in M. tuberculosis. It was identified by sequencing 
M. tuberculosis mutants resistant to pretomanid (Manjunatha et al., 2006). Phylogenetic 
profiling based on F420 biosynthesis revealed FDOR-As are present within M. smegmatis and 
M. tuberculosis, with further analysis revealing that this group is present in most actinobacteria 
(Selengut and Haft, 2010; Ahmed et al., 2015). Sequence similarity networks have categorised 
this subgroup into four subclades A1–A4 (Fig. 1.15), with A1, which includes Ddn, conserved 
in most Mycobacteria indicating evolutionary conservation and a significant physiological role 
while the A2-A3 subclades are poorly conserved throughout Mycobacteria (Ahmed et al., 
2015). 
 
 The proposed function of FDOR-As involves the reduction of quinones (Gurumurthy 
et al., 2013). It has been shown that they are able to reduce benzoquinone and naphthoquinone 
analogues, including a synthetic analogue of menaquinone, the endogenous quinone in 
Mycobacteria used in the electron transport chain, menadione (Gurumurthy et al., 2013; 
Figure 1.15 Sequence similarity network of FDOR-A in Mycobacteria. Each node 
represents an individual protein and edges represent E-values between proteins generated 
by BLAST. Proteins from M. tuberculosis H37Rv and M. smegmatis strain MC2 155 are 
marked as black triangles and those structurally characterised in Ahmed et al., 2015 are 
marked as pink triangles. Structures solved in other studies are marked as blue triangles. 
All nodes bind cofactor F420. The node clustering represented here have a logE cutoff of 
−28. Adapted from Ahmed et al., 2015 
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Ahmed et al., 2015). This activity, along with knockout data shows Mycobacteria are more 
susceptible to oxidative stress (see Section 1.3), and has led to the conclusion that the role of 
Ddn and the FDOR-As in Mycobacteria protects the cell from oxidative stress by reducing the 
level of semiquinones (Hasan et al., 2010; Gurumurthy et al., 2013). Although possible, there 
has been no direct evidence of this, as all knockout experiments eliminated F420 biosynthesis 
and not Ddn directly. Studies have shown that this quinone reductase activity is promiscuous 
throughout the other FDORs, although with lower activity than the FDOR-As (Gurumurthy et 
al., 2013; Jirapanjawat et al., 2016). FDOR-As have promiscuous activity with other organic 
compound including aflatoxins, coumarin, furanocoumarins, and arylmethanes but Ddn is the 
only FDOR shown so far that can reduce pretomanid and delamanid, (Ji et al., 2006; 
Manjunatha et al., 2006; Taylor et al., 2010; Gurumurthy et al., 2012; Jirapanjawat et al., 
2016).  
  
  
Figure 1.16 Structure of the FDOR-A, Ddn (PDB ID 3R5R) containing the conserved 
split beta-barrel fold with F420 (yellow) bound. The structure of Ddn with F420 (yellow) 
bound, which exhibits the conserved split beta-barrel fold that structurally defines the 
FDOR. Alpha helices are coloured teal and beta sheets are coloured magenta.   
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Five structures of FDOR-A have been solved, one from M. tuberculosis (ddn [3R5R]), two 
from M. smegmatis (MSMEG_2027 [4Y9I], and MSMEG_3356 [3H96]), and two orthologues 
from Nocardia farcinica (nfa33440 [3R5Y], and nfa18080 [3R5Z]) (Taylor et al., 2010; Cellitti 
et al., 2012; Ahmed et al., 2015). All the structures solved are monomeric and contain a split 
β-barrel fold while having less than 50% sequence identity between them (Fig. 1.17). F420 is 
housed by a positively charged groove, that is principally formed by lysine and arginine side-
chains, and the active site contains hydrophobic pocket formed by several aromatic or 
hydrophobic residues which differ between enzymes  (Taylor et al., 2010; Cellitti et al., 2012; 
Ahmed et al., 2015). The structure of Ddn lacked an N-terminus due to it causing aggregation 
and the full structures of nfa33440, and nfa18080 were solved in attempt to model it. The 
structures showed a helix packed against the core of the protein when F420 was bound and was 
disordered when F420 was not bound (Cellitti et al., 2012). The structure of Ddn, along with 
mutagenic studies, computational studies, and the lack of quinone activity with truncated 
MSMEG_2027, implies that the N-terminus tail is important for the function of FDOR-A 
(Cellitti et al., 2012; Ahmed et al., 2015; Mohamed et al., 2016).  
1.4.3 FDOR-AA Enzymes  
  
Figure 1.17 Sequence similarity network of FDOR-AA in Mycobacteria. Each node 
represents an individual protein and edges represent E-values between proteins generated 
by BLAST. Proteins from M. tuberculosis H37Rv and M. smegmatis strain MC2 155 are 
marked as black triangles and those structurally characterised in Ahmed et al., 2015 are 
marked as pink triangles. Structures solved in other studies are marked as blue triangles. 
All nodes bind cofactor F420. The node clustering represented here have a logE cutoff of 
−7.6. Adapted from Ahmed et al., 2015 
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FDOR-AA were first defined as FDOR-As that had the inability to reduce aflatoxins, coumarin, 
and furanocoumarins. Further phylogenetic analysis revealed two distinct clades within FDOR-
As (Lapalikar et al., 2012). One study has shown that the FDOR-AA, MSMEG_1981, can 
reduce arachidonic acid (Ahmed et al., 2015). Proteomic studies have revealed that these 
proteins in M. tuberculosis and M. smegmatis are membrane associated (Mawuenyega et al., 
2005; He and De Buck, 2010; de Souza et al., 2011) and bioinformatics studies have predicted 
enzymes to be associated with proteins that are involved in lipid synthesis and metabolism, i.e. 
cutinases, lipoproteins, and acyl-CoA synthetases (Ahmed et al., 2015). This has led to the 
hypothesis that FDOR-AAs are involved with lipid metabolism (Ahmed et al., 2015). 
Microarray data has shown four FDOR-AAs (MSMEG_1981, MSMEG_1077, 
MSMEG_3278, and MSMEG_3204) are upregulated in the presence of bedaquiline, which 
upregulates the glyoxylate cycle, a cycle that hijacks the citric acid cycle to allow fatty acids 
to be used as an energy source when the cell cannot use other carbon sources or to maintain 
redox balance (Kornberg, 1966; Hards et al., 2015). Sequence similarity networks have 
expanded the FRDOR-AA group into six clades (AA1-AA6). M. tuberculosis has proteins from 
AA2, AA4, and AA6 whereas M. smegmatis has proteins from AA1, AA3, AA5, and AA6 
(Ahmed et al., 2015). No FDOR-AA structure has been solved.  
1.4.4 FDOR-B Enzymes 
FDOR-Bs were first identified as FMN-dependent pyridoxine/pyridoxamine 5′-phosphate 
oxidases (PnPOx) due to their sequence similarity, but did not have any activity associated with 
PnPOx. (Selengut and Haft, 2010). Phylogenetic profiling re-classified seven PnPOxs in M. 
smegmatis and four in M. tuberculosis as F420-dependent PnPOx-like enzymes. This group was 
renamed to FDOR-B as it was expanded further with the discovery of these PnPOx-like 
enzymes and other related F420-dependent oxioreductases being able to reduce aflatoxins, but 
at a lower level than FDOR-A and were phylogenetically separate (Selengut and Haft, 2010; 
Taylor et al., 2010). Sequence similarity networks divided the FDOR-B class into twelve 
different functional clades, B1-B12, based on sequence (Fig. 1.18), and co-factor preference 
was confirmed by binding studies. The co-factor preference of clades B1-6 is F420 while the 
other clades co-factor preferences include, heme (B7), FAD (B8), FMN (B9), heme and FAD 
(B11) and B10 and B12, which have unknown cofactors (Ahmed et al., 2015).  
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 The function and physiological role of several FDOR-B are known. In Streptomyces, 
enzymes found in the FDOR-B1 are known to be involved in the biosynthesis of the antibiotics; 
tetracycline, oxotetracycline, and chlortetracycline (Wang et al., 2013).   The function of 
MSMEG_3880, and RV2074, found in FDOR-B4, are  F420-dependent biliverdin reductases, 
that reduces the heme oxidation product, biliverdin to bilirubin, a known antioxidant (Ahmed 
et al., 2016). The FDOR-B7, MSMEG_6519, was co-purified with biliverdin and when tested, 
MSMEG_6519 was able to oxidise heme to biliverdin (Ahmed et al., 2016). MSMEG_6519 is 
in a clade cluster containing HugZ, a heme oxygenase from Helicobacter pylori (Guo et al., 
Figure 1.18 Sequence similarity network of FDOR-B in Mycobacteria. Each node 
represents an individual protein and edges represent E-values between proteins generated 
by BLAST. Proteins from M. tuberculosis H37Rv and M. smegmatis strain MC2 155 are 
marked as black triangles and those structurally characterised in Ahmed et al., 2015 are 
marked as pink triangles. Structures solved in other studies are marked as blue triangles. 
Nodes are coloured based on their cofactor binding, F420 (green), FMN (yellow), FAD 
(Orange), Heme (red), and cyan (unknown). The node clustering represented here have a 
logE cutoff of −7.6. Adapted from Ahmed et al., 2015. 
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2008; Ahmed et al., 2016). The FDOR-B9, Rv2607, is a PnPOx, that oxidises pyridoxine 5′-
phosphate to pyridoxal 5′-phosphate (Mashalidis et al., 2011).  Despite the known function of 
some of the FDOR-B, they are known to have promiscuous activity. The FDOR-B3, Rv1155, 
is known to have biliverdin reductase activity, although at a reduced rate compared to Rv2074 
and MSMEG_3880. Reduced activity and being in a different clades has led to the hypothesis 
that Rv1155 has evolved a different function and catalyses the reduction of an alternative 
molecule yet to be identified (Ahmed et al., 2015; Ahmed et al., 2016). Other promiscuous 
activities of the FDOR-Bs include the ability to reduce aflatoxins, coumarin, furanocoumarins, 
arylmethanes, and quinones (Taylor et al., 2010; Lapalikar et al., 2012; Jirapanjawat et al., 
2016). 
 Several structures of FDOR-Bs have been solved and include the FDOR-B1 proteins 
rv2991 (PDB ID 1RFE) and MSMEG_3380 (PDB ID 3F7E), the FDOR-B2 protein 
MSMEG_6526 (PDB ID 4ZKY), the FDOR-B3 protein Rv1155 (PDB ID 4QVB with F420, 
1W9A without F420), the FDOR-B4 protein Rv2074 (PBD ID 5JAB with F420, 2ASF without 
F420), the FDOR-B7 protein MSMEG_6519 (PDB ID 5BNC), the FDOR-B9 protein Rv2607 
(PDB ID 2A2J), and the FDOR-B11 protein MSMEG_4975 (PDB ID 4YBN) (Safo et al., 
2001; Canaan et al., 2005; Biswal et al., 2006; Pédelacq et al., 2006; Taylor et al., 2010; 
Mashalidis et al., 2015; Ahmed et al., 2016). All FDOR-B structures solved contain a split β-
barrel fold similar to the FDOR-A despite having less than 30 % sequence identity and are 
homodimers, except Rv2991 (Fig. 1.19) (Greening et al., 2016). The F420 binding channels and 
substrate binding pockets of both the FDOR-A and FDOR-B enzymes occur in homologous 
regions although the identities of the residues involved are not conserved between them and 
FDOR-B require residues from both monomers to form the binding pocket and the groove that 
houses F420 (Taylor et al., 2010; Ahmed et al., 2015).  
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Figure 1.19 Structure of the FDOR-B, Rv2074 (PDB ID 5JAB) containing the 
conserved split beta-barrel fold with F420 (yellow) bound.  
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1.5 Thesis Outline 
 
This thesis is presented as a series or published, submitted, and draft journal articles with the 
manuscripts presented in the chapters below.   
1.5.1 Chapter outlines 
Chapter 2 presents a draft manuscript discussing the possible role of the nitroimidazole 
activating enzyme, Ddn, and effect of point mutations on its physiological and drug activating 
activity. This is shown by exploring the role of Ddn and F420 in the respiration of Mycobacteria 
by looking at the effect on the electron transport chain. The effect of point mutations is explored 
with directed mutagenesis, enzyme kinetics, and resistance towards nitroimidazoles in a 
clinical strain was tested. The evolution of point mutations in Ddn is discussed by assessing 
the phylogenies of sequenced tuberculosis stains. A strain that exhibited resistance to 
pretomanid in clinical cases was tested to understand the effect of the mutations on the ability 
of tuberculosis to be transmissible. I was the primary researcher of this study. 
Chapter 3 presents a draft manuscript that describes the function of the F420-dependent enzyme, 
MSMEG_6526. The role of MSMEG_6526 in Mycobacteria is explored through phenotyping 
of a knockout strain on various carbons sources. This is followed up with proteomics,, and 
metabolomics data to analyse the chemical differences in the phenotypes. Kinetics were used 
to confirm MSMEG_6526 substrate. Crystal structures of MSMEG_6526, and the orthologue 
from M. tuberculosis Rv0121c, were solved to elaborate the catalytic mechanism. I was the 
primary researcher of this study. 
Chapter 4 presents two publications that describes the function of select FDOR and the 
classification of the FDOR superfamily. The first publication uses bioinformatics, structural 
studies, binding assays, to further classify the three groups, FDOR-A, FDOR-AA, and FDOR-
B, into different clades. The function of each group is explored with activity discovered 
including quinone reduction, fatty acid reduction, and biliverdin reduction. The second 
publication describes the structure and function of a novel F420-dependent biliverdin reductase 
from M. tuberculosis, Rv2074. Kinetics and molecular dynamic simulations, using the solved 
structure with F420 bound, showed the function and the catalytic mechanism of biliverdin reduction 
by Rv2074. 
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Chapter 5 presents two publications that describe the promiscuous roles of FDOR in M. 
smegmatis. The first publication describes the role of F420 in detoxification, protecting 
Mycobacteria from a diverse range of antimicrobial compounds and detoxification. F420 and 
fgd knockout strains of M. smegmatis were used to show the increased effect of antimicrobials 
in the cell. This is further elaborated by kinetic data of a range of FDORs reducing these 
compounds. The second publication describes a range of compounds that FDORs from M. 
smegmatis can reduce and the common catalytic mechanism. Kinetic data of a range of FDORs 
reducing a range of different compounds is shown. Docking and mass spec data is used to 
identify the common catalytic mechanism. 
Chapter 6 presents a publication of a comprehensive literature review of the cofactors F420 and 
its precursor Fo in archaea and actinobacteria, including their role, biosynthesis and associated 
enzymes. The sections of the literature review relevant for the purposes of this thesis are 
highlighted in the paper introduction. 
Chapter 7 summarises the key outcomes of this thesis with a brief discussion on the role of F420-
dependent enzymes and the potential medical and biotechnology applications. 
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2.1 Introduction 
 
The nitroimidazoles pretomanid and delamanid are promising prodrugs against M. tuberculosis 
(Stover et al., 2000; Matsumoto et al., 2006). They have a dual mode of action with the release 
of nitrous oxide, which causes respiratory poisoning, and the inhibition of keto-mycolic acid 
biosynthesis, a key component of the mycobacterial cell wall (Singh et al., 2008; Purwantini 
and Mukhopadhyay, 2013). The dual mode of action is achieved through the reduction of 
pretomanid or delamanid by the F420-dependent oxidoreductase Ddn, a quinone reductase that 
normally protects the cell from oxidative stress (Ujjini H Manjunatha et al., 2006; Gurumurthy 
et al., 2013). In vitro resistance towards nitroimidazoles has been found to result from 
mutations in ddn, enzymes of the F420 biosynthesis pathway, and the F420 reducing enzyme, fgd 
(Haver et al., 2015). Acquired resistance towards nitroimidazoles in clinical strains have been 
found. This resistance arose through mutations in fbiA, which is involved in F420 biosynthesis, 
and fgd (Bloemberg et al., 2015; Hoffmann, Kohl, et al., 2016). Although the mode of action 
of nitroimidazoles, and the mechanism by which resistance occurs is understood, mutations to 
Ddn and its impact on cell fitness, and how it effects transmissible resistance has not been 
studied. Clinical strains that have mutations in Ddn with no exposure to nitroimidazoles have 
not been studied for resistance towards pretomanid and delamanid. 
 To further understand the impact of nitroimidazole resistance through mutations to ddn, 
this chapter presents a manuscript that expands our understanding of the role of Ddn in 
Mycobacteria, and examines the cost of fitness caused by mutations in ddn and what effect it 
has on transmissible resistance. This is achieved though examining the effect of F420H2 and 
Ddn on the electron transport chain using oxygen consumption assays. Activity of Ddn and 
Ddn orthologues with their proposed physiological substrate, menaquinone, was determined. 
To examine the cost of fitness of Ddn mutants, activity with a menaquinone analogue and 
nitroimidazoles was measured. MIC values of pretomanid and delamanid were measured with 
M. marinum, and M. tuberculosis strains that were expected to be resistant to nitroimidazoles 
through our activity screen. Docking experiments were used to understand the difference in the 
MIC values between delamanid and pretomanid. This chapter also examines the natural 
sequence variation within ddn and ddn orthologues using phylogenetic studies of M. 
tuberculosis clinical strains that have been sequenced. The activity of Ddn mutants that were 
of interest from the phylogenetic studies were determined to predict drug resistance.   
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2.2 The evolution of nitroimidazole antibiotic resistance in 
Mycobacterium tuberculosis  
 
The chapter contains the following paper draft:  
 
The evolution of nitroimidazole antibiotic resistance in Mycobacterium tuberculosis  
Brendon M. Lee, Livnat Afriat-Jurnou, Brian F. Forde, Htin Lin Aung, Kiel Hards, Sacha J. 
Pidot, F. Hafna Ahmed, A. Elaaf Mohamed, Matthew C. Taylor, Nicholas West, Timothy P. 
Stinear, Chris Greening, Scott A. Beatson, Gregory M. Cook, Colin J. Jackson 
Current status of paper:  Draft   
Brendon Lee cloned, expressed and purified Ddn, Ddn mutants, and Ddn orthologues, 
performed all enzymatic assays, oxygen consumption assays, sequence alignment of Ddn 
orthologues, docking experiment and designed Figures 1-3, S1, and Tables 1-2, S1. Livnat 
Afriat-Jurnou helped design the experiments and did some initial assays. Scott Beatson and 
Brian Forde performed the phylogenetic analysis and created Figure 4 and Tables S2-4. Htin 
Lin Aung performed the MIC experiment for the M. tuberculosis N0008 strain with pretomanid 
and delamanid. Kiel Hards help design the oxygen consumption assay, supervised Brendon to 
perform them and helped edit Figure 1b and c. Sacha Pidot performed the MIC experiments 
for M. Marinum. Hafna Ahmed help designing the experiments and supervised Brendon 
performing them. Elaaf Mohammad assisted with the docking experiments. Nicholas West 
provided intellectual insight. Matthew Taylor, Timothy Stinear, Brian Forde, Gregory Cook, 
and Colin Jackson supervised students. Brendon Lee and Colin Jackson wrote the paper with 
input from other authors.  
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Abstract 
 
The nitroimidazole prodrugs delamanid and pretomanid are in advanced clinical development 
to treat tuberculosis (TB). These drugs comprise one of only two new classes of antitubercular 
agents to be approved for use within the last 50 years and are active against resistant strains. 
They are administered as prodrugs, which undergo reductive activation by the deazaflavin 
(F420H2) dependent nitroreductase (Ddn). To ensure these drugs remain effective for as long as 
possible, it is important that we establish how resistance to these new drugs could develop after 
their introduction. Here, we identify mutations in Ddn that can prevent pretomanid activation 
without significantly affecting its physiological role, thereby potentially conferring 
transmissible resistance. Analysis of ~15,000 sequenced M. tuberculosis genomes revealed 
~1.5% of M. tuberculosis strains have non-synonymous mutations in the ddn gene. Notably, 
several of these were shown to prevent pretomanid activation in vitro. We confirmed that a 
transmissible M. tuberculosis isolate from the hypervirulent Beijing family already possesses 
one such mutation and is resistant to pretomanid, even though it has never been exposed to 
pretomanid. Notably, delamanid was still effective against this strain, which is consistent with 
structural analysis that indicates delamanid and pretomanid bind to Ddn differently. We suggest 
that SNPs identified in this work be monitored for informed pretomanid treatment and to slow 
the emergence of resistance. 
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Introduction 
 
Tuberculosis is currently the leading cause of death from infectious disease worldwide (WHO, 
2016). Limitations of current treatment regimens, combined with the rapid emergence of 
multidrug resistant tuberculosis (MDR-TB) strains, necessitate the development of new drugs. 
Three new antitubercular agents are now in advanced clinical development: bedaquiline 
(Andries et al., 2005) and delamanid (Matsumoto et al., 2006), which have been approved for 
MDR-TB treatment (Diacon et al., 2009; Gupta et al., 2015), and pretomanid (Stover et al., 
2000), which is part of regimens in phase III trials (Dawson, Diacon, Everitt, Niekerk, Donald, 
Burger, Schall, Spigelman, Pym, Groote-bidlingmaier, and Mendel, 2015). The 
nitroimidazoles, delaminid and pretomanid, are prodrugs that are reductively activated in an 
F420H2-dependent reaction in Mycobacterium tuberculosis by the deazaflavin-dependent 
nitroreductase (Ddn) (Singh et al., 2008; Cellitti et al., 2012). An initial hydride transfer step 
from the F420H2 cofactor leads to their decomposition into des-nitro products and releases 
reactive nitrogen species (Singh et al., 2008) that elicit a bactericidal mode-of-action linked to 
respiratory poisoning and inhibition of mycolic acid synthesis (Singh et al., 2008; Manjunatha 
et al., 2009; Cellitti et al., 2012). 
 
Due to pretomanid and delamanid being prodrugs that require activation, mutations that knock-
out the activity of Ddn or the biosynthesis of the enzyme’s cofactor (F420), could confer 
resistance. However, the fitness cost of such knockouts would be considerable given that F420 
has been shown to be conditionally essential to the survival of M. tuberculosis, being used by 
at least 28 different enzymes (Greening et al., 2016), and playing important roles in hypoxic 
survival, protection against oxidative and nitrosative damage, and in allowing M. tuberculosis 
to evade the host immune system (Purwantini and Mukhopadhyay, 2009; Hasan et al., 2010; 
Gurumurthy et al., 2013). Ddn is highly conserved across almost all species of mycobacteria 
(except Mycobacterium leprae), suggesting its physiological role is under strong evolutionary 
selection (Ahmed et al., 2015). It has been hypothesised that Ddn serves as an F420H2-
dependent menaquinone reductase given its membrane localisation (de Souza et al., 2011) and 
catalytic activity with the synthetic quinone analogue menadione (Gurumurthy et al., 2013), 
although further work is required to fully define its physiological role.  
 
Despite the recent introduction of nitroimidazoles, cases of acquired clinical resistance, i.e. 
resistance that occurs during the long treatment of TB infection but is not necessarily 
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transmissible, have already been reported (Bloemberg et al., 2015; Hoffmann, Kohl, et al., 
2016). Acquired resistance to pretomanid and delamanid can occur through genetic changes 
that cause loss of function within the biosynthetic pathway for F420 production or in the F420-
dependent glucose 6-phosphate dehydrogenase (FGD) that catalyzes F420 reduction to F420H2 
(Choi et al., 2001; Ujjini H Manjunatha et al., 2006). Laboratory studies have also shown that 
genetic changes that abolish Ddn activity can also confer resistance (Haver et al., 2015; 
Hoffmann, Borroni, et al., 2016). While such mutations will compromise treatments for already 
infected individuals, transmission of M. tuberculosis to healthy individuals after these genetic 
changes has never been documented and is unlikely given the severe fitness costs incurred by 
them.  
 
In this study, we have analysed Ddn orthologs from related mycobacteria to identify natural 
sequence variation that can make mycobacteria resistant to pretomanid, as well as analysing 
the genomes of ~15,000 M. tuberculosis isolate to identify the spectrum of naturally occurring 
non-synonymous Ddn polymorphisms. Mutations were then made to Ddn at positions 
identified in orthologs and through analysis of non-synoymous polymorphisms to analyse their 
effect on the native activity (quinone reduction) and pretomanid activation. This identified 
several mutations that can prevent pretomanid activation; a hypervirulent strain of TB from 
Vietnam that contains one such mutation (and has never been exposed to pretomanid) was 
shown to be resistant to pretomanid. Curiously, delamanid activation was not affected, which 
is consistent with structural analysis that suggests it binds to the active site of Ddn in an 
alternative orientation.  
 
Results 
 
The physiological role of Ddn. To investigate the potential for mutations in Ddn to confer 
transmissible resistance, it was first necessary to define its physiological role in M. 
tuberculosis. A role for Ddn as a quinone reductase was suggested based on activity with the 
synthetic quinone analogue menadione (Gurumurthy et al., 2013). Here, we show that purified 
Ddn catalyzes the F420H2-dependent reduction of menaquinone-1 in vitro with moderate 
efficiency (kcat/KM = 8.6 x 10
2 M-1 s-1) and physiologically relevant affinity (KM
 = 22.4 ± 3.8 
µM) ((Figure 1A; Table S1); despite a lower rate constant compared to menadione, the  
conversion rate is likely to differ in the native environment of the M. tuberculosis cell where 
Ddn and menaquinone are co-localised at the cell membrane in higher concentrations compared 
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to our in vitro assays (Sinha et al., 2005). Ddn orthologs encoded by Mycobacterium smegmatis 
(MSMEG_2027, MSMEG_5998) were also able to reduce menaquinone, suggesting Ddn 
orthologs have similar physiological roles across the genus (Table 1). Indeed, Ddn and its 
orthologs are highly conserved and abundant throughout mycobacteria (Ahmed et al., 2015).  
 
We then investigated whether the menaquinone reductase activity of Ddn was coupled to the 
mycobacterial respiratory chain by comparing the rates of respiratory oxygen consumption of 
M. smegmatis in the presence and absence of a complementation vector expressing ddn. We 
observed that the addition of Glucose 6-phosphate (G6P), F420, and FGD, which catalyzes the 
reduction of F420 to F420H2 for use by F420H2-dependent enzymes such as Ddn (Oyugi et al., 
2016), resulted in a 1.4-fold increase in oxygen consumption by mycobacterial membranes 
when the membranes are activated by NADH (Figure 1B). This was dependent on the presence 
of cytochrome bd oxidase, which utilizes reduced menaquinone (i.e. menaquinol) as an electron 
source (Figure 1B). The rate of NADH oxidation was not affected by the addition of F420H2, 
which implies endogenous NADH-dependent oxidases do not contribute to the increased 
oxygen consumption (Figure 1C). This supports the idea that mycobacteria can couple F420H2 
oxidation to O2 reduction through the respiratory chain via cytochrome bd oxidase, and 
provides the first evidence that bacteria can use F420H2 as a respiratory electron donor. We also 
observed that the extent of oxygen consumption was significantly higher in membranes 
purified from the ddn expressing strain, relative to empty vector controls (Figure 1B), which 
suggest Ddn serves as a menaquinone reductase in the respiratory chain, with the remaining 
stimulation attributable to F420H2 oxidation by native Ddn homologs of M. smegmatis.  
 
Natural sequence variation in Ddn can prevent pretomanid activation. To investigate the 
effect of natural sequence variation within Ddn from mycobacteria, we purified Ddn orthologs 
from M. tuberculosis, M. marinum, M. smegmatis, M. vanbaalenii, M. avium and M. ulcerans 
(Figure 2A&B). All Ddn orthologs catalyzed the reduction of menadione at physiologically 
relevant levels, consistent with a shared physiological function under selective pressure, but 
only Ddn from M. tuberculosis and its ortholog from M. marinum could activate pretomanid 
(Figure 2B; Table 2). This demonstrates that the native Ddn activity can exist in M. smegmatis, 
M. vanbaalenii, M. avium and M. ulcerans in the absence of nitroimidazole reductase activity.  
 
Having demonstrated that sequence polymorphisms in the active site of Ddn and its orthologs 
can result in substantial loss of pretomanid reduction activity in vitro, we investigated whether 
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this corresponded to differences in nitroimidazole susceptibility in vivo. M. tuberculosis 
H37Rv and M. marinum, which were the only two strains that encoded Ddn orthologs with in 
vitro pretomanid activation activity, were found to be susceptible to pretomanid and delamanid 
treatment (Table 3). In contrast, species from which Ddn orthologs did not exhibit pretomanid 
activation activity (M. smegmatis, M. ulcerans, M. avium) have been shown to be naturally 
resistant to pretomanid (Stover et al., 2000; Ji et al., 2006; Upton et al., 2015). 
 
Genome sequences of M. tuberculosis were then searched to identify nonsynonymous sequence 
polymorphisms within the ddn gene. We found that around 1.5% (218/14,876) of M. 
tuberculosis genomes screened had a non-synonymous mutation in ddn (Table S2). Altogether, 
we identified 47 non-synonymous substitutions and 2 deletions in ddn distributed throughout 
the M. tuberculosis phylogeny. Among these mutations, a Trp88Arg mutation was previously 
associated with resistance in a laboratory evolution study (Haver et al., 2015). Three other 
polymorphisms are located close to the active site of Ddn: Ser22Leu, Ser78Tyr, and Lys79Gln. 
Notably, the Ser78Tyr polymorphism is found in the genome of N0008 (Comas et al., 2013), 
a clinical isolate of the hypervirulent Beijing family (Hoffmann, Kohl, et al., 2016), and in two 
other genomes (ERR718320 and ERR751847) that are phylogenetically closely related, which 
indicates a shared evolutionary history (Figure 1). The effects of the Ser22Leu, Ser78Tyr, 
Lys79Gln and Trp88Arg mutations were tested in vitro (Figure 2C; Table 2). Ser22Leu and 
Lys79Gln abolished pretomanid activation with no significant loss of menadione reduction, 
Ser78Tyr abolished pretomanid activation with some loss of menadione reduction although 
there was still significant activity, while Trp88Arg abolished both activities. 
 
We obtained the hypervirulent Beijing strain R0008 (the other strains were not available) to 
investigate whether the Ser78Tyr mutation in the ddn gene, which results in loss of pretomanid 
reduction in vitro (Figure 2C), corresponded to resistance to pretomanid in vivo. No other 
genetic changes previously observed to cause nitroimidazole resistance were apparent in the 
genome of R0008. We observed a 64-fold increase in minimum inhibitory concentration (MIC) 
of R0008 (256 µg mL-1) compared to H37Rv (4 µg mL-1). This suggests SNPs, such as 
Ser78Tyr in the ddn gene can confer resistance to pretomanid and confirms that transmissible 
pretomanid-resistant populations of M. tuberculosis harbouring this SNP already exist.  
 
The potential for spontaneous pretomanid resistance mutations to arise in M. 
tuberculosis. Previous studies have used laboratory evolution/engineering to assess 
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investigating the potential for pathogens to evolve resistance to antibiotics (Orencia et al., 
2001; Hart et al., 2016). We took a similar approach here, using structure-guided mutagenesis 
to investigate the robustness of the nitroreductase activity of Ddn to mutations. We used the 
structure of Ddn to identify which residues are present in the binding site that would 
immediately effect the binding and reduction of both quinones and pretomanid. The binding 
site of Ddn has been defined over several studies (Cellitti et al., 2012; Ahmed et al., 2015; 
Mohamed et al., 2016), identifying a number of polar amino acids within the active site that 
contribute to activity, particularly Tyr65, Ser78, Tyr130, Tyr133, Tyr136. Three of the active 
site residues are highly conserved among the Ddn orthologs tested here, while Tyr65 and 
Tyr133 are significantly more variable (Fig. 2A, Fig. 3A). We mutated these five residues to a 
range of different amino acids, including those already observed in various Ddn orthologs or 
accessible via single nucleotide changes (Fig. 2C,D). Across the 24 mutants tested, 14 resulted 
in complete loss of pretomanid activation while retaining significant levels of the native activity 
(Table S2). In other words, while the native activity was not greatly affected by sequence 
variation, the nitroreductase activity was extremely sensitive and could be lost relatively easily. 
Among the Tyr65 mutants, Tyr65Phe was neutral for both activities, but Tyr65Leu and 
Tyr65Cys resulted in loss of pretomanid activity. All of the tested mutations of Ser78 (Thr, 
Ala, Cys, Val, Tyr) resulted in loss of pretomanid activity. Mutation of Tyr130 to Trp, Cys, 
Ser, His, Phe, Asp or Asn did not affect pretomanid activation, relative to the menadione 
activity. Mutations of Tyr133 and Tyr136 behaved similarly to mutations of Tyr65, where the 
Tyr to Phe mutation had no effect on catalysis, but mutations to residues with less structural 
similarity (Leu, Met, Trp, Thr, Ser, Glu) resulted in complete loss of pretomanid reductases 
activity, while retaining activity towards menadione.  
 
We used our genomic survey of ddn in M. tuberculosis to estimate the level of sequence 
variation in ddn and predict the rate at which mutations could spontaneously arise at one of the 
positions identified in this work. This revealed that virtually every distinct strain of M. 
tuberculosis contains SNPs in ddn; given the number of cells present in a typical patient 
(millions), and the number of infected individuals (millions), under conditions of selective 
pressure (the administration of pretomanid), genetic selection for mutations around the active 
site of Ddn that prevent pretomanid activation could occur rapidly. 
 
The molecular basis of resistance. The effects of the mutations shown in Fig. 2C are generally 
consistent with our mechanistic understanding of Ddn from mutagenesis and computational 
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simulation (Cellitti et al., 2012; Mohamed et al., 2016). Ser78 is thought to interact with the 
nitro-moiety of pretomanid and to stabilize the transition state; none of the Ser78 mutants 
retained pretomanid activity, suggesting this interaction is particularly important. Tyr65, 
Tyr130, Tyr 133 and Tyr136 are known to form a hydrophobic wall in the binding site, which 
can move during the catalytic cycle to shield the active site from solvent and thereby facilitate 
pretomanid reduction (Mohamed et al., 2016). This is in keeping with the observation that Tyr 
to Phe mutations at positions 65, 133 and 136 were essentially neutral, whereas substitution 
with other residues (Met, Leu, Cys, Trp, Thr, Ser, Glu) led to loss of pretomanid activation. 
Menadione is less susceptible to loss of activity through mutation, which is consistent with 
work showing native activities are substantially more robust to mutation than promiscuous 
activities (such as pretomanid activation) (Aharoni et al., 2005), as well as the observation that 
menadione is more chemically labile. Trp88 is known to be involved in F420 binding (Cellitti 
et al., 2012) and the Trp88Arg mutation that lead to a loss of activity with both menadione and  
pretomanid would be due to the inability to bind F420. 
 
Delamanid is less susceptible to resistance mutations. Surprisingly, we observed that the 
susceptibility of R0008 to delamanid was not affected by the Ser78Tyr sequence 
polymorphism. We therefore tested the in vitro activity of Ddn with delamanid as a substrate 
for both wild-type Ddn and the Ser78Tyr mutant. Owing to the low solubility of delamanid, 
full Michaelis-Menten kinetics could not be obtained, but we were able to measure specific 
activity, revealing similar substrate reduction activity for both the wild-type and mutant protein 
(Fig . S1; Table 3). To better understand the molecular basis for the insensitivity of delamanid 
to the Ser78Tyr mutation, we docked both pretomanid and delamanid into the crystal structure 
of Ddn. The in silico docking of both delamanid and pretomanid revealed ten different poses 
for each drug. For this study, we removed any pose where the drug was bound to the surface 
of Ddn and not bound into the binding site. To compare the binding of the two drugs we chose 
the poses with the bicyclic-nitroimidazole group present in the binding site with the lowest 
binding energy score. The binding of delamanid was revealed to be different than that of 
pretomanid (Fig. 3C,D), with the dual methyl and phenoxy-methyl substituents on the oxazole 
ring preventing delamanid binding to the deazaflavin ring in a ring-stacked orientation, as is 
seen in pretomanid, which has a singly-substituted oxazine ring in an analogous position. This 
results in a change in the angle at which the nitroimidazole group interacts with the cofactor, 
binding in a perpendicular orientation that results in an increase in the distance to Ser78. Thus, 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
44 
 
there appears to be structural basis for the different effects of the Ser78 mutation on delamanid 
activity in vitro and in vivo. 
 
Discussion 
 
The fitness trade-off between resistance and native function. Given the conservation Ddn-
like genes throughout mycobacteria, its activity with menaquinone and its role in respiration, 
it is likely that mutations that completely knock-out Ddn activity (such as the introduction of 
stop or large genetic deletions) will result in substantial loss of fitness given it is involved in 
both redox and energy metabolism. Loss of this function is likely to have severe consequences 
to bacterial fitness, given the bactericidal effects of inhibiting mycobacterial respiration 
(Diacon et al., 2009; Cook et al., 2014; Hards et al., 2015; Lamprecht et al., 2016). Indeed, 
phenotypic studies have linked Ddn to maintaining redox balance in response to hypoxia and 
treatment with first-line antimycobacterial drugs (Gurumurthy et al., 2013). 
 
 We have investigated the likelihood that mutations to M. tuberculosis Ddn will result in loss 
of pretomanid activation activity without substantial disruption of the native activity. 
Extending our in vitro measurements to in vivo measurement of MICs revealed that Ddn 
orthologs from related species and clinical isolates of M. tuberculosis that harbor certain 
differences within the active site do not efficiently activate pretomanid, resulting in antibiotic 
insensitivity. These results have important implications for the management of nitroimidazole 
administration in order to prevent or slow the development of resistance: if pretomanid is 
clinically administered in regions in which the R0008 strain is endemic, natural selection will 
drive selective sweeps in the ddn gene towards Ser78Tyr variants. Moreover, the chances of 
spontaneous mutation of Ddn in currently sensitive strains is significant, given our observation 
of the number of single nucleotide mutations that can knock out pretomanid activity. Given 
that the clinical isolate R0008 is highly transmissible, it is likely that other Ddn variants in 
which pretomanid activity can be abolished without substantial loss of the native activity will 
also be transmissible owing to minimal loss of fitness due to the mutations. Thus, fitness-
neutral Ddn mutations are likely to be the main route through which transmissible clinical 
pretomanid resistance spread.  
 
Our findings have broad implications for the continued clinical development of nitroimidazole 
antitubercular agents. Through two phase III clinical trials, the TB Alliance are currently 
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evaluating combination therapies using pretomanid; a trial with the three-drug PaMZ regimen 
(pretomanid, moxifloxacin, pyrazinamide) is on hold and a replacement trial with the four-drug 
BPaMZ regimen (incorporating bedaquiline) has been initiated (Murray et al., 2016). If 
pretomanid is clinically approved, we advise intensive monitoring of ddn polymorphisms to 
ensure informed drug administration and allow interventions that will avoid spreading of 
transmissible resistance. Our findings indicate that delamanid binds to Ddn in a different 
conformation than pretomanid does, suggesting that combination therapy of both 
nitroimidazoles could help prevent the evolution and spread of resistance (since the 
simultaneous loss of both activities will be less likely to result from single amino acid 
substitution). Further studies on how delamanid and pretomanid are activated in the M. 
tuberculosis cell will inform the development of improved nitroimidazole therapies and testing 
of a broad range of nitroimidazole analogs against a panel of Ddn variants could help to identify 
compounds for which resistance is less likely to evolve.  
 
Materials and Methods 
 
Plasmid construction and point mutation. The E. coli codon optimised sequences for Ddn 
from M. tuberculosis, MSMEG_5998 from M. smegmatis, MMAR_5035 from M. marinum, 
MVAN_5261 from M. vanbaalenii, MAV_0613 from M. avium, and MUL_4109 from M. 
ulcerans were purchased as gene strings from ThermoFisher Scientific (Massachusetts, USA) 
and cloned into the expression vector pMAL-c2X using Gibson assembly (Gibson et al., 2009). 
All mutations to Ddn were made by site-directed mutagenesis using Gibson assembly (Gibson 
et al., 2009). Construction of MSMEG_2027 and FGD has been described previously (Bashiri 
et al., 2008; Lapalikar et al., 2012) . For work in M. smegmatis the E. coli optimized genes 
were not used but instead the Ddn gene was amplified from M. tuberculosis DNA using the 
primers GTACTGCAGATGCCGAAATCTCCACCGCG, and 
GTAAAGCTTCTACGGTTCACAAACAACAATCGGAATG. The amplified DNA and 
pMV261 vector were cut using the Fast Digest enzymes PstI, and HindIII from ThermoFisher 
Scientific (Massachusetts, USA) and ligated together using T4 DNA ligase from New England 
Biolabs (Massachusetts, USA). 
 
Protein expression and purification. MSMEG_2027 was expressed and purified as 
previously described (Ahmed et al., 2015). Ddn, Ddn mutants, and Ddn orthologs were 
transformed into E. coli BL21 (DE3) cells and grown on LB agar containing 100 µg/ml 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
46 
 
ampicillin. Single colonies were picked and inoculated in LB media with 100 µg/ml ampicillin. 
Starter cultures were grown overnight and diluted 1/100 and grown at 37 °C until OD = 0.4. 
Cultures were induced with IPTG to a final concentration of 0.3 mM, and grown for 3 h at 25 
°C. Cells were harvested by centrifugation at 8,500 × g for 20 minutes at 4 °C and resuspended 
in lysis buffer (20 mM Tris-Cl, pH 7.5, 200 mM NaCl) and lysed by sonication using an Omni 
Sonicator Ruptor 400 (2 x 6 min. at 50% power). The soluble extract was obtained by 
centrifugation at 13,500 × g for 1 h at 4 °C. The protein was purified using amylose resin (NEB) 
using the provided protocol. Briefly the lysate was passed over the amylose resin and washed 
with 12 column volumes of lysis buffer. The protein was eluted using elution buffer (same as 
lysis buffer but with 10 mM maltose). Samples were frozen at -80 °C in 20 mM tris pH 7.5, 
200 mM NaCl, 10 mM maltose, and 10% glycerol.  
 
FGD was expressed and purified as described by Bashiri et al. (Bashiri et al., 2008), with minor 
modifications. FGD was transformed into E. coli BL21 (DE3) cells and grown on LB agar 
containing 100 µg/ml ampicillin. Single colonies were picked and inoculated in Terrific Broth 
(TB) (Sambrook et al., 1989) with 100 µg/ml. ampicillin. Starter cultures were grown overnight 
and diluted 1/100 into auto-induction media (20 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl, 6 
g/l Na2HPO4, 3 g/l KH2PO4, 6 ml/l glycerol, 2 g/l lactose, 0.5 g/l glucose, 100 mg/ml 
ampicillin) and grown at 30 °C for 24 h. The cells were harvested by centrifugation at 8500 g 
for 20 min at 4 °C and resuspended in lysis buffer (20 mM NaPO4 pH 8, 300 mM NaCl, 25 
mM imidazole) and lysed by sonication using an Omni Sonicator Ruptor 400 (2 x 6 min at 50% 
power). The soluble extract was obtained by centrifugation at 13500 g for 1 h at 4 °C. The 
soluble fraction was filtered and loaded 5-ml HisTrap HP column (GE Healthcare) and washed 
with lysis buffer. The protein was eluted with elution buffer (lysis buffer with 250 mM 
imidazole). The purified protein was dialyzed in 50 mM Tris-Cl, pH 7, 200 mM ammonium 
sulphate. Samples were frozen at -80 °C in 50 mM Tris-Cl, pH 7, 200 mM ammonium sulphate, 
and 10% glycerol. 
 
Membrane purification. M. smegmatis mc2155 wild type (Snapper et al., 1990), M. 
smegmatis mc2155 with a kanamycin cassette disruption of the cydA gene (Kana et al., 2001), 
and M. smegmatis mc2155 transformed with empty vector pMV261 or pMV261-Ddn were all 
grown on LB agar supplemented with 0.05% (v/v) Tween 80. Single colonies were picked and 
grown in Hartmans–de Bont (HdeB) medium supplemented with 25 mM glycerol and 0.05% 
(v/v) Tween 80 until an OD of 0.4 to 0.8. Cultures were diluted to an OD of 0.005 in 500 ml 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
47 
 
of HdeB and grown for 72 h with agitation (200 rpm) at 37 °C. Cultures were harvested by 
centrifugation at, 5,000 × g for 15 min at 4 °C and resuspended in lysis buffer (10 mM HEPES, 
pH 7.5, 200 mM KCl, 5 mM MgCl2, 1 mM PMSF, and 1 mg DNase), homogenised on ice, and 
passed through a French pressure cell 3 times at 20,000 psi. Unbroken cells were removed by 
centrifugation at 10,000 × g for 10 mins at 4 °C. The membranes were isolated by 
ultracentrifugation at 150,000 × g for 45 mins at 4 °C and resuspended in working buffer (10 
mM HEPES, pH 7.5, 200 mM KCl, 5 mM MgCl2). The protein concentrations of the 
membranes were measured by BCA assay (Pierce) against BSA standards. 
 
Enzymatic assays. F420 was purified from M. smegmatis mc
24517 as described by Ahmed et 
al.(Ahmed et al., 2015) F420 was reduced overnight with 10 µM FGD and 10 mM glucose-6-
phosphate in 20 mM Tris-CL, pH 7.5 under anaerobic conditions. FGD was removed by spin 
filtration in a 1 mL 10 K MWCO spin filter (Millipore) and used F420H2 within 8 hours. Enzyme 
assays were performed according to Ahmed et al. (Ahmed et al., 2015; Jirapanjawat et al., 
2016) in 200 mM Tris-HCl, pH 7.5, 0.1 % Triton X-100, 25 µM F420H2, and varying amounts 
of substrate at room temperature. Enzyme concentrations used were between 0.1 µM and 1 
µM. Activity was monitored following the oxidation of F420H2 which was measured 
spectrophotometrically at 420 nm (ε = 41,400 M−1 cm−1) (Purwantini et al., 1992)(Purwantini 
<i>et al.</i>, 1992)(Purwantini <i>et al.</i>, 1992)(Purwantini <i>et al.</i>, 
1992)(Purwantini <i>et al.</i>, 1992)(Purwantini <i>et al.</i>, 1992)(Purwantini <i>et 
al.</i>, 1992)(Purwantini <i>et al.</i>, 1992)(Purwantini <i>et al.</i>, 1992)(Purwantini 
<i>et al.</i>, 1992) and a Michaelis–Menten curve of best fit was used to calculate KM and kcat. 
Specific enzymatic activity with delamanid was measured using fluorescence 
(excitation/emission: 400 nm/470 nm). Assays were prepared the same as above, using 10 µM 
delamanid and 10 % DMSO in the reaction to solubilize the substrate. 
 
Measurement of oxygen consumption. To determine the rate of oxygen consumption, assays 
were performed as described by Pecsi et al. (Pecsi et al., 2014) in 10 mM HEPES, pH 7.5, 200 
mM KCl, and 5mM MgCl2 at 37 °C with M. smegmatis membranes that had a protein 
concentration of 0.5 mg/ml, 200 µM NADH, 1 mM glucose-6-phosphate, and 25 µM F420 and 
2.5 µM FGD where stated. The rate of oxygen consumption was measured using a model 10 
Clark-type oxygen electrode (Rank Brothers Ltd., Cambridge, England) linked to a PicoLog 
ADC-20 data logger that was calibrated with saturated sodium dithionite. 
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NADH oxidation assay. The rate of NADH oxidation was determined using purified M. 
smegmatis membranes that had a protein concentration of 0.5 mg/ml in 10 mM HEPES, pH 
7.5, 200 mM KCl, and 5mM MgCl2, 200 µM NADH, 1 mM glucose-6-phosphate, 2.5 µM 
FGD, and 25 µM F420 where stated at 37 °C. Activity was measured following the oxidation of 
NADH which was measured spectrophotometrically at 340 nm (6,220 M−1 cm−1). 
 
Computational analysis. Sequences of Ddn and orthologs were obtained from the NCBI 
sequence database. Alignment of the sequences were performed using MUSCLE (Edgar, 2008) 
via the EMBL-EBI web services (Li et al., 2015). Autodock Vina (Trott and Olson, 2010) was 
used to dock menadione and PA-824 into Ddn (PDB ID: 3R5R (Cellitti et al., 2012)).  The 
protein and ligand were prepared using in Autodock tools with default settings (Morris and 
Huey, 2009) and visualized using Pymol (DeLano, 2002). Substrate structures were obtained 
from the ZINC database (Irwin and Shoichet, 2005).  
 
Drug susceptibility test. Minimum inhibitory concentration (MIC) testing of  M. marinum 
was performed according to the method of Wiegand et al. (Wiegand et al., 2008) with some 
minor modifications. A culture was grown on Brown and Buckle media and colonies were 
scraped and diluted to an OD600 of 0.2, and was used as the inoculum for the MIC assay. Plates 
were incubated at 30 °C in a humid environment and were read after 5 days of incubation. 
MICs of M. tuberculosis isolates were determined as described previously (Heikal et al., 2016) 
with slight modifications. Briefly, U-bottomed 96-well microtitre plates containing 
Middlebrook 7H9 broth supplemented with oleic acid, albumin, dextrose and catalase were 
inoculated with M. tuberculosis H37Rv or R0008 (OD600 0.02) in the presence of delamanid 
and pretomanid (0.015-512 µg/ml), and incubated at 37 °C for 5 days. The presence/absence 
of a cell pellet was checked visually. Resazurin (0.03% w/v) was then added, and plates were 
further incubated for 7 days. Viable cells reduce resazurin (blue) to resofurin (pink). 
Bedaquiline (0.015–32 µg/ml) was used as a drug susceptibility control. 
 
Dataset. To determine the frequency of non-synonymous sequence polymorphisms in the ddn 
gene we assembled a collection of 5,184 publicly available complete and draft M. tuberculosis 
genomes from Genbank (Benson et al., 2013) and unassembled M. tuberculosis sequencing 
data from the sequence read archive (SRA; https://www.ncbi.nlm.nih.gov/sra/) on the 7th and 
28th of April 2017, respectively. Using a structured query (Illumina[Platform]) AND 
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“Mycobacterium tuberculosis”[orgn:__txid1773]) to search the SRA we identified 9692 
unassembled M. tuberculosis genome datasets. 
 
Taxonomic profiling of unassembled sequencing data. Kraken (Wood and Salzberg, 2014), 
an ultrafast sequence classification tool, was used to assign taxonomic labels to the 
unassembled M. tuberculosis genomes from the SRA. Sequence reads for each genome from 
the SRA were screened against a NCBI refseq database (https://www.ncbi.nlm.nih.gov/refseq) 
using Kraken version 0.10.5 to identify contaminants. Of the 243 M. tuberculosis genomes 
with sequence polymorphisms in ddn 67 (27.5%) were found to be contaminated with DNA 
from unidentified organisms or from Mycobacterium species other than M. tuberculosis (Table 
S2). These genomes were excluded from all further analysis. 
 
Lineage-typing of M. tuberculosis genomes. Classification of M. tuberculosis phylogenetic 
lineages was performed using KvarQ version 0.12.3a1 and default parameters (Steiner et al., 
2014). Using KvarQ scan, unassembled sequencing data were screened against a database of 
previously defined sequence polymorphisms known to delineate the 7 major M. tuberculosis 
phylogenetic lineages (Table S1).  
 
Characterisation of ddn sequence polymorphisms in M. tuberculosis. Using BLASTn (with 
default parameters) complete and draft M. tuberculosis genome assemblies from Genbank were 
queried with the ddn gene from M. tuberculosis H37Rv (Genbank accession:AL123456; (Cole 
et al., 1998)), identifying 145 M. tuberculosis genomes carrying alternative ddn alleles (relative 
to H37Rv). For these 145 genomes the Ddn sequence was extracted and aligned using Clustal 
Omega version 1.2.4 (Sievers et al., 2011) to identify non-synonymous mutation and other 
sequence polymorphism which could impact the function of Ddn (Table S2).  
For the unassembled genomes datasets, raw sequencing reads were aligned to the reference 
genome M. tuberculosis H37Rv using Snippy version 2.9 (BWA-mem version 0.7.12 (Li, 
2013))(https://github.com/tseeman/snippy). Variant calling was performed using Snippy 
(Freebayes version 0.9.21 (Garrison and Marth, 2012) with default parameters (minimum read 
coverage of 10x and 90% read concordance at the variant locus). 180 unassembled genome 
datasets were identified as having a mutation in ddn, only three of which were represented 
amongst the afore-mentioned 145 assembled genomes available in GenBank.   
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Phylogenetic reconstruction M. tuberculosis strains with sequencing polymorphisms in 
Ddn. To determine the phylogenetic distribution of ddn alleles in M. tuberculosis we carried 
out a phylogenomic analysis of M. tuberculosis strains with sequence polymorphism in ddn. 
Firstly, unassembled genomes from the SRA were assembled de novo using SPAdes version 
3.9.0 (Bankevich et al., 2012). Next all 322 complete and draft genomes (Table S4) were 
aligned with Parsnp version 1.2 (Treangen et al., 2014) using the genome of H37Rv as a 
reference to produce a core genome alignment of 848,476 bp. Core genome SNPs were 
identified and recombinant regions removed using Gubbins version 2.2.0 (Croucher et al., 
2015). Finally, a maximum-likelihood phylogenetic tree was estimated using RAxML version 
8.2.9 (Stamatakis, 2014) under the GTRGAMMA nucleotide substitution model. 
 
  
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
51 
 
Footnotes 
 
The authors declare no conflict of interest. 
 
Acknowledgements: We acknowledge Thomas Cuddihy (QFAB Bioinformatics) for 
assistance with genome data retrieval. SAB is supported by an NHMRC Career Development 
Fellowship (GNT1090456). 
 
 
  
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
52 
 
Figures and Tables 
 
Figure 1. Ddn is a respiratory primary dehydrogenase that couples F420H2 oxidation to 
menaquinone reduction. A. Michaelis-Menten curve of the activity of purified Ddn with 
menaquinone-1 in the presence of F420H2. Rates were determined by measuring change of 
absorbance at 420 nm. Error bars indicate SEM (n = 3). B. Relative oxygen consumption of M. 
smegmatis membranes. F420, NADH, and glucose 6-phosphate were present in all assays, while 
the availability of the F420-dependent glucose 6-phosphate dehydrogenase (FGD) was varied. 
Membranes were purified from four different genetic backgrounds: wild-type, a transformant 
with the empty complementation vector pMV261, a transformant with pMV261 expressing the 
ddn gene, and a strain containing a chromosomal cytochrome bd oxidase deletion (ΔcydA). 
Error bars indicate SEM (n = 3).  Stars above each column indicate a statistically significant 
difference compared to the first column. Other significant differences are shown by starred 
lines between columns. * = p ≤ 0.05, ** = p ≤ 0.01, **** = p ≤ 0.0001 n.s = p > 0.05 (one-way 
ANOVA followed by Tukey’s multiple comparison test). C. Rate of NADH oxidation in the 
presence and absence of F420H2. Rates were determined by following change of absorbance at 
340 nm. n.s indicates p > 0.05, two tailed t-test, error bars indicate SEM (n = 3). 
 
  
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
53 
 
Figure 2. Mutations in Ddn prevent pretomanid activation without affecting native activity. A. 
Multiple sequence alignment of Ddn and orthologs from other mycobacterial species. 
Highlighted residues indicate active site residues and numbers indicate their residue position 
in Ddn. *Indicates enzymes tested from a previous study (Ahmed et al., 2015) B. Comparison 
of the turnover rates of Ddn orthologs with menadione and pretomanid. Six orthologs were 
tested: Rv3547 (M. tuberculosis Ddn), MMAR_5035 (M. marinum), MSMEG_5998 (M. 
smegmatis), MVAN_5261 (M. vanbaalaenii), MAV_0613 (M. avium), and MUL_4109 (M. 
ulceran). Error bars show SEM (n = 3).  C. Comparison of the turnover rates of Ddn mutants 
with menadione and pretomanid. 24 point mutations in active site were tested. Full kinetic data 
for panels B and C are shown in Table S2. D. Nucleotide changes to obtain the aligned amino 
acid mutations. Highlighted nucleotides show indicate differences from the original sequence. 
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Figure 3. The substrate-binding pocket of Ddn (PDB: 3R5R9). A. The binding pocket in Ddn 
consists of F420/F420H2, Tyr65, Ser78, Tyr130 and Tyr136. These residues were all mutated to 
investigate their effects on the native (menadione) and drug-activating (pretomanid/delamanid) 
activities. B. Menadione binds above the deazaflavin ring of F420H2 in a complementary pocket 
formed by the aromatic rings of the tyrosine residues and the hydroxyl group of Ser78. C. 
Pretomanid docked into wild type Ddn with F420H2 bound. The nitroimidazo-oxazine moiety 
can bind parallel to the deazaflavin group of F420, extending the nitro- group deep into the active 
site, towards Ser78. D. Delamanid docked into wild type Ddn with F420H2 bound. The dual 
methyl/phenoxy-methyl substitution at the C6 position of the oxazole ring creates steric 
hindrance with the deazaflavin ring of F420, causing it to bind above F420 in a perpendicular 
orientation. This results in additional distance to Ser78. 
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Figure 4: Phylogeny M. tuberculosis strains with sequencing polymorphisms in Ddn. 
Maximum-likelihood phylogenetic tree of 332 M. tuberculosis strains built using 2099 non-
recombinant core genome SNPs (relative to H37Rv). The tree shows all M. tuberculosis strains 
for which public genome data is available in Genbank or the short read archive (SRA) that have 
either synonymous and non-synonymous mutations in Ddn (relative to H37Rv). The amino 
acid changes of the non-synonymous mutations are indicated on the branch tips. Blank tips 
represent strains with synonymous mutations in Ddn. Branches are coloured by Lineage: 
Lineage 1 (Indo-Oceanic), yellow; Lineage 2 (East Asian-Beijing), red; Lineage 3 (East 
African-Indian), purple; Lineage 4 (Euro-American), green; Lineage 5 (West African), teal. 
The scale bar indicates branch length in number of SNPs. Genome alignments, recombination 
filtering and phylogenetic reconstruction where done using Parsnp, Gubbins and RaxML, 
respectively. The phylogenetic tree was visualised using Figtree version 1.4.3 
(https://tree.bio.ed.ac.uk/software/figtree). 
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Table 1: Kinetic parameters of native F420H2-dependent menaquinone reductase activities of 
Ddn and M. smegmatis homologs in vitro assays. 
 Menaquinone 
Enzyme kcat (s
-1) KM (µM) kcat/KM (M
-1 s-1) 
Ddn 
MSMEG_2027 
MSMEG_5998 
1.9×10-2 ± 9.7×10-4 
5×10-3 ± 1.2×10-3 
1.2×10-2 ± 1.5×10-3 
22.4 ± 3.8 
80.7 ± 34.4 
97.9 ± 20.4 
8.6×102 
6.1×101 
1.2×102 
 
Table 2. MICs of different mycobacterial strains with pretomanid and delamanid.  
 
 Pretomanid Delamanid 
 
Strain 
Reduction 
(nmol min-1 
µmolenzyme-1) 
MIC  
(µg mL-1) 
Reduction 
(nmol min-1 
µmolenzyme-1) 
MIC  
(µg mL-1) 
M. tuberculosis H37Rv 243 ± 8.1 4 15.8 ± 1.4 32 
M. tuberculosis N0008a 
M. marinum M 
M. smegmatis mc2155 
0 
60.3 ± 9.3 
0 
256 
16 
>50* 
12.4 ± 1.2 
N/A 
N/A 
32 
16 
>50* 
aS78Y mutation 
*MICs obtained from Upton, A. et al. (Upton et al., 2015)   
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Table 3:  Distribution of Ddn alleles in the major TB Lineages. Distribution of Ddn alleles 
in five major lineages of M. tuberculosis.  
 
Ddn allele #Strains Lineage(s) 
A111V 12 Lineage 4 (Euro American) 
D113N 7 Lineage 5 (West Africa) 
D69N 1 Lineage 4 (Euro American) 
E105Q 1 Lineage 4 (Euro American) 
E117K 1 Lineage 2 (East Asian-Beijing) 
E83D 4 Lineage 4 (Euro American) 
G34R 11 Lineage 4 (Euro American) 
G34E 2 Lineage 4 (Euro American) 
G36V 1 Lineage 1 (Indo-Oceanic) 
G57A 5 Lineage 1(Indo-Oceanic),Animal Lineage  
G71R 1 Lineage 4 (Euro American) 
G81S 9 Lineage 2 (East Asian-Beijing) 
I102V 1 Lineage 4 (Euro American) 
K79Q 1 Lineage 4 (Euro American) 
L49P 16 Lineage 2 (East Asian-Beijing) 
L67P 2 Lineage 4 (Euro American) 
L90V 1 Animal Lineage 
M21T 1 Lineage 3(East African-Indian) 
N62D 1 Lineage 4 (Euro American) 
N91T 1 Lineage 4 (Euro American) 
P124S 1 Lineage 2 (East Asian-Beijing) 
P45L 2 Lineage 4 (Euro American),Lineage 1 (Indo-Oceanic) 
P6L 2 Lineage 2 (East Asian-Beijing) 
P6S 9 Lineage 1 (Indo-Oceanic) 
P6T 2 Lineage 3(East African-Indian) 
P86_M87del 22 Lineage 4 (Euro American) 
R23L 1 Lineage 4 (Euro American) 
R23W 14 Lineage 4 (Euro American) 
R30S 3 Lineage 2 (East Asian-Beijing) 
R72Q 3 Lineage 4 (Euro American) 
R72W 34 Lineage 1 (Indo-Oceanic) 
S78Y 3 Lineage 2 (East Asian-Beijing) 
T140I 1 Lineage 4 (Euro American) 
T26P 2 Lineage 4 (Euro American) 
T50P 2 Lineage 2 (East Asian-Beijing) 
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T51P 1 Lineage 2 (East Asian-Beijing) 
T52N 1 Lineage 2 (East Asian-Beijing) 
T52P 2 Lineage 3(East African-Indian),Lineage 4 (Euro American) 
T56P 5 Lineage 4 (Euro American),Lineage 3(East African-Indian) 
TTT50PPP 1 East African-Indian 
V147M 1 Lineage 1 (Indo-Oceanic) 
V61G 5 Lineage 4 (Euro American) 
W27C 1 Lineage 2 (East Asian-Beijing) 
W88R 2 Lineage 4 (Euro American) 
Y122_M129del 5 Lineage 4 (Euro American) 
Y133C 1 Lineage 1 (Indo-Oceanic) 
Y29del 2 Lineage 2 (East Asian-Beijing) 
Y29H 1 Lineage 4 (Euro American) 
Y29S 2 Lineage 4 (Euro American) 
Y65S 3 Lineage 4 (Euro American) 
TG56PA 6 Lineage 3(East African-Indian),Lineage 4 (Euro American) 
  
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
60 
 
References 
Aharoni, A., Gaidukov, L., Khersonsky, O., Gould, S.M.Q., Roodveldt, C., and Tawfik, D.S. 
(2005) The’evolvability’of promiscuous protein functions. Nat Genet 37: 73–76. 
Ahmed, F.H., Carr, P.D., Lee, B.M., Afriat-Jurnou, L., Mohamed, A.E., Hong, N.S., et al. 
(2015) Sequence-Structure-Function Classification of a Catalytically Diverse Oxidoreductase 
Superfamily in Mycobacteria. J Mol Biol 427: 3554–3571. 
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H.W.H., Neefs, J.-M., Winkler, H., et 
al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. 
Science 307: 223–7. 
Bankevich, A., Nurk, S., Antipov, D., Gurevich, A.A., Dvorkin, M., Kulikov, A.S., et al. (2012) 
SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. 
J Comput Biol 19: 455–477. 
Bashiri, G., Squire, C.J., Moreland, N.J., and Baker, E.N. (2008) Crystal structures of F420-
dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-
tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol 
Chem 283: 17531–17541. 
Benson, D.A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Lipman, D.J., Ostell, J., and 
Sayers, E.W. (2013) GenBank. Nucleic Acids Res 41: D36–D42. 
Bloemberg, G. V., Keller, P.M., Stucki, D., Trauner, A., Borrell, S., Latshang, T., et al. (2015) 
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med 
373: 1986–1988. 
Cellitti, S.E., Shaffer, J., Jones, D.H., Mukherjee, T., Gurumurthy, M., Bursulaya, B., et al. 
(2012) Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium 
tuberculosis involved in bioreductive activation of PA-824. Structure 20: 101–112. 
Choi, K.P., Bair, T.B., Bae, Y.M., and Daniels, L. (2001) Use of transposon Tn5367 
mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for 
fbiA and fbiB in coenzyme F420 biosynthesis by Mycobacterium bovis BCG. J Bacteriol 183: 
7058–7066. 
Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., et al. (1998) 
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. 
Nature 393: 537–544. 
Comas, I., Coscolla, M., Luo, T., Borrell, S., Holt, K.E., Kato-Maeda, M., et al. (2013) Out-of-
Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern 
humans. Nat Genet 45: 1176–1182. 
Cook, G.M., Greening, C., Hards, K., and Berney, M. (2014) Chapter One-Energetics of 
Pathogenic Bacteria and Opportunities for Drug Development. Adv Microb Physiol 65: 1–62. 
Croucher, N.J., Page, A.J., Connor, T.R., Delaney, A.J., Keane, J.A., Bentley, S.D., et al. 
(2015) Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome 
sequences using Gubbins. Nucleic Acids Res 43: e15–e15. 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
61 
 
Dawson, R., Diacon, A.H., Everitt, D., Niekerk, C. Van, Donald, P.R., Burger, D.A., et al. 
(2015) Effi ciency and safety of the combination of moxifl oxacin , pretomanid ( PA-824 ), and 
pyrazinamide during the fi rst 8 weeks of antituberculosis treatment : a phase 2b , open-label , 
partly randomised trial in patients with drug-susceptible or drug-resi. Lancet 385: 1738–1747. 
DeLano, W.L. (2002) The PyMOL molecular graphics system. http//pymol org . 
Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., et al. 
(2009) The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. N Engl J Med 360: 
2397–2405. 
Edgar, R.C. (2008) MUSCLE : multiple sequence alignment with high accuracy and high 
throughput. Nucleic Acids Res 32: 1792–1797. 
Garrison, E., and Marth, G. (2012) Haplotype-based variant detection from short-read 
sequencing. arXiv Prepr arXiv12073907 . 
Gibson, D.G., Young, L., Chuang, R.-Y., Venter, J.C., Hutchison, C. a, Smith, H.O., et al. 
(2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 
6: 343–5. 
Greening, C., Ahmed, F.H., Mohamed, A.E., Lee, B.M., Pandey, G., Warden, A.C., et al. 
(2016) Physiology, Biochemistry, and Applications of F420 - and Fo -Dependent Redox 
Reactions. Microbiol Mol Biol Rev 80: 451–493. 
Gupta, R., Gao, M., Cirule, A., Xiao, H., Geiter, L.J., and Wells, C.D. (2015) Delamanid for 
Extensively Drug-Resistant Tuberculosis. N Engl J Med 373: 291–292. 
Gurumurthy, M., Rao, M., Mukherjee, T., Rao, S.P.S., Boshoff, H.I., Dick, T., et al. (2013) A 
novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against 
oxidative stress and bactericidal agents. Mol Microbiol 87: 744–755. 
Hards, K., Robson, J.R., Berney, M., Shaw, L., Bald, D., Koul, A., et al. (2015) Bactericidal 
mode of action of bedaquiline. J Antimicrob Chemother 70: 2028–2037. 
Hart, K.M., Ho, C.M.W., Dutta, S., Gross, M.L., and Bowman, G.R. (2016) Modelling 
proteins’ hidden conformations to predict antibiotic resistance. Nat Commun 7: 12965. 
Hasan, M.R., Rahman, M., Jaques, S., Purwantini, E., and Daniels, L. (2010) Glucose 6-
phosphate accumulation in mycobacteria: implications for a novel F420-dependent anti-
oxidant defense system. J Biol Chem 285: 19135–19144. 
Haver, H., Chua, A., and Ghode, P. (2015) Mutations in genes for the F420 biosynthetic 
pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous 
in vitro-selected PA-824-. Antimicrob agents 59: 5316–5323. 
Heikal, A., Hards, K., Cheung, C.Y., Menorca, A., Timmer, M.S.M., Stocker, B.L., and Cook, 
G.M. (2016) Activation of type II NADH dehydrogenase by Quinolinequinones mediates 
antitubercular cell death. J Antimicrob Chemother 71: 2840–2847. 
Hoffmann, H., Borroni, E., Schena, E., Nedialkova, L., Hofmann-Thiel, S., and Cirillo, D. 
(2016) Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
62 
 
microtitre assay and the BACTECTM MGITTM 960 system—authors’ response. J Antimicrob 
Chemother 71: 3625–3625. 
Hoffmann, H., Kohl, T.A., Hofmann-Thiel, S., Merker, M., Beckert, P., Jaton, K., et al. (2016) 
Delamanid and bedaquiline resistance in MTB ancestral Beijing genotype causing extensive 
drug-resistant TB in a tibetan refugee. Am J Respir Crit Care Med 193: 337–340. 
Irwin, J.J., and Shoichet, B.K. (2005) ZINC − A Free Database of Commercially Available 
Compounds for Virtual Screening ZINC - A Free Database of Commercially Available 
Compounds for Virtual Screening. J Chem Inf Model 45: 177–182. 
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot, C., and Jarlier, V. (2006) In vitro and 
in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and 
PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50: 1921–1926. 
Jirapanjawat, T., Ney, B., Taylor, M.C., Warden, A.C., Afroze, S., Russell, R.J., et al. (2016) 
The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds and 
mediates a reductive detoxification system. Appl Environ Microbiol 82: 6810–6818. 
Kana, B.D., Weinstein, E.A., Avarbock, D., Dawes, S.S., Rubin, H., and Mizrahi, V. (2001) 
Characterization of the cydAB -Encoded Cytochrome bd Oxidase from Mycobacterium 
smegmatis. J Bacteriol 183: 7076–7086. 
Lamprecht, D.A., Finin, P.M., Rahman, M.A., Cumming, B.M., Russell, S.L., Jonnala, S.R., et 
al. (2016) Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat 
Commun 7: 12393. 
Lapalikar, G. V., Taylor, M.C., Warden, A.C., Scott, C., Russell, R.J., and Oakeshott, J.G. 
(2012) F 420H 2-dependent degradation of aflatoxin and other furanocoumarins is widespread 
throughout the Actinomycetales. PLoS One 7: e30114. 
Li, H. (2013) Aligning sequence reads, clone sequences and assembly contigs with BWA-
MEM. arXiv Prepr arXiv13033997 . 
Li, W., Cowley, A., Uludag, M., Gur, T., McWilliam, H., Squizzato, S., et al. (2015) The 
EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res 43: 
W580–W584. 
Manjunatha, U., Boshoff, H.I.M., and Barry, C.E. (2009) The mechanism of action of PA-824: 
Novel insights from transcriptional profiling. Commun Integr Biol 2: 215–218. 
Manjunatha, U.H., Boshoff, H., Dowd, C.S., Zhang, L., Albert, T.J., Norton, J.E., et al. (2006) 
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in 
Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 431–436. 
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., et 
al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action 
against tuberculosis in vitro and in mice. PLoS Med 3: 2131–2144. 
Mohamed, A.E., Condic-Jurkic, K., Ahmed, F.H., Yuan, P., O’Mara, M.L., Jackson, C.J., and 
Coote, M.L. (2016) Hydrophobic shielding drives catalysis of hydride transfer in a family of 
F420H2-dependent enzymes. Biochemistry . 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
63 
 
Morris, G., and Huey, R. (2009) AutoDock4 and AutoDockTools4: Automated docking with 
selective receptor flexibility. J … 30: 2785–2791. 
Murray, S., Mendel, C., and Spigelman, M. (2016) TB Alliance regimen development for 
multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 20: 38–41. 
Orencia, M.C., Yoon, J.S., Ness, J.E., Stemmer, W.P.C., and Stevens, R.C. (2001) Predicting 
the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct 
Mol Biol 8: 238–242. 
Oyugi, M.A., Bashiri, G., Baker, E.N., and Johnson-Winters, K.L. (2016) Investigating the 
reaction mechanism of F420-dependent glucose-6-phosphate dehydrogenase from 
Mycobacterium tuberculosis: kinetic analysis of the wild-type and mutant enzymes. 
Biochemistry. 
Pecsi, I., Hards, K., Ekanayaka, N., Berney, M., Hartman, T., Jacobs, W.R., and Cook, G.M. 
(2014) Essentiality of succinate dehydrogenase in Mycobacterium smegmatis and its role in 
the generation of the membrane potential under hypoxia. MBio 5: e01093-14. 
Purwantini, E., and Mukhopadhyay, B. (2009) Conversion of NO2 to NO by reduced coenzyme 
F420 protects mycobacteria from nitrosative damage. Proc Natl Acad Sci U S A 106: 6333–
6338. 
Purwantini, E., Mukhopadhyay, B., Spencer, R.W., and Daniels, L. (1992) Effect of 
temperature on the spectral properties of coenzyme F420 and related compounds. Anal 
Biochem 205: 342–350. 
Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) Molecular cloning: a laboratory manual. 
Cold spring harbor laboratory press, . 
Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., et al. (2011) Fast, scalable 
generation of high‐quality protein multiple sequence alignments using Clustal Omega. Mol 
Syst Biol 7. 
Singh, R., Manjunatha, U., Boshoff, H.I.M., Ha, Y.H., Niyomrattanakit, P., Ledwidge, R., et 
al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. 
Science 322: 1392–5. 
Sinha, S., Kosalai, K., Arora, S., Namane, A., Sharma, P., Gaikwad, A.N., et al. (2005) 
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by 
proteomics. Microbiology 151: 2411–2419. 
Snapper, S.B., Melton, R.E., Mustafa, S., Kieser, T., and WR Jr, J. (1990) Isolation and 
characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. 
Mol Microbiol 4: 1911–1919. 
Souza, G.A. de, Leversen, N.A., Målen, H., and Wiker, H.G. (2011) Bacterial proteins with 
cleaved or uncleaved signal peptides of the general secretory pathway. J Proteomics 75: 502–
510. 
Stamatakis, A. (2014) RAxML version 8: a tool for phylogenetic analysis and post-analysis of 
large phylogenies. Bioinformatics 30: 1312–1313. 
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
64 
 
Steiner, A., Stucki, D., Coscolla, M., Borrell, S., and Gagneux, S. (2014) KvarQ: targeted and 
direct variant calling from fastq reads of bacterial genomes. BMC Genomics 15: 881. 
Stover, C.K., Warrener, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., 
et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of 
tuberculosis. Nature 405: 962–966. 
Treangen, T.J., Ondov, B.D., Koren, S., and Phillippy, A.M. (2014) The Harvest suite for rapid 
core-genome alignment and visualization of thousands of intraspecific microbial genomes. 
Genome Biol 15: 524. 
Trott, O., and Olson, A.J. (2010) AutoDock Vina: Improving the Speed and Accuracy of 
Docking with a New Scoring Function, EfficientOptimization, and Multithreading. J Comput 
Chem 31: 455–61. 
Upton, A.M., Cho, S., Yang, T.J., Kim, A.Y., Wang, Y., Lu, Y., et al. (2015) In vitro and in 
vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. 
Antimicrob Agents Chemother 59: 136–144. 
WHO (2016) Global Tuberculosis Report 2016. Cdc 2016 214. 
Wiegand, I., Hilpert, K., and Hancock, R.E.W. (2008) Agar and broth dilution methods to 
determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 
3: 163–75. 
Wood, D.E., and Salzberg, S.L. (2014) Kraken: ultrafast metagenomic sequence classification 
using exact alignments. Genome Biol 15: R46–R46. 
  
Chapter 2: Pretomanid Resistance, Evolution, and Susceptibility in Tuberculosis 
65 
 
2.3 Supplementary Materials  
 
Figure S1: Ddn and Ddn Ser78Tyr can both reduce Delamanid. Comparison of the reduction 
rate of Delamanid by Ddn (15.8±1.4 nmol min-1 µmol-1 enzyme and Ddn S78Y (12.4±1.21 
nmol min-1 µmol-1 enzyme). 
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Table S2: Characterisation of non-synonymous Ddn mutations in M. tuberculosis. Table 
showing all M. tuberculosis genomes with non-synonymous mutations in ddn, substitution type 
and lineage to which the strain belongs. 
 
Strain_IDa Ddn Allele Lineage-typing (Kvarq) Lineage 
ERR1023406 W27C lineage 2 East Asian/Beijing 
ERR1034696 R72W lineage 1 Indo-Oceanic 
ERR1034824 R23W lineage 4 Euro-American 
ERR1034917 R72Q lineage 4 Euro-American 
ERR1035261 R23W lineage 4 Euro-American 
ERR1035262 G34R lineage 4 Euro-American 
ERR1035268 R23W lineage 4 Euro-American 
ERR1035277 R23W lineage 4 Euro-American 
ERR1035292 R23W lineage 4 Euro-American 
ERR1035301 R23W lineage 4 Euro-American 
ERR1035316 G34R lineage 4 Euro-American 
ERR1035334 G34R lineage 4 Euro-American 
ERR1035336 G34R lineage 4 Euro-American 
ERR1035344 R23W lineage 4 Euro-American 
ERR1035345 R23W lineage 4 Euro-American 
ERR1035350 R23W lineage 4 Euro-American 
ERR1144974 P86_M87del lineage 4 Euro-American 
ERR1144975 P86_M87del lineage 4 Euro-American 
ERR1144976 P86_M87del lineage 4 Euro-American 
ERR1144977 P86_M87del lineage 4 Euro-American 
ERR1144978 P86_M87del lineage 4 Euro-American 
ERR1144979 P86_M87del lineage 4 Euro-American 
ERR1144980 P86_M87del lineage 4 Euro-American 
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ERR1144981 P86_M87del lineage 4 Euro-American 
ERR1144982 P86_M87del lineage 4 Euro-American 
ERR1144983 P86_M87del lineage 4 Euro-American 
ERR1144984 P86_M87del lineage 4 Euro-American 
ERR1144985 P86_M87del lineage 4 Euro-American 
ERR1144986 P86_M87del lineage 4 Euro-American 
ERR1144987 P86_M87del lineage 4 Euro-American 
ERR1144988 P86_M87del lineage 4 Euro-American 
ERR1144989 P86_M87del lineage 4 Euro-American 
ERR1144990 P86_M87del lineage 4 Euro-American 
ERR1144991 P86_M87del lineage 4 Euro-American 
ERR1144992 P86_M87del lineage 4 Euro-American 
ERR1144993 P86_M87del lineage 4 Euro-American 
ERR1144994 P86_M87del lineage 4 Euro-American 
ERR1144995 P86_M87del lineage 4 Euro-American 
ERR1193688 R23W lineage 4 Euro-American 
ERR1193708 R23W lineage 4 Euro-American 
ERR1193721 G71R lineage 4 Euro-American 
ERR1193737 R23W lineage 4 Euro-American 
ERR1193814 R23W lineage 4 Euro-American 
ERR1193827 G34R lineage 4 Euro-American 
ERR1199079 A94T lineage 4 Euro-American 
ERR1200607 P6T lineage 3 East African-Indian 
ERR1200648 P6T lineage 3 East African-Indian 
ERR1213864 G81S lineage 2 East Asian/Beijing 
ERR1213871 R23W Lineage 4 Euro-American 
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ERR1213919 G34R Lineage 4 Euro-American 
ERR1465874 L67P lineage 4 Euro-American 
ERR1465959 N91T lineage 4 Euro-American 
ERR1465981 L67P lineage 4 Euro-American 
ERR1633788 R72Q lineage 4 Euro-American 
ERR1633884 R72Q lineage 4 Euro-American 
ERR233357 S78Y Lineage 2 East Asian/Beijing 
ERR718303 A111V lineage 4 Euro-American 
ERR718313 P6L lineage 2 East Asian/Beijing 
ERR718320 S78Y lineage 2 East Asian/Beijing 
ERR718334 P6S lineage 1 Indo-Oceanic 
ERR718464 A111V lineage 4 Euro-American 
ERR718477 A111V lineage 4 Euro-American 
ERR718488 Y122_M129del lineage 4 Euro-American 
ERR718491 P6S lineage 1 Indo-Oceanic 
ERR718512 P6S lineage 1 Indo-Oceanic 
ERR718553 P6S lineage 1 Indo-Oceanic 
ERR751801 A111V lineage 4 Euro-American 
ERR751827 A111V lineage 4 Euro-American 
ERR751827 S78Y lineage 2 East Asian/Beijing 
ERR751922 Y122_M129del lineage 4 Euro-American 
ERR751923 Y122_M129del lineage 4 Euro-American 
ERR752065 A111V lineage 4 Euro-American 
ERR752103 P6S lineage 1 Indo-Oceanic 
ERR752105 A111V lineage 4 Euro-American 
ERR752109 Y122_M129del lineage 4 Euro-American 
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ERR752111 A111V lineage 4 Euro-American 
ERR752112 Y29del lineage 2 East Asian/Beijing 
ERR752117 A111V lineage 4 Euro-American 
ERR752138 P6S lineage 1 Indo-Oceanic 
ERR752147 P6L lineage 2 East Asian/Beijing 
ERR752206 A111V lineage 4 Euro-American 
ERR767965 P6S lineage 1 Indo-Oceanic 
ERR768008 P6S lineage 1 Indo-Oceanic 
ERR775776 Y122_M129del lineage 4 Euro-American 
ERR841494 D113N lineage 5 West Africa 
ERR841495 D113N lineage 5 West Africa 
ERR894427 G34R lineage 4 Euro-American 
ERR894428 G34R lineage 4 Euro-American 
ERR894429 G34R lineage 4 Euro-American 
ERR894430 G34R lineage 4 Euro-American 
ERR894431 G34R lineage 4 Euro-American 
ERR979071 N62D lineage 4 Euro-American 
GCA_000159755 D113N Lineage 5 West African 
GCA_000389945 V147M Lineage 1 Indo-Oceanic 
GCA_000653935 D69N lineage 4 Euro-American 
GCA_000654255 R72W lineage 1 Indo-Oceanic 
GCA_000654275 R72W lineage 1 Indo-Oceanic 
GCA_000654555 R72W lineage 1 Indo-Oceanic 
GCA_000654755 R72W lineage 1 Indo-Oceanic 
GCA_000654775 R72W lineage 1 Indo-Oceanic 
GCA_000654815 R72W lineage 1 Indo-Oceanic 
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GCA_000654915 R72W lineage 1 Indo-Oceanic 
GCA_000654975 R72W lineage 1 Indo-Oceanic 
GCA_000655055 R72W lineage 1 Indo-Oceanic 
GCA_000655075 R72W lineage 1 Indo-Oceanic 
GCA_000657255 R30S Lineage 2 East Asian/Beijing 
GCA_000662485 R72W lineage 1 Indo-Oceanic 
GCA_000662705 R72W lineage 1 Indo-Oceanic 
GCA_000662725 R72W lineage 1 Indo-Oceanic 
GCA_000662885 R72W lineage 1 Indo-Oceanic 
GCA_000662965 R72W lineage 1 Indo-Oceanic 
GCA_000663005 R72W lineage 1 Indo-Oceanic 
GCA_000663045 R72W lineage 1 Indo-Oceanic 
GCA_000663065 R72W lineage 1 Indo-Oceanic 
GCA_000663085 R72W lineage 1 Indo-Oceanic 
GCA_000663145 R72W lineage 1 Indo-Oceanic 
GCA_000663225 R72W lineage 1 Indo-Oceanic 
GCA_000663285 R72W lineage 1 Indo-Oceanic 
GCA_000665505 R72W lineage 1 Indo-Oceanic 
GCA_000665565 R72W lineage 1 Indo-Oceanic 
GCA_000665665 R72W lineage 1 Indo-Oceanic 
GCA_000665705 R72W lineage 1 Indo-Oceanic 
GCA_000665945 D113N lineage 5 West Africa 
GCA_000671135 W88R lineage 4 Euro-American 
GCA_000671155 W88R lineage 4 Euro-American 
GCA_000706145 R72W lineage 1 Indo-Oceanic 
GCA_000797435 G34E lineage 4 Euro-American 
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GCA_001110005 V61G lineage 4 Euro-American 
GCA_001173265 R23L lineage 4 Euro-American 
GCA_001193195 K79Q lineage 4 Euro-American 
GCA_001200495 V61G lineage 4 Euro-American 
GCA_001322025 R30S Lineage 2 East Asian/Beijing 
GCA_001324745 R30S Lineage 2 East Asian/Beijing 
GCA_001325465 T51P Lineage 2 East Asian/Beijing 
GCA_001327995 T56P lineage 4 Euro-American 
GCA_001328055 V61G lineage 4 Euro-American 
GCA_001328255 T50P Lineage 3 East African-Indian 
GCA_001328375 TG56PA lineage 4 Euro-American 
GCA_001345295 Y29S lineage 4 Euro-American 
GCA_001387175 G34E lineage 4 Euro-American 
GCA_001389755 T50P Lineage 2 East Asian/Beijing 
GCA_001390435 T52P lineage 4 Euro-American 
GCA_001392215 V61G lineage 4 Euro-American 
GCA_001392375 G57A lineage 4 Euro-American 
GCA_001392915 T26P lineage 4 Euro-American 
GCA_001393335 V61G lineage 4 Euro-American 
GCA_001394175 G57A Animal Lineage 
 
GCA_001394455 T26P lineage 4 Euro-American 
GCA_001394515 D113N lineage 5 West Africa 
GCA_001395635 Y29S lineage 4 Euro-American 
GCA_001395735 D113N lineage 5 West Africa 
GCA_001396455 Y29H lineage 4 Euro-American 
GCA_001396575 TG56PA lineage 4 Euro-American 
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GCA_001396655 T56P lineage 4 Euro-American 
GCA_001396975 T52P,T56P Lineage 3 East African-Indian 
GCA_001397075 T56P Lineage 3 East African-Indian 
GCA_001397115 TG56PA Lineage 3 East African-Indian 
GCA_001397335 G57A lineage 4 Euro-American 
GCA_001397515 G57A lineage 4 Euro-American 
GCA_001397555 T56P lineage 4 Euro-American 
GCA_001397575 TG56PA lineage 4 Euro-American 
GCA_001397595 TTT50PPP Lineage 3 East African-Indian 
GCA_001397695 TG56PA lineage 4 Euro-American 
GCA_001397875 G57A lineage 4 Euro-American 
GCA_001397935 TG56PA Lineage 3 East African-Indian 
GCA_001997495 L49P Lineage 2 East Asian/Beijing 
GCA_002000965 L49P Lineage 2 East Asian/Beijing 
GCA_900120615 P124S Lineage 2 East Asian/Beijing 
GCA_900120745 P45L lineage 4 Euro-American 
SRR2467264 A111V lineage 4 Euro-American 
SRR2467268 R72W lineage 1 Indo-Oceanic 
SRR3085307 R72W lineage 1 Indo-Oceanic 
SRR3085317 E83D lineage 4 Euro-American 
SRR3085514 R72W lineage 1 Indo-Oceanic 
SRR3086377 R72W lineage 1 Indo-Oceanic 
SRR3205958 G81S lineage 2 East Asian/Beijing 
SRR3205959 G81S lineage 2 East Asian/Beijing 
SRR3675493 D113N lineage 5 West Africa 
SRR3724667 T140I lineage 4 Euro-American 
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SRR3724678 M21T lineage 3 East African-Indian 
SRR3724766 A111V lineage 4 Euro-American 
SRR3725356 Y29del lineage 2 East Asian/Beijing 
SRR5007159 L90V Animal Lineage 
 
SRR5065311 L49P lineage 2 East Asian/Beijing 
SRR5065432 P6S lineage 1 Indo-Oceanic 
SRR5065491 G36V lineage 1 Indo-Oceanic 
SRR5065629 I102V lineage 4 Euro-American 
SRR5065636 Y65S lineage 4 Euro-American 
SRR5065639 Y65S lineage 4 Euro-American 
SRR5065695 Y133C lineage 1 Indo-Oceanic 
SRR5067277 L49P lineage 2 East Asian/Beijing 
SRR5067302 L49P lineage 2 East Asian/Beijing 
SRR5067338 L49P lineage 2 East Asian/Beijing 
SRR5067366 L49P lineage 2 East Asian/Beijing 
SRR5067368 L49P lineage 2 East Asian/Beijing 
SRR5067434 L49P lineage 2 East Asian/Beijing 
SRR5067441 L49P lineage 2 East Asian/Beijing 
SRR5067504 L49P lineage 2 East Asian/Beijing 
SRR5067527 L49P lineage 2 East Asian/Beijing 
SRR5067533 L49P lineage 2 East Asian/Beijing 
SRR5067543 L49P lineage 2 East Asian/Beijing 
SRR5067612 L49P lineage 2 East Asian/Beijing 
SRR5067699 L49P lineage 2 East Asian/Beijing 
SRR5073572 Y65S lineage 4 Euro-American 
SRR5073681 T52N lineage 2 East Asian/Beijing 
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SRR5073688 E105Q lineage 4 Euro-American 
SRR5073730 E117K lineage 2 East Asian/Beijing 
SRR5074079 P45L lineage 1 Indo-Oceanic 
SRR5114017 G81S lineage 2 East Asian/Beijing 
SRR5114018 G81S lineage 2 East Asian/Beijing 
SRR5114019 G81S lineage 2 East Asian/Beijing 
SRR5114020 G81S lineage 2 East Asian/Beijing 
SRR5114021 G81S lineage 2 East Asian/Beijing 
SRR5114022 G81S lineage 2 East Asian/Beijing 
SRR5153219 E83D lineage 4 Euro-American 
SRR5153316 E83D lineage 4 Euro-American 
SRR5153811 E83D lineage 4 Euro-American 
SRR5314267 R72W lineage 1 Indo-Oceanic 
SRR5314270 R72W lineage 1 Indo-Oceanic 
aOnly strains with non-synonymous mutations in Ddn are shown 
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Table S4: M. tuberculosis strains analysed in this study. List of M. tuberculosis strains 
identified in this study as having synonymous or non-synonymous mutations in ddn. 
 
ERR1023325 ERR1193827 ERR752118 GCA_000663045 
ERR1023347 ERR1199093 ERR752138 GCA_000663065 
ERR1023406 ERR1199099 ERR752147 GCA_000663085 
ERR1034576 ERR1199106 ERR752206 GCA_000663145 
ERR1034696 ERR1199108 ERR760820 GCA_000663225 
ERR1034824 ERR1199109 ERR767965 GCA_000663285 
ERR1034917 ERR1199115 ERR768008 GCA_000665505 
ERR1035202 ERR1199127 ERR775776 GCA_000665565 
ERR1035242 ERR1199153 ERR775780 GCA_000665645 
ERR1035261 ERR1213864 ERR841494 GCA_000665665 
ERR1035262 ERR1213871 ERR841495 GCA_000665705 
ERR1035268 ERR1213919 ERR894427 GCA_000665945 
ERR1035277 ERR1367635 ERR894428 GCA_000671135 
ERR1035292 ERR1367655 ERR894429 GCA_000671155 
ERR1035301 ERR1367666 ERR894430 GCA_000672115 
ERR1035316 ERR1367687 ERR894431 GCA_000672135 
ERR1035334 ERR1413483 ERR979071 GCA_000673635 
ERR1035336 ERR1465769 GCA_000159755 GCA_000674095 
ERR1035344 ERR1465874 GCA_000220415 GCA_000674375 
ERR1035345 ERR1465885 GCA_000220435 GCA_000674515 
ERR1035350 ERR1465959 GCA_000220455 GCA_000677155 
ERR1144974 ERR1465981 GCA_000364945 GCA_000677335 
ERR1144975 ERR1633788 GCA_000389905 GCA_000681155 
ERR1144976 ERR1633884 GCA_000389945 GCA_000706145 
ERR1144977 ERR1679643 GCA_000526115 GCA_000738445 
ERR1144978 ERR233357 GCA_000652855 GCA_000738475 
ERR1144979 ERR718303 GCA_000653935 GCA_000797435 
ERR1144980 ERR718313 GCA_000654255 GCA_000804025 
ERR1144981 ERR718320 GCA_000654275 GCA_000805885 
ERR1144982 ERR718334 GCA_000654555 GCA_001086825 
ERR1144983 ERR718464 GCA_000654755 GCA_001086845 
ERR1144984 ERR718477 GCA_000654775 GCA_001108845 
ERR1144985 ERR718488 GCA_000654815 GCA_001110005 
ERR1144986 ERR718491 GCA_000654915 GCA_001112325 
ERR1144987 ERR718512 GCA_000654975 GCA_001123765 
ERR1144988 ERR718553 GCA_000655055 GCA_001144025 
ERR1144990 ERR751801 GCA_000655075 GCA_001145965 
ERR1144991 ERR751827 GCA_000656795 GCA_001160225 
ERR1144992 ERR751847 GCA_000657255 GCA_001173265 
ERR1144993 ERR751922 GCA_000659445 GCA_001193195 
ERR1144994 ERR751923 GCA_000659765 GCA_001197475 
ERR1144995 ERR752065 GCA_000659785 GCA_001199055 
ERR1193688 ERR752103 GCA_000662485 GCA_001199935 
ERR1193708 ERR752105 GCA_000662705 GCA_001200395 
ERR1193721 ERR752109 GCA_000662725 GCA_001200495 
ERR1193737 ERR752111 GCA_000662885 GCA_001204615 
ERR1193793 ERR752112 GCA_000662965 GCA_001206715 
ERR1193814 ERR752117 GCA_000663005 GCA_001207015 
GCA_001208505 GCA_001397075 SRR5065695  
GCA_001318065 GCA_001397115 SRR5067277  
GCA_001318165 GCA_001397335 SRR5067302  
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GCA_001318425 GCA_001397515 SRR5067338  
GCA_001318445 GCA_001397555 SRR5067366  
GCA_001318645 GCA_001397575 SRR5067368  
GCA_001318805 GCA_001397595 SRR5067415  
GCA_001318905 GCA_001397695 SRR5067434  
GCA_001322025 GCA_001397875 SRR5067441  
GCA_001322085 GCA_001397935 SRR5067504  
GCA_001323185 GCA_001847205 SRR5067527  
GCA_001323285 GCA_001849965 SRR5067533  
GCA_001324045 GCA_001997425 SRR5067543  
GCA_001324745 GCA_001997495 SRR5067612  
GCA_001325465 GCA_002000965 SRR5067670  
GCA_001327755 GCA_900120615 SRR5067699  
GCA_001327995 GCA_900120745 SRR5067714  
GCA_001328055 GCA_900127285 SRR5073572  
GCA_001328255 SRR2467264 SRR5073681  
GCA_001328375 SRR2467268 SRR5073688  
GCA_001345295 SRR3085285 SRR5073730  
GCA_001375835 SRR3085288 SRR5073748  
GCA_001378175 SRR3085289 SRR5074079  
GCA_001379715 SRR3085307 SRR5114017  
GCA_001381215 SRR3085317 SRR5114018  
GCA_001386495 SRR3085514 SRR5114019  
GCA_001387175 SRR3086364 SRR5114020  
GCA_001389315 SRR3086377 SRR5114021  
GCA_001389755 SRR3105735 SRR5114022  
GCA_001390435 SRR3205958 SRR5153219  
GCA_001392215 SRR3205959 SRR5153316  
GCA_001392375 SRR3675493 SRR5153811  
GCA_001392915 SRR3724659 SRR5153830  
GCA_001393335 SRR3724667 SRR5314267  
GCA_001393835 SRR3724678 SRR5314270  
GCA_001393915 SRR3724755   
GCA_001394175 SRR3724766   
GCA_001394195 SRR3725356   
GCA_001394215 SRR3725711   
GCA_001394455 SRR5007159   
GCA_001394515 SRR5007175   
GCA_001395635 SRR5065311   
GCA_001395735 SRR5065432   
GCA_001396455 SRR5065491   
GCA_001396575 SRR5065629   
GCA_001396655 SRR5065636   
GCA_001396915 SRR5065639   
GCA_001396975 SRR5065673   
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 3.1 Introduction 
 
Tuberculosis (TB) is one of the top ten causes of death worldwide and in the last five years it 
is the highest cause of death by an infectious disease, surpassing HIV/AIDS (WHO, 2016). 
Mycobacterium tuberculosis, the causative agent of TB, is difficult to combat as it has the 
ability to switch between active and latent infections (Boshoff and Barry, 2005), and can resist 
harsh conditions including hypoxia, nitrosative stress, and oxidative stress (Rohde et al., 2007; 
Rustad et al., 2008).  M. tuberculosis is becoming increasingly resilient to most drug 
treatments, as the current treatment for tuberculosis is expensive, has poor compliance and 
management, and extensive drug-drug interactions (Zumla et al., 2013). Drug development for 
tuberculosis is slow and has been largely unsuccessful (Zuniga et al., 2015). Recently two new 
drugs, Bedaquiline (Deoghare, 2013) and Delamanid (Ryan and Lo, 2014), have been 
conditionally approved for multi-resistant tuberculosis, and are the first drugs to be approved 
for tuberculosis in 40 years (Mahajan, 2013). Bedaquiline targets the mycobacterial ATP 
synthase and disrupts the membrane thereby decoupling and, subsequently, inhibiting ATP 
production (Hards et al., 2015; Preiss et al., 2015). Delamanid is a prodrug that when reduced 
by the F420-dependent enzyme, Deazaflavin-dependent nitroreductase (Ddn),  releases a des-
nitro product that inhibits ketomycolic acid biosynthesis, and nitrous oxide causing respiratory 
poisoning to the cell (Stover et al., 2000; Singh et al., 2008).  
Enzymes in mycobacteria that utilise the co-factor F420 are hypothesised to be potential 
drug targets against tuberculosis (Selengut and Haft, 2010). F420 is structurally similar to flavins 
but because of its low reducing potential, it is more functionally similar to NADH/NADPH 
(Walsh, 1986). It is found in a wide range of aerobic bacteria throughout soil and aquatic 
ecosystems, but its absence in  humans and other Mammalia allowing highly specific targeting 
of these enzymes (Ney et al., 2017). Studies have shown that F420 is conditionally essential in 
mycobacteria (Gurumurthy et al., 2013). The absence of F420 make mycobacteria more 
susceptible to hypoxia, nitrosative and oxidative stress (Purwantini and Mukhopadhyay, 2009; 
Hasan et al., 2010; Gurumurthy et al., 2013). Within mycobacteria, F420 is utilised by at least 
28 enzymes, some of which can break down a range of bactericidal agents (Selengut and Haft, 
2010; Taylor et al., 2010; Greening et al., 2016; Jirapanjawat et al., 2016). F420 is utilised by 
two super families in mycobacteria, the luciferase-like hydride transferase (LLHT) and the 
Flavin/Deazaflavin OxidoReductase (FDOR) super families (Greening et al., 2016).  
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The structures of several FDORs have been solved (Greening et al., 2016), allowing 
them to be used for structure-based drug design. However, it must first be established that their 
physiological roles are essential or conditionally essential, i.e. it must be established that 
inhibiting these enzymes would actually be deleterious to the organism. The FDORs are 
divided into three groups: FDOR-A, FDOR-AA, and FDOR-B (Taylor et al., 2010; Ahmed et 
al., 2015). The FDOR-As are quinone reductases that are predicted to have a role in oxidative 
stress protection (Gurumurthy et al., 2013; Ahmed et al., 2015) and in enhancing the respiration 
in the cell (see Chapter 2). The roles of FDOR-AAs are unknown but may be involved in fatty 
acid metabolism (Ahmed et al., 2015). The FDOR-Bs are the most diverse group and can be 
separated into 12 distinct clades that are predicted to have evolved separate physiological roles 
(Ahmed et al., 2015). Several FDOR-Bs have been functionally annotated, including FDOR-
B4, which reduces biliverdin to bilirubin, a known antioxidant (Ahmed et al., 2015; Ahmed et 
al., 2016). The FDORs can reduce a range of organic compounds including aflatoxins and 
coumarins, but this activity is most likely promiscuous and unlikely to be related to their 
physiological role (Taylor et al., 2010; Lapalikar et al., 2012; Jirapanjawat et al., 2016; 
Greening et al., 2017).  
Understanding the physiological roles of these enzymes will help in the development 
of novel treatments for tuberculosis and further our understanding of the biology of 
mycobacteria. In this study we reveal the physiological role of the FDOR-B2 clade by 
investigating the enzymes MSMEG_6526 from M. smegmatis, and its orthologue Rv0121c 
from M. tuberculosis. Knockout studies were used to identify phenotypes of partially and 
completely inhibited growth in defined growth conditions, making these enzymes conditionally 
essential. These phenotypes were shown to have an accumulative effect instead of a toxic 
effect. Proteomics and metabolomics revealed that pathways related to central metabolism and 
amino acid metabolism were affected by the knockout. Crystal structures of each protein were 
solved to examine the structure features of the protein revealing structure similarities to other 
FDOR-Bs but with an active site that is distinct than other FDORs due to a large dynamic loop.  
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3.2 Materials and Methods 
 
3.2.1 Mycobacterial strains, media, and growth conditions 
In this study, the mycobacterial strains used were M. smegmatis mc2155 WT (Snapper et al., 
1990) or M. smegmatis MSMEG_6526 knock out (this study). Strains were grown on LB agar 
plates supplemented with 0.05% (w/v) Tween80 (LBT) and inoculated into Hartmans de Bont 
(HdB) minimal medium supplemented with 25 mM glycerol (Berney et al., 2012) and grown 
at 37 °C with agitation (180 rpm) for starter cultures. For growth experiments, starter cultures 
at mid-logarithmic phase (OD600 0.2–0.8) were inoculated in HdB containing 25 mM of a 
specified carbon sources and grown either aerobically (30 ml medium in a 125 ml flask) or 
microaerobically  (30 ml medium in 120 ml sealed serum vials, butyl rubber stoppered, 
O2 impermeable) at 37 °C with agitation (180 rpm). Optical densities to assess growth were 
measured at 600 nm in a WPA CO 8000 Cell Density Meter. 
 
3.2.2 Construction of M. smegmatis Δ6526 mutant 
The MSMEG_6526 markerless knockout was created by amplifying a 1041 bp fragment 
flanking MSMEG_6526 on the left using the primers 
GTCCTGCCGTGACGGCTCAGAATTCGGCCATGGCCCCAGGG and 
GTACACTAGTCAATCCGGTGGCAGCGCAATCAC and a 1068 bp fragment 
flanking MSMEG_6526 on the right with the primers 
GTACATAGTCAGGATTCCGCACAGGTTGAACGTG and 
CTGGGGCCATGGCCGAATTCTGAGCCGTCACGGCAGGACG. The two products were 
fused by PCR-overlap extension (Ho et al., 1989). The PCR product and the vector pX33 
(Gebhard et al., 2006) were digested with SpeI from New England Biolab (Massachusetts, 
USA)  and ligated together using T4 DNA ligase from New England Biolabs (Massachusetts, 
USA). Deletion of MSMEG_6526 was carried out using the two-step method for integration 
and excision of the plasmid as described previously (Tran and Cook, 2005). Briefly the vector 
was transformed into M. smegmatis mc2155 and grown on LBT plates supplemented with 5 
μg/ml gentamycin (LBTG) and grown at 28 °C until colonies were visible. Colonies were 
picked and grown in LBTG liquid medium at 28 °C until they reached an OD600 of 0.5-1.0. The 
culture was plated on LBTG plates and incubated at 40 °C until colonies were present. The 
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colonies were exposed to 250 mM catechol and colonies that turned yellow were picked and 
streaked on a LBTG plate and incubated at 40 °C until colonies were visible. Colonies were 
picked an inoculated into LBTG liquid media and grown until OD reached 0.5-1.0 and plated 
onto low salt LBT sucrose plates containing no antibiotics (yeast extract 5 g/L, tryptone 10 g/L, 
NaCl 2g/L, sucrose 100 g/L, agar 15 g/L) until colonies were visible. Colonies were exposed 
to 250 mM catechol and colonies that remain white were picked and streaked on a LBT plate. 
Knockouts were confirmed by sequencing. 
 
3.2.3 Proteomic preparation and analysis 
Cultures for proteomics were grown at 37 ºC in 30 ml HdB containing 25 mM Glycerol in 
sealed 120 ml serum vials in biological triplicate for both wild type and Δ6526. 5 ml samples 
were harvested at OD 0.5 and 1.0 into 60 % methanol at -20 °C and pelleted by centrifugation 
at 10,000 × g for 10 mins at – 10 °C. Samples were washed 3 times in 40 % methanol (-20 °C) 
three times and stored at -80 °C. Cells were suspended in 50 mM triethylammonium 
bicarbornate and 1 % (w/v) sodium deoxycholate and boiled for 5 min. Samples were cooled 
down to room temperature and incubated with benzonase nuclease (Sigma Aldrich, Missouri, 
USA). Total protein concentration was measured using a Direct Detect® Infrared Spectrometer 
(Merck, Darmstadt, Germany) and sample were normalised to the lowest concentration. 
Samples were incubated with DTT (10 mM final concentration) at room temperature for 5 mins 
before incubating with iodoacetamide (20 mM final concentration) for 5 mins at room 
temperature. Samples were digested with 1:50 w/w protein ratio of sequencing grade modified 
trypsin (Promega, Wisconsin, United States) at 37 °C for 16 h. The tryptic digest was stopped 
by adding formic acid (1% v/v final concentration) and the soluble extract was obtained by 
centrifugation at 18,000 ×g for 5 min. samples were dried using a miVac Sample Concentrators 
(SP Scientific, New York, USA) and resuspended in 2 % acetonitrile  and 0.1 % formic acid 
and filtered through 0.22 μM filters.  
The samples were chromatographically separated on a Nanomate 3000 (ThermoFisher) 
nano LC system directly coupled to an Orbitrap Fusion Tribrid Mass Spectrometer. The 
peptides were desalted for 5 min on an Acclaim PepMap C18 (300 Å, 5 mm x 300 µm) trap 
column at a flow rate of 10 μL/min with loading solvent, and separated on an Acclaim PepMap 
C18 (100 Å, 150 mm × 0.075 mm) column at a flow rate of 0.3 μL/min at 35 C. A linear 
gradient from 5% to 40% solvent B over 60 min was employed followed by a wash and re-
Chapter 3: The role of MSMEG_6526 in Mycobacteria 
90 
 
equilibrate 40−99% B over 5 min, a 5 min hold at 99% B, return to 5% B over 6 min, and held 
for 7 min. The solvents used were: (A) 0.1% formic acid, 99.9% water; (B) 0.08% formic acid, 
80% acetonitrile, 19.92% water. The nano-LC was directly coupled to the Nanospray Flex Ion 
source of the Orbitrap Fusion MS. The ion spray voltage was set to 2400 V, the sweep gas was 
set to 1 Arb, and the ion transfer tube temperature was set to 300 °C. Data were acquired in 
data-dependent acquisition mode consisting of a Orbitap-MS survey scan followed by parallel 
acquisition of a high resolution Orbitrap scan at 120 000 resolution and multiple MS/MS events 
in the linear ion trap, over a 3 second period. First stage MS analysis was performed in positive 
ion mode over the mass range of m/z 400−1500 with an AGC target of 4 x 105 and a maximum 
injection time of 50 ms. Tandem mass spectra were acquired in the ion trap on precursor ions 
that exceeded an intensity threshold of 1000 counts with charge state 2−7. Spectra were 
acquired using quadrupole isolation with a 1.6 m/z isolation window and (Higher energy 
Collisional Dissociation) HCD set at 28% based on the size and charge of the precursor ion for 
optimum peptide fragmentation. Ion trap scan rate was set to rapid with an AGC target of 4 x 
103 and a maximum injection time of 300 ms, the instrument was set to utilise the maximum 
parallelizable time for injecting ions into the trap during a 3 second window whilst the Orbitrap 
was collecting high resolution MS spectra. Dynamic exclusion was set to exclude precursor 
ions after one occurrence with a 15 sec interval and a mass tolerance of 10 ppm. 
Protein identification was conducted using the Sequest algorithm in Proteome 
Discoverer v2.1 (ThermoFisher). Carbamidomethyl was selected as the alkylating agent and 
trypsin, was selected as the digestion enzyme, dynamic modifications for oxidation on H, M, 
W and deamidated N and Q were selected, with a maximum of three modifications. Tandem 
mass spectrometry data were searched against the M. smegmatis annotated database from 
UniProt. The database search results were manually curated to yield the protein identifications 
using a 1% global false discovery rate (FDR) determined by using the in-built FDR tool, 
Proteome Discoverer decoy database search feature, within Proteome Discoverer software.  
 
3.2.4 Metabolomic preparation and analysis  
Cultures for metabolomics were grown at 37 ºC in HdB media containing 25 mM Glycerol in 
biological triplicate to OD600  ~0.8. Cultures were pelleted and washed three times in HdB 
media containing no carbon source and then resuspended in HdB media containing 25 mM 
Sodium Acetate and grown at 37 ºC. 5 ml samples were harvested before being pelleted and 3 
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h after the carbon source was changed to Acetate. Samples were added to 60 % methanol (-20 
°C) and pelleted by centrifugation at 10,000  × g  for 10 mins at – 10 °C in pre-weighed tubes 
and then washed 3 times in 40 % methanol (-20 °C) three times and stored at -80 °C. Samples 
were dried down by freeze drying and then weighed. 100 μl of Methanol containing 8.8 ng/ml 
ribitol (-20 °C) were added to 1 mg of dried cell weight. Cells were lysed by bead beating at 
30 Hz for 5 Mins twice using a Tissue lyser (Qiagen, Hilden, Germany) and the supernatant 
was recovered by centrifugation at 20,000 ×g for 10 mins at -10 °C. Chloroform (-20 °C) was 
added at a 3:1 (methanol:chloroform) ratio, vortexed and incubated on ice for 10 mins. Ice cold 
Deionised water was added at a 3:3:1 (methanol:water:chloroform) ratio, vortexed, and 
centrifuged at  10,000 ×g for 5 mins. The aqueous layer was obtained from the organic layer 
and dried down by miVac Sample Concentrators (SP Scientific, New York, USA). Dried down 
samples were derivatised using an automated method on a PAL3 (CTC Analytics, Switzerland) 
autosampler,  as previously published (Carroll et al., 2015).  Briefly, samples were resuspended 
with 10 µl of 20 mg/ml methoxamine in pyridine and incubated at 37 C for 90 mins. 15 µl of 
BSTFA was added to the sample and incubated at 37 C for 30 mins then 5 µl of pyridine was 
added and incubated at 37 C for 60 mins, all incubation steps were conducted with incubation 
at 750 rpm. 1 µl of derivatised samples were loaded onto a GCMS-TQ8050 (Shimadzu, Kyoto, 
Japan) with a DB-5 Column (30 m × 0.25 mm, 1 µm) (Agilent, California, USA) with a starting 
temperature of 100 °C for 4 mins then ramped to 320 °C at 10 °C/min and held for 11 mins and 
a 1:1 split. The Shimadzu Smart Metabolites Database was used for both MS source and MRM 
conditions for the detection of metabolites. The retention time was corrected with the 
Automatic Adjustment of Retention Time (AART) function of the GCMS solutions software 
using a standard of alkanes (C7 to C33), as per the manufacturer’s instructions. All peaks were 
automatically integrated and manually checked for correct retention time and qualifier ion ratio. 
Data manipulation and statistical analysis was conducted using base R in RStudio and the 
tidyverse packages (Wickham, 2016)  
 
 3.2.5 Protein expression and purification  
The gene used for MSMEG_6526 in vector pETMCSIII was cloned previous work (Ahmed et 
al., 2015). MSMEG_6526 was transformed into E. coli BL21 (DE3) cells and grown on LB 
agar containing 100 µg/ml ampicillin. Single colonies were picked and inoculated in LB media 
with 100 µg/ml ampicillin. Starter cultures were grown overnight at 37 °C and diluted 1/100 
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in auto-induction media (Ahmed et al., 2015) and grown for 24 h at 30 °C. Cells were harvested 
by centrifugation at 8,500 × g for 20 minutes at 4 °C and resuspended in lysis buffer (50 mM 
NaPO4, pH 8, 300 mM NaCl, 25 mM imidazole) and lysed by sonication using an Omni 
Sonicator Ruptor 400 (2 x 6 min. at 50% power). The soluble extract was obtained by 
centrifugation at 13,500 ×g for 1 h at 4 °C and passed through a 5 mL HisTrap FF column (GE 
Healthcare), washed with lysis buffer and eluted with elution buffer (50 mM NaPO4, pH 8, 300 
mM NaCl, 250 mM imidazole). Purified protein was passed through a GE HiPrep 26/10 
desalting column for buffer exchange into TEV buffer (50 mM Tris pH 8 and 150 mM NaCl 
0.5 mM EDTA, 1 mM DTT) and the histidine-tag was cleaved by adding TEV protease at a 
1:10 ratio and left overnight at room temperature. Tag-free protein was purified from by 
passing the TEV reaction over a 5 mL HisTrap FF column and the flow through was collected. 
The collected protein was incubated with 1.5-fold excess F420 overnight at 4 °C, followed by 
size exclusion chromatography on a GE Hiload 16/ 600 Superdex 75 pg column in buffer 
containing 20 mM HEPES pH 7.5 and 150 mM NaCl. Fractions that were yellow and contained 
protein were pooled and used for crystallography after the sample diluted was in 20 mM 
HEPES pH 7.5 to a final solution of in 20 mM HEPES pH 7.5 and 50 mM NaCl and 
concentrated to 20 mg/ mL and stored at 4 °C.  
Rv0121c was ordered as a gene string from Invitrogen and cloned into the M. smegmatis 
expression vector pYUB28b (Bashiri et al., 2010) using Gibson assembly (Gibson et al., 2009). 
Rv0121c was transformed into M. smegmatis mc24517 cells (Wang et al., 2010) and grown on 
LB agar containing 0.05% Tween 80 and 50 µg/ml kanamycin and hygromycin. Single 
colonies were picked and inoculated in LB media with 0.05% Tween 80 and 50 µg/ml 
kanamycin and hygromycin. Starter cultures were grown for 3 days at 37 °C and diluted 1/100 
in auto-induction media (Ahmed et al., 2015) and grown for 5 days at 37 °C. Cells were 
harvested by centrifugation at 8,500 × g for 20 minutes at 4 °C and resuspended in lysis buffer 
(50 mM NaPO4, pH 8, 300 mM NaCl, 25 mM imidazole) and lysed by homogenisation using 
a M-110P electric benchtop homogeniser (Microfluidics, Massachusetts, USA). The soluble 
extract was obtained by centrifugation at 13,500 ×g for 1 h at 4 °C. Rv0121c was purified from 
the soluble extract as described for MSMEG_6526 above but was concentrted to 12 mg/ml. 
3.2.6 Protein crystallography 
The MSMEG_6526:F420 and Rv0121c:F420 complexes were screened for crystallisation 
conditions  using SG1 (Molecular Dimensions, Newmarket, Suffolk, UK), Index HT, Peg/Ion 
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HT, and Crystal screen HT (Hampton Research, California, USA) high-throughput 96-well 
crystallization screens, set up by hand. 
The best crystal for MSMEG_6526 that was used for data collection was grown in 100 
mM sodium acetate pH 4.6, 20 mM calcium chloride, and 28% MPD and was flash-cooled 
under a stream of nitrogen gas at 100 K. X-ray diffraction data was collected at the Australian 
Synchrotron beamline MX1 with an ADSC Q315 detector and Blu-Ice software (McPhillips et 
al., 2002). Diffraction data were integrated using XDS (Kabsch, 2010), and scaled using 
AIMLESS (Evans et al., 2013), in the CCP4 suite (Winn et al., 2011). Molecular replacement 
was performed with the previously solved apo-structure of MSMEG_6526 (PDB ID: 4ZKY) 
(Ahmed et al., 2015) using Phaser (McCoy, 2007) with F420 modelled manually into the 
difference density (mFo–DFc) at the binding site using COOT (Emsley et al., 2010). Model 
building was performed using Buccaneer (Cowtan, 2006) followed by manual loop building in 
Coot (Emsley et al., 2010). Refinement was performed using REFMAC (Murshudov et al., 
2011) 
The best crystal for Rv0121c that was used for data collection was grown in 0.1 M 
Sodium Acetate pH 4.6, 1.5 M sodium formate with seeding from initial screens. The 
cryobuffer used was the same as the crystallization conditions, with the addition of a 35% 
glycerol. The crystal was flash-cooled under a stream of nitrogen gas at 100 K and X-ray 
diffraction data was collected using the MX2 beamline at the Australian Synchrotron. 
Diffraction data were integrated using XDS (Kabsch, 2010), and scaled using AIMLESS 
(Evans et al., 2013), in the CCP4 suite (Winn et al., 2011). Molecular replacement was 
performed with the MSMEG_6526:F420 structure solved in this study (PDB ID: 5JV4) using 
Molrep (Vagin and Teplyakov, 1997) and residues were replaced to the correct sequence using 
chainsaw (Stein, 2008). Model building was performed using auto-build from PHENIX (Chen 
et al., 2010) followed by manual loop building in COOT (Emsley et al., 2010). Refinement 
was performed using REFMAC (Murshudov et al., 2011) and PHENIX (Chen et al., 2010). 
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3.2.7 Computational substrate docking 
MSMEG_6526 (PDB ID: 5JV4) was prepared using Protein Preparation Wizard (Sastry et al., 
2013) from the Schrödinger biological suite (Schrödinger, 2017) to identify the likely 
protonation state at pH 7.4 The KEGG database was obtained from the Zinc15 repository 
(Sterling and Irwin, 2015), prepared using Ligprep (Schrödinger Release, 2016) and docked in 
the active site of the protein using Glide with default settings (Friesner et al., 2004). The top 
1000 compounds successfully docked and ranked by docking score were used for selection of 
potential substrates. Of these, approximately two thirds were synthetic chemicals (650). Of the 
remaining naturally occurring chemicals, the largest chemical classes were aromatic amino 
acid, and closely related metabolites, and metabolites involved nucleic acid metabolism. 
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3.3 Results  
3.3.1 Growth of Δ6526 on Primary Carbon Sources 
Personal communication from Dr. Nicholas West of the University of Queensland revealed 
that M. tuberculosis strains that have the rv0121c interrupted via transposon mutagenesis 
cannot survive latent infection within mice. Therefore, we investigated the function and 
physiological role of Rv0121c to understand why it is essential. We used M. smegmatis as a 
non-pathogenic model of M. tuberculosis, and created a knockout of MSMEG_6526 (Δ6526), 
an Rv0121c orthologue, to identify phenotypes. The knockout was grown in different growth 
media to observed differences in growth rate compared to wild type. We observed that in a 
nutrient rich media (Lysogeny broth) there is no difference in the growth rates between 
wildtype and Δ6526 (Fig 3.1a). However, there is a slight difference in final cell density when 
the stationary phase is reached. We observed that the wildtype reached a maximum OD600 
reading of 4.1 ± 0.15 and Δ6526 reached a maximum OD600 reading of 3.6 ± 0.1. This 
difference may be due to carbon and oxygen limitation that occurs when the cell reaches the 
stationary phase (Smeulders et al., 1999) and MSMEG_6526 is needed to these conditions.  
To further the investigation of the effect of Δ6526 on M. smegmatis, we compared the 
growth of wildtype and Δ6526 in minimal media with different major carbon sources; glucose 
(carbohydrate), glycerol (polyol), and butyrate (lipid). Between carbon sources there was a 
difference in growth rate for the wild-type strain. This has been previously observed (Hasan et 
al., 2010) and the differences between the various media are most likely due to how the cells 
uptake and metabolise the various carbon sources. Despite this, the Δ6526 strain had a slower 
growth rate and lower maximum OD600 reading compared to the wildtype in all minimal media 
conditions tested. When grown on glucose (Fig 3.1b), Δ6526 had a 32% decrease in growth 
rate compared to wildtype and had a maximum OD600 reading of 1.9 ± 0.1 compared to 
maximum OD600 reading of the wildtype with 2.5 ± 0.1. The Δ6526 strain had a similar 
reduction in growth rate of 39% and a maximum OD600 reading of 1.93 ± 0.06 compare to 
wildtype type with 2.37 ± 0.11 when using glycerol, which metabolism uses part of the 
glycolysis pathway, as a carbon source (Fig 3.1b). When butyrate is used as the carbon source, 
which is metabolised differently from glucose and glycerol, Δ6526 still has a 14% slower 
growth rate and a lower maximum OD600 reading of 0.53 ± 0.06 compared to the wildtype of 
0.9 ± 0.01 (Fig 3.1c).  
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3.3.2 The Changes in Protein Expression in Δ6526  
After identifying the phenotypes of Δ6526, we wanted to understand how the biochemical 
processes were affected by the knockout. To investigate this, we compared the protein 
expression levels of wildtype M. smegmatis verses Δ6526 in the exponential phase of cell 
growth at OD600 0.5 and OD600 1.0 when both strains were grown on glycerol as the sole carbon 
source. Only a few proteins were seen to be upregulated at both growth points, including 
isocitrate lyase, one of the key enzymes of the glyoxylate pathway, and methylcitrate 
dehydratase, a key enzyme in the methylcitrate cycle (Table 3.1). Isocitrate lyase in 
mycobacteria is known to be the enzyme that converts methylisocitrate to succinate and 
pyruvate in the last step of the methyl citrate cycle instead of a separate enzyme like in other 
species (Gould et al., 2006; Upton and McKinney, 2007). Therefore, isocitrate lyase is most 
likely being upregulated for the methylcitrate cycle as well. The upregulation of these cycles 
Figure 3.1 Growth rates of wildtype and Δ6526 M. smegmatis on major carbon 
sources. The measured optical densities of wildtype (blue) and Δ6526 (red) at the given 
time points when grown in LBT (a) or in HdB minimal media containing 25 mM Glucose 
(b), Glycerol (c), or butyrate (d). All conditions contained 0.05% (w/v) tyloxapol to avoid 
clumping. Error bars represent standard deviations from three biological replicates. 
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seems to indicate that the Krebs cycle is not being fully utilised, as these cycles allow the cell 
to assimilate metabolites that cannot be produced by the Krebs cycle, such as odd chain fatty 
acids  (Muñoz-Elías et al., 2006).   
Proteins involved in the Krebs cycle were downregulated in Δ6526, including succinate 
dehydrogenase, which is downregulated in both growth points (Table 3.3), and citrate synthase, 
and 2-ketoglutarate ferredoxin oxidoreductase that were downregulated in the OD600 0.5 
growth point. Late stage glycolysis that feeds into the Krebs cycle seemed to be downregulated 
as the concurrent enzymes, pyruvate kinase, and pyruvate flavodoxin /ferredoxin 
oxidoreductase, were downregulated as well as L-lactate dehydrogenase. Amino acid 
metabolism that utilises metabolites from the Krebs cycle were downregulated in Δ6526. This 
included glutamate metabolism with glutamate decarboxylase, ferredoxin-dependent glutamate 
synthase, NADPH-glutamate synthase, and glutamate dehydrogenase all being downregulated. 
The first two enzymes in aspartate metabolism, aspartokinase and aspartate-semialdehyde 
dehydrogenase, were downregulated. This pathway is also involved in arginine, and 
methionine biosynthesis, where two key enzymes arginine biosynthesis bifunctional protein, 
and methionine synthase were downregulated. The first step of the branched amino acid 
biosynthesis from pyruvate, acetolactate synthase, was also downregulated. The electron 
transport chain was affected with the downregulation of NADH dehydrogenase A, suggesting 
a decrease in cell respiration that correlates with the slower growth seen by Δ6526. Despite 
being grown in glycerol, two enzymes that degrade it in different pathways, glycerol 
dehydratase and the co-enzyme B12-dependent glycerol dehydrogenase, were downregulated 
at the OD 0.5 growth point. The downregulation of all these proteins seem to show that several 
pathways were affected by the loss of MSMEG_6526, although there seems to be a correlation 
with central metabolism (Krebs cycle), and amino acid metabolism which have highly related 
pathways.  
Interestingly, we identified three F420-dependent enzymes that were upregulated in both 
growth points. Firstly, the FDOR MSMEG_2027, which is found in the FDOR-A clade, is 
proposed to be involved in cell respiration (see Chapter 2). As the enzymes that have altered 
regulation in Δ6526 are related to metabolism, this can be seen as further evidence for the role 
of FDOR-As in the cells energetics. The other two F420-dependent enzymes, MSMEG_4879 
and MSMEG_5732, are LLHT enzymes with unknown function (Greening et al., 2016). 
Although blast searches of these enzymes show homology to F420H2-dependent methylene-
H4MPT reductase (Mer), which are involved in the CO2-reducing pathway in methanogenesis  
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by reducing CH2=H4MPT to CH3-H4MPT (Aufhammer et al., 2005). The function of these 
enzyme will need to be tested to confirm function but it is unlikely that they retain Mer function 
as mycobacteria are unknown to perform methanogenesis. The only known activity of LLHTs 
in mycobacteria other than Fgd, are involved with cell surface lipids biosynthesis (Purwantini 
and Mukhopadhyay, 2013; Purwantini et al., 2016).  
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3.3.3 Growth Curves of Δ6526 on Central Metabolism Intermediates 
To further investigate the effect of Δ6526 on the central metabolic pathways we compared the 
growth of wildtype M. smegmatis to the Δ6526 strain on compounds related to the Krebs, 
glyoxylate, and methylcitrate cycles (Fig 3.3). We observed that wildtype M. smegmatis was 
able to grow on all selected carbon sources, but Δ6526 was not able to grow on pyruvate or 
acetate (Fig 3.3a, b), precursors to the Krebs cycle and several amino acid metabolomic 
pathways. This suggests that MSMEG_6526 is conditionally essential to M. smegmatis. The 
Δ6526 strain was able grow on propionate, a precursor to the methylcitrate cycle, although had 
a 25% slower growth rate compared to the wildtype and a lower maximum OD600 reading of 
0.93 ± 0.06 compared to the wild type with 1.17 ± 0.06 (Fig 3.3c). The Δ6526 strain was also 
able to grow on succinate, a key metabolite involved in the Krebs, glyoxylate, and methylcitrate 
cycle, but with a 33% slower growth rate compared to wildtype (Fig 3.3d). A difference in final 
cell density was observed when grown on succinate with the Δ6526 strain having a lower 
maximum OD600 reading of 1.36 ± 0.06 compared to the wildtype maximum OD600 reading of 
1.83 ± 0.15. These growths are similar to the previous growth curves above (glucose, glycerol, 
and butyrate). This suggests that these compounds as carbon sources can use an alternative 
pathway whereas pyruvate and acetate cannot. 
The Δ6526 strain can recover growth when glycerol is added to the culture that has 
been incubated with acetate or pyruvate as the sole carbon source. As the Δ6526 strain cannot 
grow on acetate or pyruvate, we wanted to investigate if this is due to cell’s inability to utilise 
a pathway that relies on these compounds, or if there was an accumulation of a toxic compound 
due to the loss of MSMEG_6526. To investigate this, we grew the Δ6526 strain for 100 h and 
then added glycerol to examine any effect (Fig 3.4). We also grew wildtype strain on acetate 
as a positive control.  Both the wildtype and the Δ6526 strain grew as previously shown (Fig 
3.3a), while the addition of glycerol to the Δ6526 strain allowed growth to recover. We also 
observe a higher growth reading for the Δ6526 with glycerol than the wildtype strain on acetate 
as different carbon sources dictate different growth rates and cell density as seen in figure 3.1. 
The recovery of growth by the Δ6526 strain incubated on acetate implies that the lack of growth 
is not due to cell death by the accumulation of a toxic compound, as we would expect no growth 
recovery due to the death of cells if that was the case. We therefore predict that the inability to 
grow is due to the inhibition of a pathway by the lack of MSMEG_6526 that utilises acetate. 
This pathway seems to be bypassed if a carbon source earlier in the pathway is available, such 
as glycerol.  
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Figure 3.4 Growth of Δ6526 on acetate can be restored by other carbon source. The 
measured optical densities of wildtype (blue), Δ6526 (red), Δ6526 with 0.2% Glycerol 
at 100 h (green)  at the given timepoints when grown in HdB minimal media containing 
25 mM Acetate. The black arrow indicates when glycerol to a final concentration of 
0.2% was added. All conditions contained 0.05% (w/v) tyloxapol to avoid clumping. 
Error bars represent standard deviations from three biological replicates. 
Figure 3.3 Growth rates of wildtype and Δ6526 M. smegmatis on different carbon 
sources. The measured optical densities of wildtype (blue) and Δ6526 (red)  at the given 
timepoints when grown in HdB minimal media containing 25 mM acetate (a) pyruvate (b), 
proprionate  (c), or succinate (d). All conditions contained 0.05% (w/v) tyloxapol to avoid 
clumping. Error bars represent standard deviations from three biological replicates. 
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 3.3.4 The Change in the Metabolome of Δ6526 
To investigate the changes to the metabolome when grown on acetate, we grew both wildtype 
and Δ6526 on glycerol until the exponential growth phase and switched the carbon source to 
acetate and analysed the change in the metabolome (Table 3.5). We first analysed changes that 
were observed in both strains as that would suggest effects caused by the carbon source change 
to acetate. This included the accumulation of several metabolites directly involved in the Krebs 
cycle including citrate, aconitate, and fumarate. Arginine and tyrosine, amino acid precursors 
to fumarate, were also accumulated in both stains. The accumulation of these metabolites seen 
in both strains would suggest that when grown on acetate the Krebs cycle is limited, as seen in 
our proteomics. This may also explain the slower growth rate on acetate compared to glycerol 
(Fig 3.1, 3.2). The ability to synthesis pyruvate may also effect the energetics of the cell grown 
on acetate as homoserine, threonine, glycine, and serine, which all form one pathway that 
synthesises pyruvate, and are accumulated in both strains.  
 In the Δ6526 strain, the glutamate metabolomic pathway was affected with the 
accumulation of the key metabolites 2-ketoglutaric acid, 4-aminobutyric acid (GABA), and 
glutamate. This complements our proteomics, as we saw this entire pathway downregulated in 
Δ6526. We observed several pathways that were related to glutamate metabolism being 
affected by Δ6526. This included the metabolism of lysine, which was accumulated in Δ6526, 
where one of the two biosynthetic pathway has 2-ketoglutarate as a precursor. Aspartate was 
also accumulated in Δ6526, and is involved in serval other amino acid pathway but is also a 
metabolite involved in lysine’s second biosynthesis pathway. Proteins involved in aspartate 
metabolism, aspartokinase and aspartate-semialdehyde dehydrogenase were also 
downregulated in Δ6526. We also observed the accumulation of the lysine degradation product, 
N6-acetyllysine, which was not detected in the wildtype at all and was not detected in Δ6526 
when grown on glycerol. 2-ketoglutarate can be reduced to 2-hydroxylglutarate to feed into 
butanoate metabolism. We observed that in the wildtype strain that this compound was 
accumulated but was not affected in Δ6526 suggesting the knockout could be affecting the 
butyrate metabolism as well amino acid metabolism. Interestingly, as Δ6526 was also not able 
to grown on pyruvate, we observe accumulation of the valine, and isoleucine. These amino 
acids have pyruvate as a precursor and degradation product.
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Table 3.5: Change in metabolome when grown in acetate 
Metabolite Strain Fold Changea P valueb 
2-Aminoethanol Δ6526 1.428 0.0296 
2-Aminopimelate Wt/Δ6526 23.895/7.223 0.0327/0.0022 
2-Hydroxyglutarate Wt 1.562 0.0399 
2-Ketoglutarate Δ6526 4.831 0.0004 
3-Aminoglutarate Δ6526 1.594 0.0001 
3-Aminopropanoate Wt/Δ6526 0.142/0.569 0.026/0.0367 
3-Methylglutarate Wt 0.583 0.0406 
4-Aminobutyrate Δ6526 2.274 0.0004 
4-Hydroxyproline Δ6526 1.538 0.0008 
5-Hydroxymethyl-2-furoate Δ6526 0.882 0.0463 
Aconitate Wt/Δ6526 Upregulated/5.011 na/0.0023 
Adenine Δ6526 1.695 0.0094 
Adenosine Δ6526 3.078 0.0034 
Arginine Wt/Δ6526 2.539/11.937 0.0272/<0.0001 
Aspartate Δ6526 1.595 0.0001 
Benzoate Δ6526 0.786 0.0072 
Citrate Wt/Δ6526 22.984/7.405 0.0286/0.0024 
Cystathionine Δ6526 2.576 0.0075 
Cytosine Δ6526 1.417 0.0284 
Decanoate Wt 0.591 0.0389 
Dihydroxyacetone phosphate Δ6526 2.117 0.0022 
Erythrulose Δ6526 14.029 <0.0001 
Fumarate Wt/Δ6526 2.753/3.431 <0.0001 
Glucono-1,5-lactone Δ6526 2.014 0.0002 
Glutamate Δ6526 1.582 0.0012 
Glutamine Δ6526 3.422 0.0202 
Glycerol 2-phosphate Δ6526 1.705 0.0038 
Glycerol 3-phosphate Δ6526 2.126 0.0021 
Glycine Wt/Δ6526 8.47/3.744 0.0043/0.0014 
Guanine Δ6526 1.711 0.0082 
Homocysteine Δ6526 2.498 0.0030 
Homoserine Wt/Δ6526 9.581/21.61 0.0069/0.0014 
Hydroquinone Δ6526 1.221 0.0365 
Isoleucine Δ6526 2.14 0.0047 
Lysine Δ6526 8.951 0.0010 
Maleate Wt/Δ6526 2.066/2.941 0.0123/<0.0001 
Mesaconate Wt 2.854 0.0262 
Methionine Δ6526 2.016 0.0017 
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N6-Acetyllysine Δ6526 Upregulated na 
N-Acetylaspartate Wt/Δ6526 23.642/17.886 0.0095/0.0006 
Niacinamide Δ6526 1.865 0.0213 
Nicotinate Δ6526 1.689 0.0356 
Nonanoate Δ6526 0.752 0.0126 
Norvaline Wt/Δ6526 2.316/11.342 0.006/0.0002 
Octanoate Wt/Δ6526 0.53/0.633 0.045/0.0022 
Ornithine Δ6526 12.914 0.0002 
Proline Wt/Δ6526 3.994/4.211 0.0097/0.0003 
Protocatechuate Wt 1.921 0.0203 
Serine Wt/Δ6526 3.71/3.372 0.0134/0.0017 
Threonine Wt/Δ6526 7.735/9.712 0.0029/<0.0001 
Thymine Wt 0.338 0.0405 
Tryptophan Δ6526 2.326 0.0011 
Tyramine Δ6526 8.598 0.0011 
Tyrosine Wt/Δ6526 2.967/3.375 0.0196/0.0002 
Valine Δ6526 2.746 0.0008 
 a upregulated is defined as only being present in the samples when switched to acetate as a 
carbon source 
b
 na
  = P value cannot be calculated for upregulation due to lack of compound present in the 
reference  sample   
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3.3.5 The Structures of MSMEG_6526 and Rv0121c 
The apo structure of MSMEG_6526 has been previously solved and published with little 
comment (Ahmed et al., 2015). To expand our understanding of the structural aspects of 
MSMEG_6526, we solved the structure with F420 bound at a resolution of 1.7 Å. As expected 
the structure revealed a split β-barrel fold homodimer. The asymmetric unit contained 3 
homodimers with F420 bound with only one molecule of F420 having electron density past the 
phosphate group, containing two well-resolved glutamate moieties. F420 in mycobacteria 
typically has a chain lengths of five to eight glutamates (Bair et al., 2001). The lack of electron 
density for the  full molecule of F420 can be explained by the flexibility of the glutamate chain 
(Ahmed et al., 2016). We also solved the structure of the M. tuberculosis orthologue, Rv0121c 
at a resolution of 2.99 Å, to compare structural aspects and to enable us to be able to perform 
structure based drug design. The structure revealed a split β-barrel fold monomer, although the 
native homodimer can be generated by crystal symmetry. Residues 41 to 47 and 58 to 67 had 
no discernible electron density, which is most likely due to disorder in the crystal. This may 
also explain why density corresponding to F420 was not clearly visible in the structure. It is also 
possible that F420H2 would be the preferred bound co-factor, as it is the form that is used when 
reducing substrates but since F420 is present in the MSMEG_6526 structure. Despite this, F420H2 
would be difficult to get in a crystal structure as it will oxidise too quickly before obtaining 
crystal and would have to be done in an anaerobic or harsh reducing conditions. F420 is also 
present in other FDOR structures (Ahmed et al., 2015) and therefore it may be possible to get 
a structure of Rv0121c with F420 by improving the crystal used to diffract. 
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Figure 3.6 Structures of MSMEG_6526 and Rv0121c. Structure of MSMEG_6526 (green) with 
bound F420 (yellow) at 1.7 Å resolution and structure of Rv0121c (cyan) at 2.99 Å resolution. 
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Crystal MSMEG_6526 Rv0121c 
PDB ID 5JV4 To be submitted 
Data collection   
Space group  C 1 2 1 H 3 2 
Unit-cell parameters   
a, b, c (Å) 139.95, 82.24, 75.98 98.74, 98.74, 76.41 
α, β, γ (°) 90, 90.85, 90 90, 90, 120 
Wavelength (Å) 0.9501 0.953735 
Resolution range (Å) a 75.97- 1.7 (1.74-1.7) 37.31-2.99 (3.17– 2.99) 
Total reflections a 360146 (17700) 43353 (7408) 
Unique reflections a 96899 (6750) 3004 (475) 
Completeness (%)a 99.9 (99.9) 100 (100) 
Multiplicity a 3.7 (3.7) 14.4 (15.6) 
Rmerge 
a 0.122 (0.803) 0.525 (2.985) 
Rpim
 a 0.075 (0.482) 0.144 (0.778) 
Mean <I/σ(I)> a 6.6 (1.7) 4.3 (0.9) 
CC1/2
 a 0.986 (0.626) 0.994 (0.445) 
Refinement   
Rwork / Rfree 0.189/0.231 0.2242/0.3264 
No. of Macro molecules 6 1 
Number of atoms (all) 7362 973 
Protein 6544 962 
Water molecules 
Ligands 
542 
276 
11 
0 
B-factor (Å2)   
Main chains 26.30 72.9 
Water molecules 28.00 71.7 
Ligands 27.30 0 
RMSD   
Bond Lengths (Å) 0.018 0.011 
Bond Angles (°) 1.831 2.05 
Ramachandran plot regions (%)   
Favored  98 88.7 
Allowed  2 10.43 
Outliers 0 0.87 
aValues in parentheses are for the highest-resolution shell. 
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The structure of MSMEG_6526 contained three enlarged loops that seem to be unique 
to these proteins as highlighted in Figure 3.5a. We have designated these loops as I (residues 
38 to 46), II (residue 52 to 62), and III (residue 81 to 88). Loop I is not involved in the active 
site and seems to have no involvement in the catalytic reaction based on placement. This loop 
most likely has no structural importance as the residues between MSMEG_6526 and Rv0121c 
are not conserved (Fig 3.5c). Loop II and III flank both sides of the active site and create a 
more define and smaller active site compared to other FDORs (Fig. 3.5a).  Loop II creates a 
hinge that has an open and closed conformation over the active site when F420 binds, and loop 
III flanks the opposite side of the active site with no notable conformational changes (Fig 3.5b). 
Both of these loops are conserved between MSMEG_6526 and Rv0121c. Aligning Rv0121c 
to MSMEG_6526 shows the active site is highly conserved (Fig 3.7D). Except for aspartate 53 
and lysine 55, which seem to have different conformations between the two structures. This 
will probably be due to the position of loop II as we observed these two residues are in different 
conformations in the active site depending if loop II is in the closed or open state. The position 
of lysine 55 when the loop is in the closed conformation is siting over the F420 and therefore 
most likely in a different conformation when a substrate is bound. 
 To investigate the substrate that can be utilised by these enzymes, we performed high 
throughput in silico docking of MSMEG_6526:F420 with the KEGG database. From the top 
1000 hits, we observed two pathways that contain a high level of hits within the top substrates 
docked, aromatic amino acid biosynthesis and nucleic acid metabolism. The docking of both 
these pathways as demonstrated by 3-dehydroshikimate (Fig 3.8a), a key precursor in aromatic 
amino acid biosynthesis, and guanine (Fig 3.8b), are shown to involve aromatic rings that allow 
for pi stacking between F420 and Trp85. The docking also revealed that the residues Tyr120 
and Asp53 are important in binding these substrates.  Tyr120 interacts with the hydroxyl groups 
of 3-dehydroshikimate while this residue interacts with the carbonyl group of guanine and the 
Asp53 interacts with the nitrogen groups. Unfortunately, binding assays of tyrosine, 
tryptophan, phenylalanine, shikimate, and 3-dehydroshikimate with MSMEG_6526 and F420 
revealed no binding, and activity assays did not reveal any activity (data not shown). Several 
of nucleotide metabolism substrates have been shown to have no activity with MSMEG_6526 
including all the dNTPs, xanthine, hypoxanthine, caffeine and adenosine (Greening et al., 
2017). Interestingly, in the crystal structure of MSMEG_6526 we found the crystallisation 
agent 2-Mehtyl-2,4-pentadiol (MPD) present in all the active sites with open conformations 
(Fig 3.8c). This revealed that despite the bias towards compounds containing aromatic rings 
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found in our in silico docking, MSMEG_6526 can bind aliphatic substrates. This could allow 
it to bind other aliphatic compounds, such as carboxylic acids found in the Krebs cycle.   
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I
II 
III
Figure 3.7 Structural aspects and comparisons of MSMEG_6526 and Rv0121c. (a) 
Structural comparison of MSMEG_6526 (green) with F420 (yellow) and Rv2074 (PDB ID: 
5JAB) (orange) highlighting difference in loop size as indicated by arrows. (b) Comparison 
of MSEG_6526 with F420 (yellow) in a closed (orange) and open state. (c) Sequence 
alignment of MSMEG_6526 and Rv0121c shaded black for identical residues, and grey for 
similar residues. Lines above sequence indicate the region relating to the loop indicated, 
active site residues are indicated by A below the sequence. (d) Comparison of the active site 
residues of MSMEG_6526 (green) with F420 (yellow) and Rv012c (cyan)  
A
D
Y81/83 W85/87 Y120/122 
D53/55 K55/57 
L88/90 
V33 
B
C
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Figure 3.8 Binding of substrates in MSMEG_6526 active site. In silico docking of 3-
dehydroshikimate (A) and guanine (B) into the active site of MSMEG_6526 with F420 
bound. The binding of 2-Mehtyl-2,4-pentadiol (C) into the active site of MSMEG_6526 
with F420 bound as found in the crystal structure. 
A
B
C
Y81 
W85 
L88 
Y120 
D53 
Y117 
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3.4 Discussion 
 
In this study we explored the role of MSMEG_6526 in M. smegmatis as a model to understand 
the role of Rv0121c in M. tuberculosis. We showed that that MSMEG_6526 was conditionally 
essential as the MSMEG_6526 knockout was not able to grow on acetate or pyruvate and had 
a slower growth rate compared to the wildtype when grown on other carbon sources. Due to 
this, it is probable that MSMEG_6526 is involved in a conditionally important metabolomic 
pathway (such as would be required for emergence from dormancy) and the cell can use an 
alternative pathway if the carbon source supplied, such as glycerol or glucose, can utilise the 
alternative pathway. These data reveal that the pathway, which we are yet to fully identify, 
does not have an alternative if pyruvate or acetate are the only source of carbon. The data from 
Dr. Nick West showed that Rv0121c is essential in latent tuberculosis, therefore the pathway 
MSMEG_6526 is involved with is only used when the cell is in latency and does not have 
access to the other pathway. The effect of MSMEG_6526/Rv0121c should therefore be further 
explored for understanding the metabolism of mycobacterial is latency. 
 Proteomics and metabolomics were used to understand the underlying biochemical 
processes that happen in the Δ6526 phenotype and are summarised in Figure 3.6. Comparison 
of the proteome in wildtype and Δ6526 revealed that the central metabolism was highly 
affected with proteins displaying upregulation generally belonging to either the glyoxylate 
cycle or the methylcitrate cycle being upregulated. These cycles both allow the cell to utilised 
other substrates to be used for energy and synthesis of carbohydrates and amino acids when 
glucose is not available (Lorenz and Fink, 2002; Wang et al., 2003; Upton and McKinney, 
2007). This was complemented with the downregulation of several enzymes in the Krebs cycle 
showing that it was underutilised in the cell. Although this does not imply the that 
MSMEG_6526 is directly involved in the Krebs cycle as M. smegmatis has all the functioning 
enzymes needed for the Krebs cycle (Tian et al., 2005) and previous studies have shown similar 
growth defects including lack of growth on acetate with the knockout of gluconeogenesis 
(Marrero et al., 2010), suggesting that MSMEG_6526 is involved indirectly with the Krebs 
cycle. Interesting we saw the downregulation of citrate synthase, the first step in both the Krebs 
cycle and glyoxylate cycle, but as isocitrate lyase is also used in the methylcitrate cycle in 
mycobacteria, this suggest that the glyoxylate cycle is not being used and is being used primary 
in the methyl citrate cycle. 
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We complemented this by examining the metabolome of Δ6526 in acetate to identify 
the changes that stop it from growing. We observed the same pathways were affected as we 
observed in proteomics. Some of these changes happen in both strains and although these 
changes are not a direct effect of the Δ6526 strain, it helps understand the differences between 
carbons sources and why the knockout cannot grown on acetate while still being able to grow 
other carbon sources. As a result of acetate, we see the Krebs cycle is affected suggesting that 
acetate is not an effective energy source. This may explain why we see the wildtype grow 
slower on it compared to other carbon sources. As there seems to be lower energetics with 
acetate, the effect that Δ6526 causes may amplify this defect this making it too hard for the cell 
to grow. Within the Δ6526 strain we saw the glutamate pathway being affected which was also 
downregulated in the proteomics. Glutamate is important for many functions of the cell as it 
feeds into the Krebs cycle, but also feeds into other pathway including lysine biosynthesis that 
also seemed to be affected by the knockout. The first two steps into aspartate catabolism were 
downregulated in proteomics and aspartate itself was affected by Δ6526. Aspartate also feed 
into a separate pathway for lysine biosynthesis. Interestingly a degradation product of lysine, 
N6-acetyllysine was only detected on Δ6526 when it had been grown on acetate suggesting that 
lysine metabolism may play a role in the function of MSMEG_6526.  
The structures of both MSMEG_6526 and Rv0121c revealed the split β-barrel fold that 
defines the FDORs (Ahmed et al., 2015). These structures also revealed three extended loops, 
two of which make a more defined active site compared to the structures of other FDORs that 
reveal less define, open active sites (Taylor et al., 2010; Ahmed et al., 2016). There is no 
immediate evidence for the function of the third loop that is not involved in the active site. It 
is possible it could be involved in other interaction, such as protein-protein interactions but as 
the loop is not conserved, it may not be important to the enzyme or the loop sequence is specific 
to the species. Since the active site of both enzymes are the same, it will allow the use of 
MSMEG_6526 to be used as a model for Rv0121c for further studies. These structures will 
allow for structure-based drug design, although the position of the loop when a substrate is 
bound will need to be further investigated to identify the position of the key lysine and aspartate 
in loop II. High throughput in silico docking revealed the binding of compounds containing 
aromatic rings and included substrates involved in the aromatic amino acid biosynthesis 
pathway and nucleic acid metabolism. Binding and activity assays showed that MSMEG_6526 
is not associated with these compounds. Although the docking did not reveal the physiological 
substrate, the data from the docking study may help for a starting point of identifying potential 
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inhibitors once activity is found. However, the position of loop II will need to be identified to 
account for all of the interactions of residues in the active site.  Despite this, the crystal structure 
revealed the binding of MPD, an aliphatic compound that is structurally similar to compounds 
related to the Krebs cycle. This reveals that despite our omics data not containing pathways 
that contain aromatic substrates, it is feasible for MSMEG_6526 to bind compounds found in 
our omics data. 
 Our findings have implications in the understanding of the metabolism of mycobacteria 
that can allow for the development of a new novel treatment against tuberculosis. As the burden 
of TB is becoming more apparent with the rise of drug resistance, there is a need for new novel 
treatments. The distribution of F420-dependent enzymes can allow for very specific targeting, 
and with our data revealing the importance of MSMEG_6526/Rv0121c to mycobacteria, we 
have reveal a new potential target. The WHO has announced as part of their End TB strategy 
that eliminating latent tuberculosis, especially in areas where HIV/AIDS is prevalent, is a key 
step (WHO, 2016). Since Rv0121c is essential to tuberculosis in latency, this research can be 
helpful in the development of new treatments to preventing more active infections arising from 
those already affected. Future studies to discover the role and function of 
MSMEG_6526/Rv0121c in mycobacteria will allow for the understanding of its unique 
biology in latency. This will allow us to set up system that can test new compounds and have 
a true understanding of the treatment that this will allow us to develop. 
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Chapter 4 
 
Structure and Function Classification of 
Flavin/Deazaflavin Oxidoreductases 
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4.1 Introduction 
 
The flavin/deazaflavin oxidoreductase (FDOR) superfamily in Mycobacteria has a large 
number of enzymes separated into three groups: FDOR-A, FDOR-AA, and FDOR-B (Taylor 
et al., 2010; Lapalikar et al., 2012). Ddn (Rv3547) was the first described FDOR and was 
discovered because it is responsible for activating the prodrug pretomanid (Ujjini H 
Manjunatha et al., 2006). After the discovery of Ddn, 28 proteins that utilised F420 in M. 
tuberculosis, including FDORs, were identified using phylogenetic profiling and were 
separated into the following three families: the luciferase-like monooxygenase (LLM) family, 
the pyridoxamine 5’-phosphate oxidase (PNPOx) family, and the Ddn family (Selengut and 
Haft, 2010). During the same time Taylor et al. identified 30 Ddn and PNPOx homologues in 
M. smegmatis that were able to degrade aflatoxins using F420H2. Phylogenetic analysis divided 
the enzymes into two clades: FDOR-A (Ddn family), and FDOR-B (PNPOx family) (Taylor et 
al., 2010). The FDOR-A clade was further divided into two groups, FDOR-A, and FDOR-AA, 
based on their ability to reduce aflatoxins (Lapalikar et al., 2012). As well as phylogenetic 
profiling, several structures of FDOR-Bs have been solved including: Rv1155 (1W9A), 
Rv2074 (2ASF), Rv2991 (1RFE), and MSMEG_3380 (3F7E) (Canaan et al., 2005; Biswal et 
al., 2006; Taylor et al., 2010). These structures have revealed that FDOR-Bs are dimers and 
contain a conserved split β-barrel fold despite sequence identify of less than 30%. Two 
structures of FDOR-As have been solved, MSMEG_3356 (3H96), and Ddn (3R5R) (Taylor et 
al., 2010; Cellitti et al., 2012). These structures show that FDOR-As contain the spilt β-barrel 
fold but are monomeric.  
Despite the initial profiling of the FDORs, the physiological roles of these enzymes are 
generally unknown and there has been no systematic classification of FDORs that includes the 
potential cofactors FMN, FAD and heme. The only proposed physiological role for a FDOR is 
Ddn, which has been shown to reduce quinones and is proposed to protect the cell from 
oxidative stress (Gurumurthy et al., 2013). To further the structure classification of FDORs, 
this chapter presents two published papers. The first paper classifies the sub-groups of FDOR-
A, FDOR-AA, and FDOR-B by sequence, structure, function and co-factor preference. This is 
achieved using experimental spectroscopic assays, enzymatic assays, phylogenetic analysis, 
and structural comparison and analysis. The preliminary functions of several groups were 
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identified including F420H2-dependent fatty acid reductases, F420H2-dependent biliverdin 
reductases, heme oxygenases and potential electron transfer proteins.  
The second paper reveals the physiological role of the M. tuberculosis FDOR-B 
Rv2074. This is achieved using enzymatic assays to identify activity and confirmed using 
NMR, and spectrum scanning to identity the product. The structure of Rv2074 with F420 bound 
was solved and in silico docking, molecular dynamics, and mutagenic studies were used to 
identify the binding mode of F420 and biliverdin, and catalytic mechanism was proposed. Using 
bioinformatics the abundance and distribution of F420-dependent biliverdin reductases was 
identified. 
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4.2 Sequence–Structure–Function Classification of a 
Catalytically Diverse Oxidoreductase Superfamily in 
Mycobacteria 
 
The following paper is presented in this chapter.  
 
Sequence–Structure–Function Classification of a Catalytically Diverse Oxidoreductase 
Superfamily in Mycobacteria  
F. Hafna Ahmed, Paul D. Carr , Brendon M. Lee, Livnat Afriat-Jurnou, A. Elaaf Mohamed, 
Nan-Sook Hong, Jack Flanagan, Matthew C. Taylor, Chris Greening and Colin J. Jackson 
Journal of Molecular Biology 2015, 427(22): 3554-3571 
Current status of paper:  Published   
Hafna Ahmed performed the majority of the experiments including all bioinformatics analysis, 
in silico substrate docking, and the majority of protein purification, crystallography, and assays. 
Paul Carr collected the crystallography data and helped with refinement. I analysed the in silico 
docking results from the high throughput screen performed by Jack Flanagan, I purified 
Rv1155, MSMEG_1981, and MSMEG_6526, and solved and refined the structure of 
MSMEG_6526. I designed and performed the biliverdin reduction assays with Rv1155 and 
MSMEG_3380 and performed the arachidonic acid binding and reduction assay with 
MSMEG_1981. Livnat Afriat-Jurnou helped with the initial FDOR classification and the 
development of experimental methods. Elaaf Mohamed purified the F420 used in the 
experiments and helped with the development of experimental methods. Nan-Sook Hong 
performed the binding assay for MSMEG_3880. Matthew Taylor assisted with the preparation 
and purification of F420. Hafna Ahmed and Colin Jackson wrote the paper with input from all 
authors.  
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4.3 Supplementary Material 
 
Fig. S1. Phylogenetic tree of the FDORs from Mycobacteria. All proteins characterised in this 
work from M. smegmatis (MSMEG_) and M. tuberculosis (rv) are annotated, where the solved 
crystal structures (in this work and previously) are annotated in red. 
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Fig. S2. Abundance and conservation of FDORs in mycobacteria. Nodes from the SSN (Fig. 2) 
were separated for cofactor specificity (FMN,yellow; FAD,orange; heme,red; non-
specific,blue; not tested, gray) at a logE cutoff of − 7.6. The F420-dependent proteins (green) 
were further separated at a logE cutoff of − 28, where each cluster represents proteins with 
~ 50% sequence identity. Black and pink triangles represent proteins characterized and 
structures solved in this study, respectively. Blue triangles represent previously published 
structures 
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Fig. S3. Ligand-bound absorbance spectra of MSMEG_6519 and MSMEG_4975. (a) Heme 
coordination to MSMEG_6519 and spectra of co-purified biliverdin. (b) FAD and heme 
binding protein MSMEG_4975 and its reduction with sodium dithionite. 
 
 
 
 
 
 
 
 
S4 Table. Comparison of F420H2 dependent reductase activity by proteins in the FDOR-A1 
sub-group 
substrate enzyme Km (µM) Kcat (s-1) Kcat/Km (s-1 M-1) 
Menadione 2027 23.4 ± 2.56 0.567 ± 0.009 2.42 × 104 
3356 8.67 ± 1.09 2.39 ± 0.04 2.76 × 105 
rv3547* 3.44 ± 1.27 0.295 ± 0.002 8.58 × 104 
PA-824 2027 nd nd nd 
3356 nd nd nd 
rv3547* 28.6 ± 3.55 0.078 ± 0.004 2.74 × 103 
* data from Gurumurthy et al. [1] 
Data are averaged from two independent experiments  ± standard error from the mean 
nd, no detected activity 
 
[1] Gurumurthy, M., Rao, M., Mukherjee, T., Rao, S. P., Boshoff, H. I., Dick, T., Barry, C. E., 
3rd & Manjunatha, U. H. (2013). A novel F(420) -dependent anti-oxidant mechanism protects 
Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol 
87, 744-55. 
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S5 Table. Data collection and refinement statistics for crystallography. 
Crystal MSMEG_2027 MSMEG_4975 MSMEG_6526 MSMEG_6519 
PDB ID 4Y9I 4YBN 4ZKY 5BNC 
Data collection     
Space group  I1 2 1 C1 2 1 P 21 21 21 P 61 
Unit-cell parameters     
a (Å) 37.49 84.72 56.7 62.10 
b (Å) 36.85 59.88 59.42 62.10 
c (Å) 77.59 89.66 95.99 301.41 
α, β, γ (°) 90, 96.59, 90 90, 93.83, 90 90, 90, 90 90, 90, 120 
Wavelength (Å) 1.5418 0.9655 0.9537 0.9537 
Resolution range (Å)* 26.19-1.50 
(1.52-1.50) 
44.73-1.90 
(1.94-1.90) 
19.81-1.65 
(1.67-1.65) 
43.77-2.25 
(2.32-2.25) 
Unique reflections 16332 35306 39312 31095 
Completeness (%)* 95.6 (92.1) 99.6 (99.2) 98.3 (76.8) 99.9 (99.2) 
Multiplicity* 2.7 (2.7) 7.5 (7.6) 7.0 (3.9) 5.2 (3.2) 
Rmerge 
*# 0.062 (0.514) 0.101 (1.109) 0.057 (0.901) 0.097 (0.637) 
Rpim
*^ 0.044 (0.369) 0.039 (0.428) 0.031 (0.667) 0.046 (0.417) 
Mean <I/σ(I)>* 13.0 (2.1) 13.0 (2.1) 21.3 (1.4) 14.1 (1.9) 
CC1/2
*† 0.997 (0.699) 0.998 (0.760) 0.999 (.467) 0.996 (0.516) 
Molecules per 
asymmetric unit 
1 2 2 2 
solvent content (%, v/v) 41 45 51 56 
Refinement     
Reflections used 16330 33553 39257 29399 
Resolution range (Å)* 26.2-1.50  
(1.54-1.50) 
43.6-1.90  
(1.95-1.90) 
19.4-1.65  
(1.68 -1.65) 
43.8-2.25  
(2.31-2.25) 
Rwork / Rfree
*‡ 0.155/0.199 
(0.267/0.334) 
0.176/0.223 
(0.274/0.313) 
0.222/0.259 
(0.324/0.362) 
0.185/0.230 
(0.282/0.332) 
Number of atoms (all) 1170 3805 2398 3989 
Water molecules 188 326 165 250 
Average B-factor (Å2)     
Main chains 10.3 30.2 29.7 31.4 
Side chains 13.6 36.5 33.0 35.7 
Water molecules 26.2 41.5 32.2 36.0 
FAD molecules - 39.9 - - 
Heme molecules - 35.1 - - 
R.M.S Deviations     
Bond Lengths (Å) 0.02 0.02 0.01 0.01 
Bond Angles (°) 1.91 1.90 1.11 1.77 
Chain A to B (Å) - 0.51 1.1 1.4 
Ramachandran plot 
regions (%) 
    
Favored  99.1 99.0 97.8 98.0 
Allowed  0.9 1.0 1.8 1.8 
Outliers 0 0 0.4 0.2 
*Values in parenthesis are for the highest-resolution shell 
#Rmerge = (Σh Σi |Ihi – Ih|) / (Σh Σi Ih) where Ih is the average intensity of i symmetry-related observations of the 
unique refection h. 
^Rpim = (Σh Σi (1/(nh – 1))1/2 |Ihi - Ih|) / (Σh Σi Ih) 
†CC1/2 = linear correlation coefficient between intensities from random half-datasets 
‡Rwork = Σh |F(obs) – F(calc)| / Σh |F(obs)| and 5% of the data that were excluded from the refinement were used to 
calculate Rfree. 
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S6 Table. Genomic context and co-occurrence analysis of AA1-AA3 subgroups 
 
 
  
Group Protein Associated protein Biological role/process 
of associated protein 
STRING 
score 
AA1 MSMEG_1981 MSMEG_1982 (acyl 
coA synthetase) 
Fatty acid biosynthesis 0.520 
AA2 Rv1871c Rv0593 (lipoprotein 
LprL) 
Found when searching for 
genes that are present in 
M. avium that may help 
invade intestinal mucosa 
[47]. LprL and LprK are 
membrane bound 
lipoproteins. 
0.860 
Rv0173 (lipoprotein 
LprK) 
0.760 
AA3 MUL2188 Cut5 (cutinase) Cutin (fatty acid) 
hydrolysis, facilitates 
pathogenesis 
0.601 
Cut1 (cutinase) 0.488 
Cut4 (cutinase) 0.469 
Lppx (lipoprotein) Lipoprotein  0.561 
MUL_3253 (lipid A 
biosynthesis lauroyl 
acyltransferase) 
Lipopolysaccharide 
synthesis for outer cell 
membrane 
0.475 
AA3 MSMEG_1077 MSMEG_1528 
(cutinase) 
Cutin (fatty acid) 
hydrolysis, facilitates 
pathogenesis 
0.530 
Cut3 (cutinase) 0.515 
MSMEG_1526 
(cutinase) 
0.485 
MSMEG_4465 
(cutinase) 
0.439 
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Fig. S7. Preliminary functional characterization of the FDOR-AAs. (a) Arachidonic reductase 
activity by MSMEG_1981 in the presence of 25 μM F420H2 (Km = 113 ± 21 μM,  
Kcat = 5.4 × 10
− 4 ± 2.0 × 10− 5 s− 1, andKcat/Km = 4.8 M
− 1 s− 1). (b) Affinity for arachidonic acid 
by FDOR-AAs 
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S8 Table. Text representation of conserved motifs in FDORs  
No
. 
Motif (regular expression) Role Group 
1 LT[TH]TG[RA]K[ST]G[KQ]PRxTP F420 binding All As and 
AAs 
2 P[DA]W[YV]RN[LV][RK]A[NA][PG]x[VA][TE][
VLI] 
F420 binding All As and 
AAs 
3 [GD]R[YV][IV][VIL]V[AG]S[KN]GG[AR][PD]K
[HN] 
F420 and 
substrate 
binding 
All As 
4 EYQA[KR]T[DS]R[VQ]IP[VL][FV][VEI][LC] Substrate 
binding 
All As 
 V[TR]ARE[LAV]TG[DEA]ER[DA][RE]L[WL]  All As 
AA1, AA2 
5 L[AT]T[VLF][RT][PA]DGRP[HQ][LV][SVT]P[V
I]W[FY]AV 
Cofactor 
binding 
All Bs 
 
6 SRK[VA]R[NR][IL]R[RA]DPR[VA][TSA][LVI] F420 binding B1-B6 
7 F[FS]T[HDN]A[GT]S[RAQ]K[GAV][RH][EQ][IL][AE
][HQ][NT]P[WR][AV][SA] 
FMN 
binding 
B9 
8 EG[KT]K[IL]EM[AIM][ER]AN[PDN][NR]V[CL][
FIV][ELT][AF]D 
FAD 
binding 
B8, B11 
9 [IL][YC][IV]Sx[IL]AEH[GY]RNL[EA]A[ND]PR[
AV][SD] 
heme 
binding 
B7 
 G[RW][YW][VL]S[VA][ED]G[TR]A[ET][VIL]xx
D[PG][AD]AV 
 B1-B4, B6, B8 
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S9 Text. Materials and Methods 
 
Cloning, expression and purification of proteins. All sequences for the FDOR-B related 
proteins were ordered as Gene Strings from Invitrogen, with additional 50 base pair flanking 
regions at each end, homologous to the multiple cloning site (Nde1 – EcoR1) of the target 
cloning vector pETMCSIII. The sequence at the 5’ end introduced a TEV protease cleavage 
site (GAGAACCTGTATTTTCAGGGT) between the His-tag and the N-terminus of the 
protein as well. These genes were amplified (forward primer: 
GTTTAATCGGATCCTAAGGAGGTTAATATTATG, reverse primer: GTTAGCAGCCG-
GATCTATCGATGCATGCCATGGTAC) and cloned into pETMCSIII using Gibson 
assembly 1. The genes for MSMEG_2027, MSMEG_3356 and the FDRAAs in the expression 
vector pDEST17 were generously provided by CSIRO 2. Truncated MSMEG_2027 (Δ26 
amino acids at the N-terminus) for protein crystallography was also cloned into petMCSIII 
using the Nde1 and EcoR1 restriction sites. (forward primer: 
CAAATAGTCATATGGTGCACGTGCTGGACCG, reverse primer: CAAGAATTCCT-
ATTCGACGATGAACACGGGGATC). 
 
The FDRAAs and MSMEG_3863 were purified using previously published methods 2. For the 
rest of the proteins, Escherichia coli strain BL21DE3 cells were transformed and starter 
cultures were grown in TB media containing 0.5% glucose at 37 °C. After 6 hours, the starter 
cultures were transferred to and grown overnight at 25-30 °C in 1 L of modified auto-induction 
TB media 3, containing 5 g yeast extract, 20 g tryptone, 85.5 mM NaCl, 22 mM KH2PO4, 42 
mM Na2HPO4, 0.6% glycerol, 0.05% glucose, 0.2% lactose and 100 µg/ml Ampicillin. Cell 
pellets were harvested by centrifugation at 5000 × g for 15 min at 4 °C, resuspended in 30 mL 
of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 25 mM imidazole, pH 8) and lysed by 
sonication using an Omni Sonicator Ruptor 400 (3 × 3 min at 60% power). The soluble fraction 
was separated by further centrifugation at 13000 × g for 1 hr at 4 °C and the lysate was passed 
onto a Qiagen or GE NiNTA column, where the purified protein was eluted with the same 
buffer containing an additional 250 mM imidazole.  
 
An additional step was performed before elution for the MSMEG_5243 and MSMEG_5675 
prepared for cofactor binding assays. The flavin co-purified with the protein was stripped by 
partial on-column protein refolding 4, which involved washing with buffer containing 50 mM 
NaH2PO4, 300 mM NaCl, 2 M urea and 2 M KBr at pH 6.5. The eluted samples were dialyzed 
into 50 mM Tris-HCl, 200 mM NaCl, pH 8 and stored at 4°C. Proteins used for crystallography 
were further purified by cleaving off the His-tag with TEV protease (expressed and purified 
in-house) and removing it by a second pass through the NiNTA column. They were then further 
purified by size exclusion chromatography using a GE Hiload 16/600 Superdex 75 pg column, 
and the final sample was concentrated to 1.3 mM (~30 mg/mL) in buffer containing 20 mM 
HEPES, 50 mM NaCl, pH 7.5. 
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Protein crystallography. High-throughput screens from Hampton Research were used to 
identify initial crystal forming conditions for MSMEG_2027, MSMEG_6526, MSMEG_6519 
as well as cofactor-bound MSMEG_4975. Truncated MSMEG_2027 (NΔ26) was used since 
the full-length protein failed to crystallize, similar to what was observed for the closely related 
protein rv3547 5. Refined conditions for the crystals used for data collection were as follows: 
MSMEG_2027 = 20% PEGMME5000, 0.05 M imidazole pH 6.7; MSMEG_4975 = 25 % 
PEG4000, 0.2 M ammonium sulfate, 0.1 M sodium acetate pH 4.6; MSMEG_6526 = 0.2 M 
sodium iodide, 22% PEG3350; and MSMEG_6519 = 0.2 M magnesium acetate, 0.1M HEPES 
pH 7.5 and 23% PEG3350. 
 
Data for MSMEG_2027 was collected in house (Xenocs GeniX 3D Cu HF microbeam X-ray 
generator, MAR345 plate detector) and MSMEG_4975, MSMEG_6526 and MSMEG_6519 
were collected at the Australian Synchrotron (beamline MX1 and detector ADSC Q210r for 
MSMEG_6519, beamline MX2 and detector ADSC Q315r for MSMEG_4975 and 
MSMEG_6526). Crystals were cryo-cooled under a stream of 100K nitrogen gas in the 
following cryobuffers: MSMEG_2027 - 35% PEGMME5000, 0.05 M imidazole pH 6.7, 500 
µM FMN; MSMEG_4975 - 35 % PEG4000, 0.2 M ammonium sulfate, 0.1 M sodium acetate 
pH 4.6; MSMEG_6526 - 0.2 M sodium iodide, 22% PEG3350, 13% ethylene glycol; 
MSMEG_6519 - 0.2 M magnesium acetate, 0.1M HEPES pH 7.5 and 24% PEG3350, 11% 
ethylene glycol. Diffraction data were integrated using XDS 6, and the CCP4 suite 7 was used 
for scaling using AIMLESS 8, followed by molecular replacement using Phaser 9. The 
structures 3R5Z 5 3FHK,2FUR, 4QVB 10 and 2ARZ were obtain phases for MSMEG_2027, 
MSMEG_5243, MSMEG_4975, MSMEG_6526 and MSMEG_6519 respectively. Model 
building was performed using Buccaneer 11 and ARP/wARP 12 followed by manual loop 
building in Coot 13. Interspersed refinements were done using Refmac 14 and PHENIX 15. Local 
non-crystallographic symmetry restraints were used for the refinement of MSMEG_4975, 
MSMEG_6519 and MSMEG_6526. A difference (mFo – dFc) omit map for FAD and heme in 
MSMEG_4975 was generated by refining the structure with the ligands removed (restrained 
refinement with no prior phase information using Refmac 14). 
 
 
1. Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A. & Smith, H. 
O. (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. 
Nat Meth 6, 343-345. 
2. Lapalikar, G. V., Taylor, M. C., Warden, A. C., Scott, C., Russell, R. J. & Oakeshott, 
J. G. (2012). F420-H2-Dependent Degradation of Aflatoxin and other Furanocoumarins 
Is Widespread throughout the Actinomycetales. PLoS One 7, e30114. 
3. Tartof, K. D. & Hobbs, C. A. (1987). Improved media for growing plasmid and cosmid 
clones. Focus 9. 
4. Hefti, M. H., Milder, F. J., Boeren, S., Vervoort, J. & van Berkel, W. J. H. (2003). A 
His-tag based immobilization method for the preparation and reconstitution of 
Chapter 4: Structure and Function Classification of Flavin/Deazaflavin Oxidoreductases 
156 
 
apoflavoproteins. Biochimica et Biophysica Acta (BBA) - General Subjects 1619, 139-
143. 
5. Cellitti, Susan E., Shaffer, J., Jones, David H., Mukherjee, T., Gurumurthy, M., 
Bursulaya, B., Boshoff, Helena I., Choi, I., Nayyar, A., Lee, Yong S., Cherian, J., 
Niyomrattanakit, P., Dick, T., Manjunatha, Ujjini H., Barry Iii, Clifton E., Spraggon, 
G. & Geierstanger, Bernhard H. (2012). Structure of Ddn, the Deazaflavin-Dependent 
Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation 
of PA-824. Structure 20, 101-112. 
6. Kabsch, W. (2010). XDS. Acta Crystallographica Section D 66, 125-132. 
7. Collaborative Computational Project, N. (1994). The CCP4 Suite: Programs for Protein 
Crystallography. Acta Crystallogr. D50, 760-763. 
8. Evans, P. R. & Murshudov, G. N. (2013). How good are my data and what is the 
resolution? Acta Crystallographica Section D 69, 1204-1214. 
9. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & 
Read, R. J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674. 
10. Mashalidis, E. H., Gittis, A. G., Tomczak, A., Abell, C., Barry, C. E. & Garboczi, D. 
N. (2015). Molecular insights into the binding of coenzyme F420 to the conserved 
protein Rv1155 from Mycobacterium tuberculosis. Protein Sci. 24, 792-740. 
11. Cowtan, K. (2008). Fitting molecular fragments into electron density. Acta 
Crystallographica Section D 64, 83-89. 
12. Carolan, C. G. & Lamzin, V. S. (2014). Automated identification of crystallographic 
ligands using sparse-density representations. Acta Crystallographica Section D 70, 
1844-1853. 
13. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Features and development 
of Coot. Acta Crystallographica Section D 66, 486-501. 
14. Murshudov, G. N., Skubak, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, 
R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). REFMAC5 for the refinement of 
macromolecular crystal structures. Acta Crystallographica Section D 67, 355-367. 
15. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., 
Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., 
Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., 
Terwilliger, T. C. & Zwart, P. H. (2010). PHENIX: a comprehensive Python-based 
system for macromolecular structure solution. Acta Crystallographica Section D 66, 
213-221. 
  
Chapter 4: Structure and Function Classification of Flavin/Deazaflavin Oxidoreductases 
157 
 
4.4 Rv2074 is a novel F420H2‐dependent biliverdin reductase 
in Mycobacterium tuberculosis 
 
The following paper is presented in this chapter  
 
Rv2074 is a novel F420H2‐dependent biliverdin reductase in Mycobacterium tuberculosis 
F. Hafna Ahmed, A. Elaaf Mohamed, Paul D. Carr, Brendon M. Lee, Karmen Condic-Jurkic, 
Megan L. O’Mara, and Colin J. Jackson 
Protein Science, 25(9), 1692-1709. 
Current status of paper:  Published   
Hafna Ahmed performed most of the experiments including enzyme assays, NMR, 
bioinformatics, protein purification and crystallography. Elaaf Mohamed performed and 
analysed all the computational simulations assisted by Karmen Condic-Jurkic and Megan 
O’Mara. Paul Carr collected the crystallography data and helped with structure refinement. I 
prepared and purified F420 for the experiments and developed the enzyme assay. Hafna 
Ahmed, Elaaf Mohamed, and Colin Jackson wrote the paper with input from all authors. 
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5.1 Introduction 
 
The FDOR superfamily have a range of promiscuous activities that allow Mycobacteria to be 
resilient against several conditions including hypoxia, oxidative stress, and resistance to 
bactericidal agents (Gurumurthy et al., 2013). The range of activities that the FDORs exhibit 
includes the degradation of toxic compounds such as aflatoxins, furanocoumarins, 
triarylmethane dyes, and a range of quinones (Guerra-Lopez et al., 2007; Taylor et al., 2010; 
Lapalikar et al., 2012; Gurumurthy et al., 2013; Greening et al., 2017). This promiscuity 
extends to the activation of nitroimidazole drugs including pretomanid, delamanid, and cgi-
17341, a nitroimidazole activated by a range of FDORs (Gurumurthy et al., 2012). Due to this, 
F420 in Mycobacteria and the enzymes that utilise it are attractive targets for anti-
mycobactericial development and enzyme engineering for biocatalysis (Williams and Duncan, 
2007; Taylor et al., 2013). Although interesting, the extent of these promiscuous activities and 
their involvement in cell protection and potential biotechnological applications has not been 
fully explored. This includes understanding how effective F420 is for protecting the cell against 
known bactericidal agents, and the range of compounds that can be reduced by FDOR and by 
which mechanism. 
 To further explore the potential and effect of the various promiscuous activities of 
FDORs, this chapter presents two published papers. The first paper presented identifies 
compounds that can be reduced by FDORs and are known to have bactericidal effects. This is 
achieved through enzymatic assays of these compounds with FDORs from M. smegmatis and 
confirmed using mass spectrometry to identify the product. A time course using LC-MS 
analysis is used to show the degradation of these compounds by M. smegmatis and fgd and 
fbiC knockouts are used to show the loss of this activity. MIC values were determined of 
wildtype M. smegmatis, and fgd and fbiC knockouts against the assayed compounds to show 
the effect of F420 loss on Mycobacteria detoxification.  
The second paper presented reveals a range of compounds, ranging from synthetic 
building blocks to more complex polycyclic compounds, which contain activated alkene 
groups and can be reduced by a range of FDORs from M. smegmatis. This was achieved using 
enzymatic assays to identify activity. Using substrate docking to determine the binding mode 
and donor-acceptor distance, and LC-MS and GC-MS to identify the products of the enzyme 
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assays including modified compounds. A common mechanism of the promiscuous activities of 
the FDORs is proposed.  
5.2 The redox cofactor F420 protects mycobacteria from 
diverse antimicrobial compounds and mediates a reductive 
detoxification system 
 
This section contains the following paper 
 
The Redox Cofactor F420 Protects Mycobacteria from Diverse Antimicrobial Compounds and 
Mediates a Reductive Detoxification System 
Thanavit Jirapanjawat, Blair Ney, Matthew C. Taylor, Andrew C. Warden, Shahana Afroze, 
Robyn J. Russell, Brendon M. Lee, Colin J. Jackson, John G. Oakeshott, Gunjan Pandey, Chris 
Greening 
Applied and Environmental Microbiology, 82(23), 6810-6818. 
Current status of paper:  Published   
Thanavit Jirapanjawat expressed and purified the enzymes and F420, and performed the 
enzymatic assays. Blair Ney performed the whole-cell consumption analysis and LC-MS 
analysis. Chris Greening performed the phenotyping analysis including MIC and CFU analysis. 
I designed the enzymatic assays and supervised Thanavit Jirapanjawat performing assays and 
data analysis, and created Figures 3b and S4. Colin Jackson, Matt Taylor, and Chris Greening 
supervised students. Thanavit, Blair, and Chris designed the figures and wrote the paper with 
input from all authors. 
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5.3 Supplementary Material  
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5.4 Mycobacterial F420H2-dependent reductases 
promiscuously reduce diverse compounds through a 
common mechanism 
 
This section contains the following paper: 
 
Mycobacterial F420H2-dependent reductases promiscuously reduce diverse compounds through 
a common mechanism 
Chris Greening, Thanavit Jirapanjawat, Shahana Afroze, Blair Ney, Colin Scott, Gunjan 
Pandey, Brendon M. Lee, Robyn J. Russell, Colin J. Jackson, John G. Oakeshott, Matthew C. 
Taylor, Andrew C. Warden,  
Frontiers in Microbiology 8 (2017) 
Current status of paper:  Published   
Thanavit Jirapanjawat expressed and purified the enzymes and F420, and performed the 
enzymatic assays. Shahana Afroze performed the LC-MS assay. Blair Ney performed the GC-
MS analysis. Andrew Walden performed the substrate docking. I designed the kinetic assays 
and supervised Thanavit Jirapanjawat performing assays and data analysis and created Figure 
4. Colin Jackson, Matt Taylor, John Oakeshott, Robyn Russell, Colin Scott, Gunjan Pandey 
and Chris Greening supervised students. Thanavit, Blair, and Chris designed the figures and 
wrote the paper. All Authors contributed to the editing of the manuscript. 
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5.5 Supplementary Material 
Table S1. Enzyme subgroups, molar absorption coefficients, and amino acid 
sequences of the eleven F420H2-dependent reductases tested from Mycobacterium 
smegmatis. 
  
Enzyme 
locus 
Enzyme 
subgroup 
Coefficient 
(M-1 cm-1) 
Protein sequence 
MSMEG_
5998 
FDOR-A1 23950 MADTSRPLNAKQLERLNAKSTGTLIKWMSRFQTFLFKTTNGKLGN
KFLRGTEVGILTTIGRKSGEPRDTPLLFLQEGRRIVLVASQGGRA
TNPMWYLNLKANPKVTFQTRSEKLALVAREATDAERDEYWPKLDA
MYPDFANYRSYTDRKIPIVICDPA 
 
MSMEG_
2850 
FDOR-A1 16960 MTDAELSPTDWVREQTERILEQGTTDGVHVLDRPIVLFTTTGAKS
GKKRYVPLMRVEENGKYAMVASKGGDPKHPSWYFNVKANPTVSVQ
DGDKVLPDRTARELEGEEREHWWKLAVEAYPPYAEYQTKTDRLIP
VFIVE 
 
MSMEG_
2027 
FDOR-A1 30940 MTDAELSPTDWVREQTERILEQGTTDGVHVLDRPIVLFTTTGAKS
GKKRYVPLMRVEENGKYAMVASKGGDPKHPSWYFNVKANPTVSVQ
DGDKVLPDRTARELEGEEREHWWKLAVEAYPPYAEYQTKTDRLIP
VFIVE 
 
MSMEG_
5030 
FDOR-A2 32430 MPWWERYIGLPLLLLHDKVYKATDGRIGHRIPGGPATLILHTVGA
KTGQHRASSLAYARDGDDYLVVASKGGEPKAPGWYHNLKADPNVE
INVGPKRLRATARAVFPDDPDFPRLWEIVNNMPGNKDRYIGYQKR
TTRQIPVIVLTPVS 
 
MSMEG_
6325 
FDOR-A3 44920 MDDKLHGIPRVDLETRPRWKRDLAWWFGGKVLATARASAIWRKIA
MPYEVPLIKATGGRARLSVGIPIAVLTSTGARSGKTRQTALAYFT
DGDDVVLIASNYGQARHPGWYHNLRAHPECELYVGRRGGRFVARE
VDGPQRDRLYALAASRLYPGWVAYEKRAEGVRRIPVLRLTPADP 
 
MSMEG_
3380 
FDOR-B1 21430 MVAVPEGYESLLERPLYGHLATVRPDGTPQVNAMWFAWDGEVLRF
THTTKRQKYRNIKANPAVAMSVIDPDNPYRYLEVRGLVEDIVPDP
TGAFYLKLNDRYDGPLTEPPADKADRVIIVVRPTAFSKQ 
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MSMEG_
0048 
FDOR-B1 29450 MGKNERTKIVMSDEEIAEFVERSRTATMATVLPDGRPHLVAMWYA
VVDGEIWFETKAKSQKAVNLRRDPTVTVLIEDGHTYDTLRGVSID
GTAEIVDDPETLLRVGISVWERYTGPYTDEMRPFVDQMMNNRIAV
RVVPGRTRSWDHRKLGMPAMPLGGSTAQYLNS 
 
MSMEG_
6848 
FDOR-B1 27515 MGVSPARLRQVLDAPVFGTVATIDPDGAPQQSVVWVGRDGDDVLF
AVATGSRKERNLRRDPRVSILLSPPDEPYTYAVIHGKATLHTEGG
HQLRDALAVKYTGKTYAEGNADAAARYGDVAMTVVRVTPERTVGR
L 
 
MSMEG_
6526 
FDOR-B2 34950 MAEFDAVTAFADAPAAVLSTLNADGAPHLVPVVFAVHVPHVEGQP
ARIYTAVDAKRKTTRNLRRLANIDRDSRVSLLVDHYSDDWTQLWW
VRADGVATTHHSGDEVATGYALLRAKYHQYERVSLDGPVISVEVS
RWASWQA 
 
MSMEG_
5170 
FDOR-B3 16960 MGRQVFDDKLLALICNNSLGVLATIKQDGRPQLSNVSYHFDPRAQ
TFQVSITEPRAKTRNLRRDPRASIHVSSDDGWAYAVAEGDAILTP
PAASTHDDTVEGLIALYRNISGEHPDWDEFRQAMVDDRRVLMTLP
ITHVYGMPPGMR 
 
MSMEG_
3880 
FDOR-B4 8480 MAASRGKATTRLTTDALAFLTERHLAMLTTLRSDGSPHVVAVGFT
FDPKTHIARVITTGGSQKAVNAQERGVAVLSQVDGARWLSLEGKS
TVSSDPDAVRDAELRYAQRYRTPRVNPRRVVIEVRIERVLGSSEL
LDRS 
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Table S2. Chemical structures of the 16 compounds tested that were reduced by 
F420H2-dependent FDORs. 
 
Compound Compound class Structure 
Menadione Quinones 
 
 
1,4-napthoquinone Quinones 
 
 
1,2-napthoquinone Quinones 
 
 
Coumarin Coumarins 
 
 
3-cyanocoumarin Coumarins 
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3-chlorocoumarin Coumarins 
 
 
3-aminocoumarin Coumarins 
 
 
7,8-dihydroxy-6-
methoxycoumarin 
Coumarins 
 
   
7-hydroxycoumarin Coumarins 
 
 
5,6-dihydro-2H-pyran-2-
one 
Pyrones 
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Khellin Pyrones 
 
 
6-hydroxy-2-(4’-
methoxy[1,1’-biphenyl]4-
yl)-2-methyl-2H-pyran-
3(6H)-one 
Pyrones 
 
 
3,4-dihydro-2H-pyran Pyrans 
 
 
2-cyclohexen-1-one Cyclohexenones 
 
 
Crystal violet Arylmethanes 
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Malachite green Arylmethanes 
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Table S3. Chemical structures of the 31 compounds tested that were catalytically 
incompatible with F420H2-dependent FDORs. 
 
Compound Compound class Structure 
Anthraquinone Quinones 
 
 
1,4-benzoquinone Quinones 
 
 
3-hydroxycoumarin Coumarins 
 
 
4-hydroxycoumarin Coumarins 
 
 
4-methoxy-6-methyl-2H-
pyran-2-one 
Pyrones 
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3-hydroxy-2,6-
bis(hydroxymethyl)-4H-
pyran-4-one 
Pyrones 
 
 
EHT 1864 Pyrones 
 
   
Chelidonic acid Pyrones 
 
 
Phenol red Triarylmethanes 
 
 
Benzonitrile Benzene 
derivatives 
 
 
2-aminobenzonitrile Benzene 
derivatives 
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2,4-difluorobenzonitrile Benzene 
derivatives 
 
 
Cinnamic acid Benzene 
derivatives 
 
 
3-phenoxybenzaldehyde Benzene 
derivatives 
 
 
Terephthalic acid Benzene 
derivatives 
 
 
Indole-3-carboxylate Indoles 
 
 
   
Potassium indole-6-
trifluoroborate 
Indoles 
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Cytosine Pyridines 
 
 
Thymine Pyridines 
 
 
Guanine Purines 
 
 
Adenine Purines 
 
 
Xanthine Purines 
 
   
Hypoxanthine Purines 
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Caffeine Purines 
 
 
Adenosine Purines 
 
   
5-nitroimidazole Imidazoles 
 
   
Benzimidazole Imidazoles 
 
   
2-aminobenzimidazole Imidazoles 
 
   
Paraquat dichloride Other 
 
   
Azure B Other 
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Thiamine Other 
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Table S4. Comparison of the donor-acceptor distances inferred from molecular 
docking studies and specific activities calculated from enzyme assays.  
 
 Donor-acceptor 
distance (Å) 
Specific activity (nmol 
min-1 (μmol enzyme)-1) 
 
MSMEG_2027 (A1) 
  
Menadione 4.8 917 ± 10 
3-cyanocoumarin 4.2 7.7 ± 0.4 
2-cyclohexen-1-one 3.8 4.6 ± 1.5 
Malachite green 4.8 7.0 ± 0.2 
   
MSMEG_6526 (B2)   
Menadione 7.5 4.1 ± 1.8 
3-cyanocoumarin N/A 0 
2-cyclohexen-1-one N/A 0 
Malachite green 6.9 6.1 ± 0.8 
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Figure S1. Comparison of the in rates of F420H2-dependent reductase activity 
observed in two different assay setups. The specific activities are shown for (a) 1,4-
napthoquinone, (b) 3-cyanocoumarin, and (c) 5,6-dihydro-2H-pyran-2-one based on 
initial reduction rates. Yellow bars show reduction rates with pre-reduced F420H2, 
whereas red bars show rates in a cofactor-recycling system containing F420 and Fgd. 
Error bars show standard deviations from three independent replicates. 
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Figure S2. Structural basis of substrate activation by MSMEG_6526. The secondary 
structure and surface rendering of the cofactor- and substrate-binding site of 
MSMEG_6526 are shown based on the 1.7 Å resolution crystal structure (PDB: 4ZKY) 
of the enzyme (Ahmed et al., 2015). The structures are computationally docked with 
(a) menadione and (b) malachite green. The distance between the proposed hydride 
donor (C5 of F420H-) and hydride acceptor (electrophilic carbon of the substrate) are 
shown. Residues within 5 Å of the substrate are shown. Computational docking 
suggested that 3-cyanocoumarin and 2-cyclohexen-1-one cannot specifically bind to 
this enzyme.  
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Figure S3. GC/MS detection of menadione, reaction products, and their methoxime 
derivatives. The mass spectra shown are of (a) menadione standard, (b) 2,3-
dihydromenadione reaction product, (c) single methoxime derivative of menadione, (d) 
single methoxime derivative of 2,3-dihydromenadione, and (e) double methoxime derivative 
of 2,3-dihydromenadione. The corresponding compounds are shown to the right of the 
spectra. It is likely that 2,3-dihydromenadione will be converted to menadiol under 
physiological conditions through keto-enol tautomerism. 
 
  
 225 
 
 
 
Chapter 6 
 
Literature Review of Fo and F420 
  
Chapter 6: Literature review of Fo and F420 
 
226 
 
6.1 Introduction 
 
The deazaflavins F420 and Fo are found in a large number of bacteria and Archaea including 
Mycobacteria and methanogens. Organisms that contain F420 are found in numerous 
environments but are absent in humans (Ney et al., 2017). F420 and Fo are structurally similar to 
flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN) but are functionally 
similar to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide 
phosphate (NADP) by having a low redox potential (Eirich et al., 1976; Jacobson and Walsh, 
1984; Walsh, 1986). F420 is utilised by a range of enzymes for different roles in various 
organisms. Within methanogens, F420-dependent enzymes are known to be important for 
central metabolism, which includes the oxidation of H2 and formate as energy sources, and the 
reduction of cofactors including NADP, and tetrahydromethanopterin (Tzeng et al., 1975; 
Tzing et al., 1975; Hartzell et al., 1985). There are two superfamilies of F420-dependent 
enzymes in Mycobacteria, the LLHT superfamily, and the FDOR super family (Selengut and 
Haft, 2010; Ahmed et al., 2015). The roles of these enzymes are predicted to include cell 
protection, especially from oxidative stress, and virulence (Gurumurthy et al., 2013; 
Purwantini and Mukhopadhyay, 2013; Purwantini et al., 2016). The large range of enzymes 
that utilise F420, and their absence in humans, has made F420-dependent enzymes potential 
targets for drug therapies against M. tuberculosis, such as Ddn, which activates the prodrugs 
Pretomanid, and Delamanid (Stover et al., 2000; Matsumoto et al., 2006). The low redox 
potential of F420 allows F420-dependent enzymes from Mycobacteria to be able to break down 
a range of compounds including aflatoxins highlighting its potential in bioremediation (Taylor 
et al., 2010; Lapalikar et al., 2012). They are also seen as a potential tool in biocatalysis and 
biotechnology (Taylor et al., 2013).  
 The majority of the research on F420 and F420-dependent enzymes has been done in 
methanogens and sulphur-reducing Archaea (Berk and Thauer, 1997). However, there has been 
increasing interest in F420-dependent enzymes in Mycobacteria due to the recent discovery of 
the FDOR superfamily and the discovery of Ddn and its ability to reduce pretomanid (Ujjini H 
Manjunatha et al., 2006; Selengut and Haft, 2010; Taylor et al., 2010; Ahmed et al., 2015). 
This chapter presents a published review of the current literature on F420 and Fo. It provides 
details on the physiological properties, biochemistry, distribution, and biosynthesis of both 
compounds. There is an in-depth description on the role of F420 in Archaea with an emphasis 
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on methanogens and an in-depth description on the role of F420 in Mycobacteria. The 
implications and applications of F420 and related enzymes from current understandings are 
discussed. The sections of this review that are most relevant to this thesis address the role of 
F420 in Mycobacteria and the development of anti-tubercular drugs, which are found in sections 
2, 4, and 5, respectively.  
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6.2 Physiology, Biochemistry, and Applications of F420-and 
Fo-Dependent Redox Reactions 
 
The chapter contains the following paper:  
 
Physiology, Biochemistry, and Applications of F420-and Fo-Dependent Redox Reactions 
Chris Greening, F. Hafna Ahmed, A. Elaaf Mohamed, Brendon M. Lee, Gunjan Pandey, 
Andrew C. Warden, Colin Scott, John G. Oakeshott, Matthew C. Taylor, Colin J. Jackson 
Microbiology and Molecular Biology Reviews 2016 80(2): 451-493 
Current status of paper:  Published   
Chris Greening was mostly responsible for writing review. Hafna Ahmed designed Figures 1-
3, 5-14, 16-21, and contributed to the sections on enzyme structure and catalysis, Fo and F420 
biosynthesis, and mycobacterial enzymes. Elaaf Mohamed designed Figures 4, and 20 and 
contributed to the sections on the properties of Fo and F420, the photoactivation reaction of Fo, 
and the activation of nitroimidazoles. I designed Figure 15 and edited Figure 20 with the 
addition of fHMAD inhibition, and contributed to the section on tuberculosis treatment. Gunjan 
Pandey, Andrew Warden, Colin Scott, John Oakeshott and Matthew Taylor contributed to the 
sections on biomitigation and industrial biocatalysis. Colin Jackson co-wrote the whole 
manuscript. All authors helped to edit the manuscript. 
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7.1 Summary 
 
The aim of this thesis was to investigate the function of F420-dependent enzymes to understand 
their role in Mycobacteria, specifically the enzymes that are part of the FDOR super family. In 
doing so we can expand our understanding of mycobacterial physiology and help in developing 
treatment against tuberculosis. 
 In Chapter 2, we defined the role of the nitroimidazole prodrug reducing enzyme Ddn, 
and demonstrated that mutations can arise that confer pretomanid resistance without 
substantially affecting fitness. Previous work has shown that Ddn is able to reduce a range of 
non-physiological quinone analogues, leading to their proposed roles in protection from 
oxidative stress. We showed direct evidence that Ddn and the M. smegmatis orthologues, 
MSMEG_5998 and MSMEG_2027, can reduce the physiological substrate menaquinone and 
that this activity is coupled to the electron transport chain via cytochrome bd in a role that 
enhances respiratory activity. Having further expanded the role of Ddn and knowing that it is 
the only enzyme to activate the prodrug pretomanid, we sought to understand the fitness cost 
of mutations that eliminated this activity. We first tested Ddn orthologues from other 
mycobacterial species, showing that they were able to reduce quinones in a similar manner to 
Ddn, but lacked activity with pretomanid (consistent with the lack of pretomanid efficacy 
against these species), demonstrating that it is possible to eliminate pretomanid activity while 
maintaining its physiological role. The exception to this was the orthologue from M. marinum 
that had activity with both the quinone and pretomanid and was demonstrated to be susceptible 
to both pretomanid and delamanid. Sequence alignment revealed that Ddn and the M. marinum 
orthologue’s active site was homologous whereas the other orthologues lacked key residue, 
which explained why they lacked activity with pretomanid.  
To test whether Ddn could lose pretomanid activity with little to no fitness cost, we 
mutated the residues in the active site, and other mutations found in clinical strains and tested 
activity with pretomanid and menadione. We demonstrated that single point mutations in Ddn 
could remove pretomanid activity and maintain the ability to reduce quinones. We validated 
this in vivo by measuring the MIC of pretomanid and delamanid with a clinically relevant strain 
that contained one of our tested mutation and showed that it was resistance to pretomanid but 
that this mutation did not affect delamanid. The reduction of delamanid by this mutant was 
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confirmed with an enzymatic kinetic fluorescence assay, although full kinetics could not be 
obtained due to solubility issues. We revealed using computational docking studies that the 
difference in drug resistance between pretomanid and delamanid is due to the different modes 
of binding. Finally, we analysed the evolution of Ddn mutations in sequenced strains revealing 
that every distinct strain of M. tuberculosis contains SNPs in Ddn and the chance of resistance 
causing mutations arising is highly likely.   
This chapter has expanded the understanding of Ddn in its physiological role in the cells 
energetic  
In Chapter 3, we have made substantial progress towards characterising the role of 
MSMEG_6526/Rv0121c. The functions of most of the FDORs are unknown. We attempted to 
elucidate the role of the M. smegmatis FDOR, MSMEG_6526 as a model for Rv012c from M. 
tuberculosis. Using a Δ6526 strain we showed that there was no difference in growth between 
Δ6526 and wildtype in high nutrient growth media. When we compared the two strains in 
minimal media with different carbon sources we showed a slower growth rate for Δ6526 
compared to wildtype. When acetate or pyruvate was the sole carbon source we observed no 
growth by Δ6526 revealing that MSMEG_6526 is conditionally essential to M. smegmatis.  
To understand the biochemical differences resulting in the observed phenotypes, we 
used proteomics and metabolomics to investigate these changes in the Δ6526 strain. Using 
proteomics, we observed that proteins from the methylcitrate and glyoxylate cycles were 
upregulated, while proteins from the Krebs cycle, late stage glycolysis, the glutamate 
metabolomic pathway, and the aspartate metabolomic pathway were downregulated in the 
Δ6526 strain. We expanded on this with metabolomics showing the effect of acetate on the M. 
smegmatis metabolome, which revealed the down regulation of the Krebs cycle and the 
aspartate metabolomic pathway with the accumulation of related metabolites that were not 
metabolised due to downstream effects. This was interesting as the proteomics revealed that 
the enzymes involved in these pathways were downregulated in the Δ6526 grown on glycerol.  
This may explain the difference in growth and maximum cell density between acetate and 
glycerol as the cell struggles to utilise acetate for energy and amino acid metabolism. 
Metabolites that had accumulated in the Δ6526 strain metabolome that differed from the 
wildtype included several metabolites that related to amino acid metabolism. Lysine 
metabolism and catabolism was particularly affected in the Δ6526 strain, as it is involved in 
two different biosynthetic pathways where there was an accumulation of metabolites from both, 
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as well as an accumulation of a lysine degradation product. Altogether, these data suggest that 
MSMEG_6526 may be involved with amino acid metabolism. The lack of growth by the Δ6526 
strain on acetate is most likely due to acetate not allowing for an alternative pathway to the one 
MSMEG_6526 is involved in, where other carbon sources such as glycerol can allow for an 
alternative pathway to be utilised. More work will be required to identify the exact 
physiological substrate and function. 
Finally, we solved the structures of Rv0121c and MSMEG_6526 with F420 bound. 
These structures both revealed homodimers and contained the split β-barrel fold that defines 
the FDOR superfamily. Both structures revealed three extended loops that were unique to these 
proteins. Two of these loops formed a more defined active site with one of the loops forming 
a hinge that had an open and closed conformation. We showed that the third loop was not 
involved in the active site and that this loop is not conserved between the enzymes. Alignment 
of the structures showed that the active site between the two structures are highly conserved 
and that the catalytic mechanism should be similar between the two. To identify possible 
substrates for these enzymes we performed high throughput in silico docking. We observed 
that the common structural feature of high scoring substrates contained aromatic rings due to 
the pi stacking between F420 and a tryptophan present in the active site. The two largest 
pathways found in the top hits were aromatic amino acid biosynthesis and nucleic acid 
metabolism. Unfortunately, tested compounds from these pathways revealed no activity or 
binding. The crystal structure of MSMEG_6526 with F420 bound revealed MPD bound in the 
active site. This reveals that despite the bias towards aromatic rings revealed by the docking, 
MSMEG_6526 can bind aliphatic compounds such as those found in the Krebs cycle. 
In Chapter 4, two papers are presented that definitively classify the FDOR super family 
and annotated the function of certain enzymes. Although this family had been previously 
classified, the first paper presented in this chapter further defined each group by revealing 
amino acid motifs unique to each group. We expanded each group into separate clades 
revealing the diversity within them. This was especially true of the FDOR-B group as it had 
the most distinct clades and included proteins that did not have F420 as their primary co-factor 
but still retained the split β-barrel fold that defines this superfamily. We also solved the 
structures for many proteins of each clade, allowing for structural classification of each clade. 
The function of some of the clades were discovered, including the confirmation that enzymes 
within the FDOR-As are quinone reductases, the FDOR-B4s are biliverdin reductases, and the 
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FDOR-AAs have some fatty acid reductase activity. The second paper presented in this chapter 
expands on the biliverdin reductases. The first chapter presents enzymes from two different 
clades (FDOR-B3 and FDOR-B4) that reduced biliverdin but showed a distinct difference in 
activity between the clades. We concluded that the activity of the FDOR-B4, which had higher 
activity, was its physiological function and the activity in the FDOR-B3 was promiscuous 
activity due to being highly related.  As the activity of the FDOR- B4 in the first paper was 
from the M. smegmatis enzyme, the second paper confirmed the orthologue from M. 
tuberculosis, Rv2074, was a biliverdin reductase. The structure of Rv2074 was solved with 
F420 bound. This was used to understand the catalytic mechanism of reducing biliverdin, as well 
as showing that the tail of bound F420 is highly dynamic while the rest of the molecule is stable. 
Finally, we demonstrated that orthologues of this protein are highly conserved throughout 
actinobacteria. 
In Chapter 5, two papers are presented expanding the promiscuous activity of FDORs. 
Previously it was shown that FDORs could reduce coumarins and aflatoxins. We expanded the 
list of compounds that FDORs have promiscuous activity with in both papers. In the first paper, 
we demonstrated that the FDORs can reduce multiple antimicrobials including first line anti-
tuberculosis drugs. We demonstrated that M. smegmatis is more susceptible to the anti-
microbials that are reduced by FDORs when F420 is knocked out. In the second paper, we 
revealed a range of compounds that the FDORs can reduce. We defined the common catalytic 
mechanism revealing a hydride transfer to an electron deficient alkene group when the C5 of 
reduced F420 is proximal to the acceptor. 
Overall the research presented in this thesis has expanded the biological understanding 
of Mycobacteria of the FDOR super family in mycobacteria and the understanding of drug 
regimens that target these enzymes.  The work done on the nitroimidazoles, pretomanid and 
delamanid, with Ddn allows for an understanding of resistance towards these compounds and 
will hopefully help in the understanding of how to administer these drugs that minimalises the 
amount of resistance that occurs. This research allows further understanding into how to 
develop the next generation of nitroimidazoles to help eliminate tuberculosis with minimal 
resistant strains occurring. Previously, little was known about the role of FDORs in 
Mycobacteria. This research has expanded this especially that of MSMEG_6526/Rv0121c, 
includes understanding their function, role, structure and has expanded the phylogenetic 
understanding of the FDORs. Expanding the knowledge of these enzymes will help towards 
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drug development targeting these enzymes. Elucidating their function will also allow the 
development of biocatalysts using these enzymes to produce industrially relevant compounds.  
 
7.2 Future Directions 
 
Future work should seek to further the work done in Chapter 2 to expand our knowledge of 
how nitroimidazole resistance could develop, allowing us to develop more suitable drugs to 
combat tuberculosis. This could be achieved by exploring mutations throughout the whole 
sequence of Ddn to fully identify all mutations that will knock out pretomanid activity while 
maintaining it physiological role. This will allow for physicians to identify resistance strains, 
so they can avoid overprescribing pretomanid, thereby minimising the rise of resistant 
tuberculosis. Having identify resistance mutations, it will be important to develop 
nitroimidazoles that would still be effective against these mutants. As well as testing new 
nitroimidazoles against these mutants, a structure of Ddn with the nitroimidazoles bound will 
help to further understand the binding modes of different nitroimidazoles and lead to more 
rationalised designs. To achieve this, work may need to be done to solve the full-length 
structure as the current structure of Ddn is truncated. Since we now have evidence that Ddn 
has a role in respiration, we can expand on this by using a knockout to understand the effect 
that the loss of Ddn has in infection and respiration of M. tuberculosis.  
 Future directions on the work presented in Chapter 3 will include identifying the exact 
substrate of MSMEG_6526/Rv0121c and its potential role in metabolism. To show that this 
activity is conserved in M. tuberculosis, experiments analysing the effect on the loss Rv0121c 
should be done. This would include making a knockout in M. tuberculosis and analysing 
changes in phenotype and what effect it has in infections. Once the role of Rv0121c is 
established, inhibitors that target Rv0121c should be developed which can be used to develop 
a novel treatment for tuberculosis, with an emphasis on latent infections. As with the 
nitroimidazoles, it will be important to understand how resistance can occur to any new 
inhibitors developed to maximise the potency. 
The later chapters of this thesis presented work that expanded on defining the FDOR 
super family. Therefore, future directions should include understanding the roles of these 
enzymes in Mycobacteria by discovering the function of each clade. This will allow for the 
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ground work of drug development against tuberculosis if any of the groups outside of FDOR-
A (Ddn) and FDOR-B2 (MSMEG_6526/Rv0121c) are found to have any physiological 
properties that allow them to be targeted. As well as drug development, knowing their 
physiological function along with expanding the list of compounds that the FDORs have 
promiscuous activity with can allow for the development of these enzymes as biocatalysts that 
utilise the low reducing potential of F420.  
 Previous work on F420-dependent enzymes before this study was focused on Ddn and 
the mode of action of nitroimidazoles, particularly pretomanid, with some insight into its 
function in Mycobacteria, or the promiscuous activity of F420-depedndent enzymes, in 
particular aflatoxins and coumarins. The work presented here has allowed the further validation 
of the function of Ddn in mycobacteria and expanded it with regards to its role in the electron 
transport chain. This is important when understanding what happens to the cell when resistance 
occurs and the decisions made in regards to drug regimes. This work has also shown the effect 
that nitroimidazole resistance has on the fitness of the cell, the differing binding of pretomanid 
and delamanid, and the identification of SNPs present in clinical strains of tuberculosis. The 
translation of this work will help develop regimes in using the current approved nitroimidazole 
drugs in avoiding resistance and detecting pre-admission resistance. This work can also 
translate into the development of nitroimidazole pro drugs that will also help to avoid resistance 
in the future.  This study also shows the importance of understanding resistance in new drugs 
and can be used as a foundation in regards to developing new drugs for tuberculosis and other 
diseases while avoiding resistance.  
This study expanded the understanding of the function of F420-dependent enzymes and 
the physiological role they have in mycobacteria. As previous work only showed the FDOR’s 
outside of Ddn to have promiscuous activity with aflatoxins and coumarins, the work in this 
study has expanded the compounds that the FDORs have promiscuous activity with, which can 
translate into developing new biocatalyst for industrial relevant compounds. This study also 
revealed the physiological function of serval of the FDORs which has expanded the 
understanding of the biology of mycobacteria and can translate into helping with the design of 
new drugs and regimes that can target these FDORs. This is especially true of 
MSMEG_6526/Rv0121c, as the work done is this study has shown the impact to the cell when 
this FDOR is inhibited or knocked out. This has validated the enzymes as a drug target which 
would translate into the development of inhibitors towards Rv0121c that can be used as anti-
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tuberculosis drugs. This is enhance with the structures of this enzyme being solved and that 
work will translate into structure based drug design. 
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